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ABSTRACT 
Molecular-targeted antitumor therapy has found favor in antitumor drug discovery 
programs. Hypoxia (< 5% oxygen) is a common feature of solid tumors and hypoxia-inducible 
factor-1 (HIF-1) represents an important antitumor target. Bioenergetic homeostasis is typically 
altered in tumor cells and HIF-1 plays an important role to produce a glycolytic phenotype. 
Glycolysis inhibitors are an emerging class of potential tumor-selective adjuvant therapeutic 
agents. Natural product aerobic glycolysis inhibitors may enhance the effectiveness of current 
therapies. Mitochondrial oxidative phosphorylation inhibitors in botanical dietary supplements 
(BDS) possess a potential health hazard which should be identified and appropriately regulated. 
Chapter one briefly reviews the molecular-targeted natural product antitumor drug 
discovery process. Descriptions of tumor hypoxia, HIF-1, HIF-1 regulatory pathways and the 
effect of HIF-1 on tumor cell bioenergetics are presented. Cellular bioenergetic pathways and 
natural products that inhibit HIF-1 by interfering with cellular bioenergetics are discussed. 
Mitochondriotoxic small-molecule natural products reported previously are further reviewed. 
Chapter two discusses the effect of chromatographic media on molecular-targeted 
antitumor drug discovery. A panel of crude extracts was eluted through columns of various 
chromatographic media using a step gradient method. Total recoveries from the various columns 
and various elution protocols were compared and statistically analyzed. The crude extracts and 
column eluates were evaluated for HIF-1 inhibitory activity. 
Chapter three discusses the development of a bioenergetics-based screening method to 
screen crude extracts for glycolysis inhibitors. Crude extracts (10,648) were screened and seven 
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hits (hit rate 0.72%) were identified. Bioassay-guided isolation of Moronobea coccinea crude 
extract resulted in isolation of a protonophoric compound moronone (1) (false positive). The 
structure of 1 was determined by a combination of spectroscopic and spectrometric means. The 
protonophoric compounds must be rapidly dereplicated for successful discovery of glycolysis 
inhibitors. 
Chapter four discusses the screening of BDS products and pure compounds for 
mitochondrial uncouplers or electron transport chain inhibitors. The blue cohosh (Caulophyllum 
thalictroides) extract and three saponins cauloside A (3), saponin PE (4) and cauloside C (5) 
permeabilize the mitochondrial membrane. Sesamin (6) and guggulsterol III (7) and guggul 
(Commiphora wightii) extract inhibit mitochondrial complex I. These extracts and compounds 
are cytotoxic in nature. 
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1.1 Molecular-targeted, natural product antitumor drug discovery  
1.1.1 Overview of molecular-targeted antitumor drug discovery 
 Cytotoxic compounds have until recently been the focus for antitumor drug discovery 
programs. With the completion of the human genome sequence in the1990s, along with a better 
understanding of the cellular and molecular biology of cancer, the focus of these programs has 
gradually shifted towards development of molecular-targeted drugs. Prior to the molecular-
targeted era, antitumor therapy was based on the premise that cancer cells can be eradicated by 
damaging cellular DNA or by blocking the cell division machinery. This approach stemmed 
from the limited concept that cancer cells divide more rapidly than normal cells, and that cancer 
cells need DNA replication in order to proliferate. Arguably, these cytotoxic drugs are 
considered the first generation of ‘targeted cancer therapy’ (Varmus, 2006). However, many of 
the processes targeted by these drugs were also critical for the survival of normal cells. Hence, 
low tumor cell specificities and narrow therapeutic windows limited the use of these cytotoxic 
compounds in the standard chemotherapeutic regimen. Molecular-targeted cancer therapies were 
recently developed to overcome these limitations. The goal of the contemporary molecular-
targeted approach is to eliminate tumor cells in a selective manner without affecting normal 
cells, which can be achieved by exploiting the pharmacokinetic, biochemical, and molecular 
biological differences between normal and malignant cells. 
 Understanding the molecular basis of cancer is the key factor in the development of 
antitumor molecular-targeted therapies. Elucidation of the genetic causes of cancer began as 
early as 1911 with the discovery of the first tumor-causing virus (Rous, 1911). However, the first 
oncogene was not identified until 1970 (Duesberg and Vogt, 1970). This discovery provided the 
conceptual breakthrough of gene mutation, which is one of the major factors that contribute to 
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tumorigenesis. To date, mutations of 487 human genes (~1%) have been shown to contribute to 
the etiology of cancer (Wellcome Trust Sanger Institute, 2012). Gain-of-function mutations for 
oncogenes and loss-of-function mutations of tumor suppressor genes both lead to tumorigenesis. 
These mutations are also often accompanied with epigenetic abnormalities, which results in 
altered gene expressions (Yoo and Jones, 2006). Such alterations in gene expression (pro-
oncogenic) are critical for the survival and maintenance of the malignant cancer cell phenotype. 
Any perturbation of these pro-oncogenic signaling pathways can profoundly impact cancer cell 
viability. This phenomenon is known as ‘oncogene addiction’ (Weinstein, 2002). Studies 
conducted in a mouse xenograft model revealed that brief pharmacological inactivation of the 
oncogene Myc could prolong animal survival and cause tumor regression (Jain et al., 2002). 
Numerous studies using transgenic mice that bear activated oncogenes have supported this 
concept (Varmus et al., 2005). These results support the development of molecular-targeted 
antitumor therapies. 
 The process of molecular-targeted drug discovery starts with identification of a target. 
The prospective target can be a receptor [i.e., human epidermal growth factor receptor2 (HER2)] 
(Shawer et al., 2002), an enzyme (metalloproteinase) (Li and Wu, 2010), or a transcription factor 
[i.e., hypoxia-inducible factor (HIF)-1] (Patiar and Harris, 2006). The major criteria for the 
selection of a molecular target are its unique presence in tumor cells and high importance in 
tumor cell survival, proliferation, and metastasis. In addition to these factors, feasibility for high-
throughput screening is also taken into consideration (Sun, 2006). Certain characteristics (e.g., 
growth factor-independent cellular proliferation, apoptosis resistance, immortality, angiogenesis, 
invasion, and metastasis) are attributed as inherent to the cancer cells, and are the distinguishing 
features from normal cells (Hanahan and Weinberg, 2000). In addition, aerobic glycolysis and 
4 
 
disabling immune destruction are considered to be emerging ‘hallmarks’ of cancer (Hanahan and 
Wienberg, 2011). These unique properties of cancer cells allow for targeted therapeutic 
intervention, and can be exploited for the development of tumor-selective molecular-targeted 
therapies.  
 Following its selection, a target must be validated (Benson et al., 2006). The goal of 
target validation is to assess the correlation between target modulation and disease progression. 
Target validation also helps to identify any undesirable effect(s) of target inhibition or 
stimulation. In oncology, an ideal target should enhance cellular survival/proliferation, 
metastasis or confer resistance when upregulated in tumor cells. On the other hand, inhibition or 
downregulation of the same target should rapidly and selectively eliminate cancer cells, stop the 
spread of tumor, reverse drug resistance, and/or have any other specific desirable effects 
determined by the evaluators (Sun, 2006; Collins and Workman, 2006). In addition, proteins 
with critical functions should be selected as targets, while proteins with redundant functions 
should not be pursued (Perry and Weitzman, 2005).  
 For lead generation, thousands of compounds can be screened, directly or indirectly, 
against a valid target in a high-throughput manner. The compounds used for screening can 
originate from either natural product or synthetic compound libraries.  This screening approach 
can be either ‘forward’ (phenotype to target) or ‘reverse’ (target to phenotype) (Bredel and 
Jacoby, 2004). The biochemical high-throughput screening (HTS) assays involving isolated 
targets have been partially successful in lead generation (Wesche et al., 2005; McDonald et al., 
2006). However, due to the overdependence on the assays using isolated targets, the global 
effects of modulating these targets do not always become clear until the later stages of drug 
development. A thorough investigation and prediction of possible unwanted effects arising from 
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the modulation of a particular target should be performed at the earlier stages, which would 
prevent late stage drug attrition and minimize drug development costs. One prominent example 
of late stage drug attrition is the farnesyltransferase (FTase) inhibitors, which were developed to 
treat advanced pancreatic, lung, and colon cancers. Ras (H-Ras/K-Ras) prenylation is essential 
for the plasma membrane association, as well as oncogenic activity. This prenylation is 
preferentially catalyzed by FTase in cancer cells; but in the event of pharmacologic inhibition of 
FTase, the enzyme geranylgeranyltransferase (GGTase) can prenylate and activate K-Ras, thus 
bypassing this inhibition of the Ras signaling pathway (Rowinsky, 2006). Efforts to 
simultaneously target FTase and GGTase have failed, due to high incidences of toxicity (Lobel et 
al., 2001). 
 Phenotypic screening using intact cells, organisms or animals can be employed for 
screening of natural product-rich extracts and other substances which are incompatible with 
isolated targets (Mishra et al., 2008). The main advantage of phenotypic screening is that one can 
monitor whether the targeted pharmacological intervention can produce the desirable effects at 
the cellular or organismic level. Phenotypic screening systems also allow for the discovery of 
novel targets or drug candidates with novel mechanisms of action. However, post-screening 
determination of the mechanisms of action is difficult, and the precise molecular targets often 
remain elusive. 
 Some of the established/validated and emerging antitumor molecular targets include: 
tyrosine kinases (TrK) (Shawer et al., 2002), endothelial growth factor receptors (EGFR) 
(Ciardiello and Tortora, 2008), histone deacetylases (HDAC) (Jones and Steinkühler, 2008), 
cyclin-dependent kinases (CDKs) (Malumbres and Barbacid, 2009), mammalian target of 
rapamycin (mTOR) (Bjornsti and Houghton, 2004), matrix metalloproteinases (MMP) (Overall 
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and Kleifeld, 2006), HIF-1 (Semenza, 2007), vascular endothelial growth factor (VEGF) 
(Ferrara, 2005), VEGF-receptors (Schwartz et al., 2010), proteasome (Adams, 2004), Bcl family 
proteins (Lessene et al., 2008), topoisomerase (Chikamori et al., 2010), tubulin (Cragg and 
Newman, 2004), kinesin (Cox and Garbaccio, 2010), 90 kDa heat-shock protein  (Hsp90) 
(Neckers, 2006), and protein kinase C (PKC) (Collins and Workman, 2006). High-throughput 
screening of synthetic and natural product libraries is carried out to identify novel leads that 
inhibit one or more of these targets. Some of the tumor phenotype-targeted screenings include 
screening for agents that target tumor angiogenesis (Spannuth et al., 2008), cancer stem cells 
(Gupta et al., 2009), multidrug efflux (Szakács et al., 2006), and aerobic glycolysis (Kitagawa et 
al. 2011).  
 
Figure 1.1 The process of molecular-targeted small-molecule drug discovery. The figure was 
reproduced with appropriate permission from the Nature publishing group (Collins and 
Workman 2006) 
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Critics of molecular-targeted antitumor drug discovery suggest that an overemphasis on 
isolated target-based screening has been the main reason for the lack of productivity in recent 
drug discovery (Hellerstein, 2008; Sams-Dodd, 2005). Two major problems plaguing the 
molecular-targeted drug discovery programs are late attrition of drugs due to lack of efficacy 
and/or toxic off-target effects. It is argued that the difference in functionality of any molecular 
target in a complex network, as well as the adaptability of cellular signaling pathways, are often 
overlooked while developing molecular-targeted drugs; these lead to late stage drug attrition 
(Hellerstein, 2008). Inhibition of drug targets that interconnect several pathways in the 
physiological setting will affect all the associated pathways, and may produce unwanted off-
target effects. Indeed, the immense theoretical potential of the molecular-targeted approach is yet 
to be fully realized at the clinical level (Broxterman and Georgopapadakou, 2004). However, 
these pitfalls can be avoided by, (a) employing initial cell-based assays instead of the isolated 
target-based assays; (b) employing toxicity studies at the earliest feasible stage; (c) careful 
patient population recruitment in whom the molecular target is overexpressed; and (d) 
determination of valid molecular target endpoints.    
 
1.1.2 Tumor hypoxia 
 Mammalian cells undergo oxidative metabolism to produce energy in an efficient 
manner. Under physiological conditions, most cells need oxygen as the ultimate electron 
acceptor, to synthesize adenosine triphosphate (ATP) through oxidative phosphorylation 
(Semenza, 2009). Intracellular O2 concentrations depend on O2 diffusion from the vasculature 
that supplies blood to the tissue.  The O2 diffusion geometry is inversely proportional to the 
distance of the cells from the vessel walls. A tissue-dependent 24 – 66 mm Hg oxygen partial 
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pressure [pO2] (normoxic condition) (Weeks et al., 2010) is usually maintained up to 70 µm 
from the vessel walls (Vaupel and Harrison, 2004). Apart from the diffusion geometry, the 
maintenance of tissue-specific normoxic conditions also depends on several factors, such as the 
O2 carrying capacity of the blood; morphological and functional normality of the vasculature; 
perfusion of blood through the vessels, and cellular oxygen demand. Formation of solid tumors is 
initiated through rapid and uncontrolled cell proliferation. Owing to the sharp increase in oxygen 
demand caused by rapidly dividing tumor cells, normal tissue vasculature is unable to maintain 
tissue-specific normoxic conditions (Vaupel et al., 2001). This imbalance in oxygen demand and 
supply creates ‘hypoxia/hypoxic conditions’, which can be defined as the oxygen deficiency 
level (~ 7 mm Hg) that compromises normal cellular functions, and triggers adaptive responses 
(Semenza, 2009; Goonewardene et al., 2002). One of these adaptive responses to hypoxic 
conditions is the occurrence of an aberrant and chaotic angiogenesis (formation of new blood 
vessels) in solid tumors. The new microvasculature, unlike the normal vasculature, is 
morphologically and functionally deformed, and hence, it is less efficient in supplying nutrients 
and oxygen to the surrounding tissue (Tredan et al., 2007). The difference between the rate of 
cell proliferation and the rate of angiogenesis is maintained during the growth of tumors. As a 
result, a heterogeneous pattern of oxygen partial pressure and chronically hypoxic areas are 
commonly observed throughout solid tumors. 
In the early twentieth century, tumor hypoxia was identified as a major factor in 
determining tumor sensitivity to ionizing radiation (Mottram, 1936). Since then, the effects of 
hypoxia on tumor cells have been extensively evaluated. Numerous clinical studies in various 
solid tumors have shown that tumor hypoxia (2.5 – 22 mm Hg of O2 partial pressure) is inversely 
correlated with disease-free and overall survival rates (Hockel and Vaupel, 2001). In an animal 
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model, several cytotoxic agents, such as doxorubicin, carboplatin, vincristine, etoposide, and 
cyclophosphamide, have been shown to affect tumors in an oxygen-dependent manner (Teicher 
et al., 1990). Hypotheses of hypoxic chemoresistance have been formulated, which include 
decreased cell proliferation, decreased drug penetration to the hypoxic cells, hypoxia-mediated 
clonal selection, and adaptive modification of the cellular genome and proteome (e.g., induction 
of multidrug resistance mechanism) (Cosse and Michiels, 2008; Zhu et al., 2005). Currently, 
tumor hypoxia (< 10 mm Hg of O2 partial pressure) is an accepted adverse prognostic marker for 
solid tumor chemo and radiosensitivity to standard antitumor therapeutic regimens.  
Measurement of tumor hypoxia had been primarily performed with polarographic needle 
electrodes. The polarographic needle electrode has been the gold standard in measuring tumor 
pO2. Currently, exogenous markers (e.g., pimonidazole and EF5) and endogenous markers (e.g., 
carbonic anhydrase IX and HIF-1α) of hypoxia are primarily used for clinical tumor hypoxia 
measurement (Rademakers et al., 2008). 
 
1.1.3 Hypoxia-inducible factor-1α 
Adaptive responses to tumor hypoxia are primarily mediated by a group of proteins 
known as hypoxia-inducible factors (HIF). These proteins are heterodimeric transcription factors 
that consists of an α and a β subunit protein of basic helix-loop-helix Per-ARNT-Sim (bHLH-
PAS) protein superfamily (Wang et al., 1995). Three HIF α subunit isoforms have been 
discovered, namely HIF-1α, HIF-2α and HIF-3α. The β subunit is also known as aryl 
hydrocarbon receptor nuclear translocator (ARNT) and is constitutively expressed. Among these 
three HIF isoforms, HIF-1 is the most prevalent and is ubiquitously expressed in all human 
tissues examined (Semenza et al., 1997). The HIF-1α subunit is a 120-kDa, 826 amino acid 
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protein that consists of several distinct functional domains. The major HIF-1α subunit domains 
that are involved in self-regulation and HIF-1 transcriptional activation are as follows: bHLH 
domain (amino acid residues 17 – 71, required for heterodimerization and DNA binding); PAS 
domain (amino acid residues 85 – 298, required for heterodimerization and DNA binding) 
(Wang et al., 1995); oxygen-dependent degradation domain (ODDD, amino acid residues 401– 
603, required for oxygen-dependent degradation) (Huang et al., 1998); N-terminal 
transactivation domain (N-TAD, amino acid residues 531 – 575); and C-terminal transactivation 
domain (C-TAD, amino acid residues 786 – 826, required for transcriptional coactivator binding) 
(Jiang et al., 1997). The HIF-1α subunit contains two nuclear localization signal (NLS) domains 
(amino acid residues 17 – 33 and 718 – 721). The C-terminal NLS is essential for the hypoxia-
induced nuclear localization of HIF-1α (Kallio et al., 1998). The HIF-1α protein also contains a 
nuclear export signal that is responsible for shuttling of HIF-1α between the cytosol and the 
nucleus (amino acid residues 616 – 658) (Mylonis et al., 2008). Each HIF-1β subunit (91 – 94 
kDa, 789 amino acid residues) contains a single transactivation domain. The HIF-1β subunits are 
devoid of ODDD but contain bHLH and PAS domains (Semenza, 1999). 
Under physiological conditions, the limiting factor for HIF-1 activation is the stability of 
the HIF-1α subunit, which is rapidly degraded in the presence of adequate oxygen (> 5% O2) 
(Huang et al., 1996). The lack of ODDD in HIF-1β prevents the oxygen-dependent degradation 
of HIF-1β and makes the subunit constitutionally active (Semenza, 1999). Hypoxia-inducible 
factor-1α stabilization allows HIF-1α and β to dimerize. This results in a transcriptionally active 
HIF-1 that translocates to the nucleus (Wang et al., 1995). Following the transcriptional 
activation, HIF-1 binds to the cis-acting DNA sequence 5' –(A/G)CGTG– 3' [hypoxia-response 
element (HRE)] located in the promoter regions of the target genes (Semenza et al., 1996). 
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Following DNA binding, HIF-1 typically recruits and binds to transcriptional coactivators, such 
as p300/CBP [CREB (cAMP reactive element binding protein) binding protein] and/or PKM2 
(pyruvate kinase isozyme M2) (Luo et al., 2011). However, the direct repression of a target gene 
by HIF-1 is rare and usually downregulation of genes by HIF-1 is achieved by an indirect 
mechanism (Semenza, 2011). The HIF-1–p300/CBP interaction is mediated by the first 
cysteine/histidine-rich region of p300 (p300-C/H1) and HIF-1α-C-TAD, and the HIF-1 
coactivator interaction is essential for the HIF-1-induced gene transcription (Bhattacharya et al., 
1999; Arany et al., 1996). 
 
1.1.4 Non-mitochondrial HIF-1α regulatory mechanisms 
The rapid degradation of HIF-1α under tissue-specific physiological normoxic conditions 
(>5% O2) is due to the presence of the ODDD in the subunit structure (amino acid residues 401 – 
603). A family of dioxygenases known as prolyl-4-hydroxylases (PHD) is primarily responsible 
for the oxygen-dependent degradation of the HIF-1α subunit. Three isoforms of PHD are known, 
namely PHD-1, PHD-2, and PHD-3. All three isoforms can hydroxylate the HIF-1α protein at 
the proline-402 and proline-564 residues, by using molecular oxygen as a substrate, and iron 
(Fe2+), 2-oxoglutarate, and ascorbate as cofactors (Figure1.2) (Bruick and McKnight, 2001; 
Hirota and Semenza, 2005). However, PHD-2 is thought to be the major HIF-1α hydroxylating 
enzyme in vivo (Berra et al., 2003). 
 
 
Figure 1.2 Prolyl-4-hydroxylation reaction catalyzed by prolyl-4-hydroxylases (PHDs) 
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Proline hydroxylation of HIF-1α (residues 402 and 564) allows the recognition of HIF-1α 
by the von Hippel-Lindau protein (pVHL), and subsequent HIF-1α polyubiquitination by the 
pVHL-E3 ubiquitin ligase complex [pVHL, elongins B and C, cullin 2, and ringbox protein1 
(Rbx1)] (Czyzyk-Krzeska and Meller, 2004; Kamura et al., 1999). Polyubiquitinated HIF-1α is 
recognized and degraded by the 26S proteasome (Kallio et al., 1999). Any perturbation of this 
pathway, such as inhibition of  the PHDs by small-molecules or transition metals [Co2+, Ni2+, 
and Mn2+] (Schofield and Ratcliffe, 2004), depletion of any of the cofactors (e.g., depletion of 
Fe2+ by an iron chelator) (Roy et al., 2004), pVHL deficiency (Maxwell et al., 1999), and/or 
inhibition of 26S proteasome, stabilize HIF-1α under normoxic conditions and cause intracellular 
accumulation of HIF-1α protein in the absence of hypoxia (Kallio et al., 1999). However, it has 
been reported that the accumulation of intracellular HIF-1α protein does not necessarily 
transform into the transcriptionally active HIF-1. In fact, inhibition of the 26S proteasome by 
bortezomib has been shown to inhibit the transcriptional activity of HIF-1 under both normoxic 
and hypoxic conditions, but caused significant accumulation of HIF-1α protein under normoxic 
conditions (Kaluz et al., 2006). The paradoxical response of HIF-1 in response to proteasome 
inhibitors is suggested to be partially mediated by a protein known as CITED2 [p300/CBP-
interacting transactivator with glutamate (E)/aspartic acid (D)-rich tail 2] (Shin et al., 2008). The 
CITED2 protein is a p300-CH1 domain-binding protein, which inhibits HIF-1 transcriptional 
response by preventing HIF-1α-p300 interaction (Bhattacharya et al., 1999).  Aspargine 
hydroxylation within the C-TAD at residue 803 by an aspargine hydroxylase (Factor inhibiting 
HIF-1 [FIH]) prevents the HIF-1-p300/CBP interaction and inhibits subsequent HIF-1 gene 
transcription (Mahon et al., 2001; Lando et al., 2002).  
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Other post-translational modifications (PTM) that have been reported to modulate HIF-
1α stability, and therefore HIF-1activity, include sumoylation (Bae et al., 2004; Cheng et al., 
2007), de-ubiquitination (Li et al., 2005), and phosphorylation of the HIF-1α subunits (Mylonis 
et al., 2006). In an in vitro study, covalent attachments of a SUMO (small ubiquitin-like modifier 
protein) at lysine-391 and lysine-471 have been shown to increase HIF-1α stability (Bae et al., 
2004). However, a later study using sentrin/SUMO-specific protease-1 (SENP-1)-knockout mice 
showed that sumoylation promotes HIF-1α degradation through the pVHL-proteasome pathway 
(Cheng et al., 2007). It has been argued that SUMO overexpression in presence of SENP-1 led to 
HIF-1 stabilization via sumoylation. A pVHL-interacting de-ubiquitinating enzyme (VDU2) has 
been identified that mediates the pVHL-dependent HIF-1α de-ubiquitination. De-ubiquitination 
of HIF-1α leads to intracellular accumulation of HIF-1α and expression of downstream target 
genes, such as VEGF (Li et al., 2005). Various kinases have been reported to phosphorylate 
amino acid residues in HIF-1α with opposing effects. Serine-641 and serine-643 phosphorylation 
by p42/p44 mitogen-activated protein kinase (MAPK) enhances nuclear accumulation and HIF-1 
transcriptional activity (Mylonis et al., 2006), whereas serine-551, threonine-555, and serine-589 
phosphorylation by glycogen synthase kinase 3 (GSK-3) causes a pVHL and proteasome-
dependent HIF-1α destabilization (Flugel et al., 2007). Polo-like kinase 3 (Plk3) has been shown 
to destabilize HIF-1α by directly phosphorylating serine-576 and serine-657 (Xu et al., 2010). 
Apart from post-translational modifications, various cellular signaling pathways can 
regulate HIF-1α at the translational level. Well-studied cellular signaling pathways that regulate 
HIF-1α translation include the PI3K (phosphatidylinositol-3-kinase)/Akt (protein kinase B, 
PKB)/mTOR (mammalian target of rapamycin) pathway and the MAPK pathway (Yee Koh et 
al., 2008). Growth factors and oncoproteins, such as Ras, upregulate HIF-1α cap-dependent 
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translation under normoxic conditions in a cell line-dependent manner (Patiar and Harris, 2006). 
Ras oncoprotein enhances the normoxic HIF-1α translation via Raf-MEK (MAPK kinase)-ERK 
(extracellular signal-regulated kinases) signaling cascade activation that phosphorylates 4E-BP1 
[eukaryotic initiation factor (eIF) 4E-binding protein]. Phosphorylation of 4E-BP1 causes 
dissociation of 4E-BP1 from eIF-4E and allows the initiation factor to be incorporated into the 
active eIF-4F, thereby facilitating enhanced HIF-1α translation (Yee Koh et al., 2008; De 
Benedetti and Graf, 2004). Under normoxic conditions, the PI3K/Akt/mTOR pathway also 
converges on eIF-4E phosphorylation. Activation of PI3K by the receptor tyrosine kinases (e.g., 
HER2) enhances the formation of PIP3 (phosphatidylinositol-3,4,5-triphosphate). Subsequently, 
PIP3 activates the Akt/mTOR signaling cascade that results in 4E-BP and ribosomal S6 kinase 
hyperphosphorylation (Yee Koh et al., 2008; Ruvinsky et al., 2005; Bronchud, 2007). Under 
normoxic conditions, this enhances HIF-1α translation. 
In an acute response to hypoxia, the phosphorylation of eIF-2α by PERK (protein kinase 
RNA-like endoplasmic reticulum kinase) prevents the formation of eIF2-GTP-met-tRNA ternary 
complex and thereby inhibits initiation of protein translation (Koumenis et al., 2002). 
Additionally, prolonged hypoxic exposure results in a decrease in mTOR activity and 4E-BP 
hypophosphorylation, which leads to repression of eIF-4F complex activity (Reiling and 
Sabatini, 2006). The mTOR inhibition is mediated through a hypoxia-inducible protein REDD1 
(regulated in development and DNA damage responses 1) and its downstream effector TSC-1/2 
(tuberous sclerosis) (DeYoung et al., 2008). However, HIF-1α translation is not compromised 
under hypoxia. A controversial cap-independent translation mechanism involving an internal 
ribosome entry site (IRES) has been suggested for hypoxic translation of HIF-1α (Zhou et al., 
2004; Lang et al., 2002; Young et al., 2008; Bert et al., 2006). An alternative mechanism that 
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involves PTB (polypyrimidine binding protein) and HuR (human antigen R) binding to the 3'- 
and 5'- untranslated regions (UTR) of HIF-1α mRNA, respectively, has also been proposed 
(Galban et al., 2008; Schepens et al., 2005). A recent study has identified HIF-2α as a translation 
facilitator under hypoxia. Recognition of an RNA hypoxia-responsive element (rHRE) by RBM4 
(RNA binding protein 4) is essential for translation under hypoxic stress in an eIF-4E2 dependent 
manner (Uniacke et al. 2012; Montoya, 2012). Modulation of HIF-1α translation by microRNAs 
(miRs, “noncanonical RNA species of 18 – 23 nucleotides in length”) (Loscalzo, 2010) is 
observed under both normoxic and hypoxic conditions. MicroRNA-199a inhibited HIF-1α 
translation under normoxia, but the hypoxic conditions downregulated miR-199a and reversed 
the HIF-1α inhibition (Rane et al., 2009). Conversely, enhanced miR-130 family levels under 
hypoxic conditions increased HIF-1α translation in an IRES-dependent manner (Saito et al., 
2011). 
Another non-mitochondrial HIF-1 regulatory mechanism involves 90kDa heat-shock 
protein (Hsp90) and RACK1 (receptor of activated protein C kinase). Binding of Hsp90 to the 
HIF-1α PAS domain promotes HIF-1α nuclear localization and prevents O2/PHD/VHL-
independent degradation (Katschinski et al., 2004; Liu and Semenza, 2007). Conversely, 
RACK1 binding promotes HIF-1α polyubiquitination and proteasomal degradation by an 
O2/PHD/VHL-independent mechanism (Liu et al., 2007). Spermidine/spermine-N1-
acetyltransferase-1 (SSAT1) stabilizes the RACK1-HIF-1α complex and is essential for RACK1-
mediated HIF-1 polyubiquitination (Baek et al., 2007). Both Hsp90 and RACK1 compete for the 
same HIF-1α binding site, and downregulation of HIF-1 by the Hsp90 inhibitors [e.g., 17-
(allylamino)-17-demethoxygeldanamycin (17AAG) (1)] is mediated by RACK1 (Liu et al., 
2007; Isaacs et al., 2002). 
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1.1.5 Mitochondrial HIF-1α regulatory mechanism  
Hypoxia-inducible factor-1α stabilization by reactive oxygen species (ROS) from the 
hypoxic mitochondrial electron transport chain (ETC) is a well-studied HIF-1 regulatory 
pathway. Based on the pioneering study by Schumacker and Chandel (Chandel et al., 1998), it 
was proposed that ROS, generated by the mitochondrial ETC, are responsible for hypoxic (1.5% 
O2) HIF-1α stabilization and transactivation.  This study demonstrated that molecules that inhibit 
the electron transport chain complexes (specifically complex I and complex III), such as 
rotenone (2) (complex I inhibitor), diphenylene iodonium chloride (3) (complex I inhibitor), and 
myxothiazol (4) (complex III inhibitor), decrease mitochondrial ROS and inhibit hypoxic 
stabilization of HIF-1α. In addition, mitochondrial DNA depletion (ρ0 cells) or treatment with 
antioxidants abolished the ROS generation and transcription of erythropoietin (EPO, a target 
gene of HIF-1) in cells. In a later study, Chandel and coworkers proposed that ROS generation at 
the Qo site of mitochondrial complex III is essential for hypoxic HIF-1α transactivation (Bell et 
al., 2007).  
The electron transfers from complexes I and II to complex III is carried out by 
ubiquinone (Q), a membrane soluble electron carrier (Trumpower, 1990; Klimova and Chandel, 
2008). A ubiquinone molecule accepts two electrons and is subsequently converted to ubiquinol 
(QH2). The QH2 molecule transfers the electron pair to complex III via the Q cycle. In the Q 
cycle, QH2 transfers one electron to the Rieske iron-sulfur protein within complex III and is then 
oxidized to form a reactive semiubiquinone (QH·) radical. The formation of QH· occurs in the Qo 
site of mitochondrial complex III. The transport of the electron from the Rieske Fe-S protein to 
complex IV is performed by cytochrome c1 (complex III) and cytochrome c (electron carrier 
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from complex III to complex IV). The remaining electron on the ubisemiquinone radical reduces 
the bL reaction center of cytochrome b which is passed on to the cytochrome bH and finally to Qi 
site of complex III. The now fully oxidized ubiquinone, that is at the center “i” site of complex 
III again produce the semiquinone. The QH· radical is very reactive and can readily transfer the 
single electron to available molecular oxygen leading to production of superoxide radicals (O2·−) 
at the Qo site (Figure 1.3) (Trumpower, 1990; Klimova and Chandel, 2008). In accordance with 
the ROS hypothesis, the Qo site inhibitor stigmatellin (5), prevents mitochondrial ROS 
generation while, the Qi site inhibitor antimycin A (6), had no effect on mitochondrial ROS 
generation (Guzy et al., 2005; Chandel et al., 1998). The ROS hypothesis is further supported by 
other independent studies. Using JunD−/− cells, Gerald and coworkers demonstrated that under 
normoxic conditions, oxidative stress could stabilize HIF-1α by decreasing the Fe2+ availability 
and thus inhibiting PHD activity (Gerald et al., 2004).  
 
 
Figure 1.3 Electron transfer and ROS production by the ubiquinone (Q) cycle in mitochondrial 
complex III at Qo site. The figure was reproduced with appropriate permissions from the Nature 
publishing group (Klimova et al., 2008).   
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Figure 1.4 Natural products that inhibit Hsp90 [17AAG (1)] and mitochondrial respiratory 
complexes (complexes I and III). 
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In a separate study, Pan and coworkers used a fusion protein containing HIF-1α ODDD 
to demonstrate that under hypoxic conditions (1.5% O2) a loss of PHD activity occurs, which can 
be restored by the presence of mitochondrial ETC inhibitors, such as rotenone (2) and 
myxothiazol (4). In addition, HIF-1α stabilization by exogenous H2O2 was also observed. 
However, this study was unable to determine whether the HIF-1α stabilization was ROS-
mediated or due to “oxygen redistribution” (Pan et al., 2007). This evidence indicates that 
hypoxic conditions enhance ROS generation by mitochondrial ETC and the enhanced ROS 
levels oxidize Fe2+ to Fe3+. Depletion of the intracellular Fe2+ pool inhibits the PDH-dependent 
degradation of HIF-1α, and activates HIF-1. Inhibition of the mitochondrial complexes I and III 
under hypoxia decrease mitochondrial ROS generation, and thus prevent HIF-1α stabilization. 
An “oxygen redistribution” hypothesis was later proposed for hypoxic HIF-1α 
stabilization. A study by Hagen and coworkers observed that inhibition of normal mitochondrial 
oxygen consumption under hypoxia by an NO donor increased oxygen concentrations in the 
cytosol. They further observed that inhibition of PHD activity under hypoxia (1% O2) could be 
reversed by the presence of a mitochondrial inhibitor. In addition, antioxidants (ascorbate, 
glutathione, and N-acetylcysteine) did not affect hypoxic HIF-1α stabilization. These 
observations led to the formulation of the hypothesis that under hypoxic conditions, normal 
mitochondrial activity inhibits PHD activity by limiting the availability of O2 for the HIF-1α 
hydroxylation reaction. On the other hand, mitochondrial ETC inhibitors increase the cytosolic 
O2 concentrations and destabilize HIF-1α under hypoxia by restoring PHD activity (Hagen et al., 
2003). 
The ‘oxygen redistribution hypothesis’ appears to be inconsistent with the ROS 
hypothesis. The observation that cells which lack cytochrome b showed drastically less oxygen 
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consumption, yet retained the ability for hypoxia-induced ROS generation and HIF-1α 
stabilization, contradicts the oxygen redistribution hypothesis (Bell et al., 2007). The observed 
interexperimental inconsistency in the effects of antioxidants on HIF-1α stabilization (Chandel et 
al., 1998; Hagen et al., 2003) may be due to the mechanistic nature of antioxidants used in the 
experiments or the inherent difference in the cell lines used (hepatoma vs. embryonic kidney 
cells). However, under physiological conditions both mitochondrial ROS and oxygen 
redistribution by mitochondria may act together to stabilize HIF-1α under hypoxic conditions 
(Taylor, 2008). 
Apart from mitochondrial respiration-mediated regulation, HIF-1α is also regulated by 
tricarboxylic acid (TCA) cycle intermediates, namely succinate and fumarate. Prolyl 
hydroxylases generate succinate from 2-oxoglutarate in the cytoplasm during hydroxylation of 
HIF-1α. The succinate is then transported to the mitochondrial matrix, and converted to fumarate 
by the enzyme succinate dehydrogenase (mitochondrial complex II). Theoretically, increased 
succinate/fumarate concentrations in the cytoplasm can stabilize HIF-1α by preventing HIF-1α 
hydroxylation by a negative feedback mechanism. Indeed, dysfunctional succinate 
dehydrogenase has been demonstrated to increase ROS, tumorigenecity and intracellular HIF-1α 
protein accumulation (Selak et al., 2005; Guzy et al., 2008). Similarly, accumulation of fumarate 
can inhibit the forward reaction by PHDs and a number of studies demonstrate that mutations in 
fumarate hydratase (FH) or FH deficiency can stabilize HIF-1α (Pollard et al., 2005; Isaacs et al., 
2005; Sudarshan et al., 2009). 
The mitochondrial deacetylase sirtuin-3 (SIRT3) has been shown to negatively regulate 
HIF-1α in a mitochondrial ROS and PHD-dependent manner (Finley et al., 2011a; Bell et al., 
2011). Knockout of SIRT3 imparts a glycolytic phenotype in the mouse embryonic fibroblasts 
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(MEF), which can be reversed by genetic HIF-1α removal (Finley et al., 2011a). Conversely, 
overexpression of SIRT3 under hypoxic conditions destabilizes HIF-1α and reduces HIF-1 
transcriptional activity. In addition, tumorigenicity in xenografts are reduced in mice that 
overexpressed SIRT3 (Bell et al., 2011). Sirtuin-3 can also affect HIF-1α stability via succinate 
dehydrogenase. It has been shown that succinate dehydrogenase is deacetylated by SIRT-3, and 
SIRT-3 is essential for normal succinate dehydrogenase activity. Loss of SIRT3 reduces 
succinate dehydrogenase activity, which may contribute to HIF-1α upregulation (Finley et al., 
2011b). The cytosolic sirtuins SIRT1 and SIRT6 have also been shown to regulate HIF-1 
activity. While SIRT1 decreases HIF-1 transcriptional activity by deacetylating HIF-1α at 
Lysine-674 (Lim et al., 2010), SIRT6 negatively regulates HIF-1 activity by acting as a 
transcriptional corepressor of HIF-1 target genes involved in glycolysis. In addition, SIRT6 
knockout cells show enhanced HIF-1α translation suggesting that SIRT6 may downregulate HIF-
1α protein synthesis under physiological conditions (Zhong et al., 2010). 
 
1.1.6 HIF-1 and tumor cell bioenergetics 
Metabolic analysis revealed that cellular ATP utilization regulates approximately 50% of 
mitochondrial respiration, in contrast to the less than 15% regulation by the actual electron 
transport (Brown et al., 1990). In this study, nicotinamide adenine dinucleotide (NADH) supply 
or concentration (15 – 30%) and proton leak (20%) were suggested as the other regulating 
factors for mitochondrial respiration. Later, a study by Chandel and his coworkers under hypoxic 
conditions demonstrated a control coefficient for NADH concentration similar to the earlier 
study (Chandel et al., 1997). Decreasing cellular ATP consumption is an acute adaptive response 
to hypoxia. Cellular processes that consume ATP, such as Na/K ATPase activity and protein 
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translation, are immediately shut down in response to decreased oxygen (< 5%) (Tormos and 
Chandel, 2010). Prolonged exposure to hypoxia has also been shown to decrease mitochondrial 
oxygen consumption in a time-dependent manner. Hypoxic activation of HIF-1 mediates long-
term adaptive responses to hypoxia, and plays a pivotal role in shaping tumor cell bioenergetics.  
Hypoxia-inducible factor-1 stabilization shifts cellular bioenergetics towards a glycolytic 
phenotype by actively downregulating mitochondrial oxidative phosphorylation and 
simultaneously upregulating glycolytic flux. One of the mechanisms by which HIF-1 
downregulates mitochondrial oxidative phosphorylation is by decreasing the availability of 
pyruvate to the TCA cycle (Kim et al., 2006; Papandreou et al., 2006). The glycolytic end 
product pyruvate is transported across the mitochondrial inner membrane by the pyruvate 
transporters and then decarboxylated to acetyl coenzyme A (AcCoA) by the pyruvate 
dehydrogenase (PDH) complex; the AcCoA then enters into the TCA cycle for further oxidation. 
The enzymatic activity of PDH is inversely proportional to the concentration of AcCoA, NADH 
and ATP. In addition, phosphorylation of the E1 subunit of PDH by pyruvate dehydrogenase 
kinase (PDK) deactivates PDH. Deactivated PDH can be dephosphorylated and subsequently 
reactivated by pyruvate dehydrogenase phosphatase (PDP) (Papandreou et al., 2006; Sugden et 
al., 2003). Pyruvate dehydrogenase kinase-1 was identified as a HIF-1 target gene, and it was 
demonstrated that under hypoxia, the absence of PDK1 in HIF-1−/− lymphoma cells enhanced 
mitochondrial ROS generation and hypoxia-induced cell death. In an independent study, 
exposure to prolonged hypoxia demonstrated decreased cellular oxygen consumption in a PDK1-
dependent manner (Papandreou et al., 2006). These results indicate that one of the mechanisms 
of HIF-1 mediated adaptation of cellular bioenergetics is by induction of PDK1. 
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 Activated HIF-1 can reduce the cellular mitochondrial content by inhibiting 
mitochondrial biogenesis via repression of c-Myc activity and induction of BNIP3-mediated 
mitophagy. The HIF-induced mitophagy and repression of mitochondrial biogenesis provide a 
selective advantage to hypoxic cells by preventing the lethal mitochondrial ROS generation 
under hypoxia (Zhang et al., 2007; Zhang et al., 2008). 
 Complementary to the effect of hypoxic conditions on PDK1 induction, HIF-1 activates 
conversion of pyruvate to lactate, in order to shunt pyruvate away from mitochondrial 
metabolism. Lactate dehydrogenase is an enzyme that converts pyruvate to lactate. Lactate 
dehydrogenase type 5 (LDH-5 or LDH-A, that consists of four LDH-A subunits) is a HIF-1 
target gene (Semenza et al., 1994). Hypoxia-inducible factor-1 also activates the gene MCT4, 
which encodes a plasma membrane lactate transporter to facilitate lactate efflux from the cell 
(Ullah et al., 2006). 
 Apart from the aforementioned modifications to mitochondrial metabolism, HIF-1 is 
responsible for modifying the mitochondrial respiratory complex structure and function. Under 
hypoxia, the composition of mitochondrial complex IV changes in a HIF-1-dependent manner. 
Mitochondrial complex IV (Cytochrome c oxidase, COX) consists of 13 subunits, and subunit 4 
(COX4) performs a regulatory role by mediating ATP-induced allosteric COX inhibition 
(Napiwotzki and Kadenbach, 1998). Under hypoxic conditions, HIF-1 mediates the substitution 
of COX4 isoform 1 (COX4-1) by COX4 isoform 2 (COX4-2) in vitro. The COX4-1 isoform 
substitution enhances COX oxygen utilization efficiency, and represents an adaptive response to 
hypoxia (Fukuda et al., 2007). Complex I inhibition by HIF-1 was observed in an in vitro model. 
Hypoxia induces NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 4-like 2 
(NDUFA4L2), a HIF-1 target protein, which shares a 65% homology with NDUFA4, a subunit 
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of complex I.  Under hypoxia (1% O2), silencing of NDUFA4L2 prevents a decrease in 
mitochondrial complex I activity, causes an increase in mitochondrial oxygen consumption, and 
decreases the cell viability. The exact mechanism by which NDUFA4L2 inhibits complex I 
activity is not clear. However, within 24 h of hypoxia, a decrease in NDUFA4 and an increase in 
NDUFA4L2 levels were observed. It was proposed that these proteins may be independently 
regulated (Tello et al., 2007).  
 Chan and coworkers showed that mitochondrial oxidative metabolism could be 
suppressed by a HIF-1-induced microRNA miR-210. Induction of miR-210 prevents the 
assembly of iron-sulfur cluster assembly proteins ISCU1 and ISCU2 (Chan et al., 2009). Iron 
sulfur cluster assembly proteins 1 and 2 are responsible for the assembly of prosthetic groups 
that facilitate electron transfer and redox reactions at the respiratory complexes. However, in this 
study the relatively low oxygen concentration of 0.2% was used. 
 While mitochondrial oxidative metabolism is downregulated, glycolytic flux is 
upregulated by HIF-1 via an increase in glucose catabolising enzymes (Semenza et al., 1994). 
Tumor cells show enhanced glucose uptake and an increased expression of specific glucose 
transporter isoforms, namely glucose transporter type 1 (GLUT1) and glucose transporter type 3 
(GLUT3) (Macheda et al., 2005). The enhanced expression of glucose transporters (GLUT1 and 
GLUT3) is mediated by HIF-1 (Macheda et al., 2005). Activation of HIF-1 enhances tumor-
specific expression of glycolytic enzyme isoforms, such as hexokinase I and II (HKI and HKII), 
phosphofructokinase L (PFKL), aldolase A (ALDA), enolase 1 (ENO1), phosphoglycerate 
kinase 1 (PGK1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate kinase 
muscle isozyme (PKM2), and LDH-A (Semenza et al., 1994; Semenza, 2012; Higashimura et 
al., 2011). Apart from these glycolytic enzymes, HIF-1 also regulates the glycolysis-associated 
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enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-3 (PFKBF3). This bifunctional 
enzyme is responsible for fructose-2,6-bisphosphate (F2,6BP) synthesis; F2,6BP acts as a potent 
PFK1 activator. Because PFK1 catalyzes the first control of flux reaction in the glycolysis 
pathway, activation of PFK1 results in increased glycolytic flux. In addition, PFKBF3 also 
diverts fructose-6-phosphate (F6P) to the pentose phosphate pathway (PPP) for synthesis of 5-
phosphoribosyl-1-pyrophosphate (precursor for nucleic acid biosynthesis). The enzyme PFKBF3 
is reported to be constitutively active in human cancer cell lines and serves as one of the 
contributors to the aerobic glycolysis (Warburg effect) (Minchenko et al., 2002). In addition, 
HIF-1 mediates the PPP enzyme transketolase upregulation (Zhao et al., 2010). Luo and 
coworkers recently discovered a novel role for PKM2 in metabolic reprogramming (Luo et al., 
2011). Independent of its enzymatic activity, PKM2 acts as a HIF-1 coactivator, and enhances 
the expression of HIF-1 downstream targets, such as VEGF. Prolyl hydroxylation enhances the 
coactivator activity of PKM2. Because PKM2 is a HIF-1 target gene, PKM2 can create a positive 
feedback response that alters tumor cell bioenergetics (Luo et al., 2011). Taken together HIF-1 
alters tumor cell bioenergetics, and imparts a highly glycolytic tumor cell phenotype which is 
crucial for cellular survival and proliferation under hypoxic conditions. 
 
1.1.7 Downregulation of HIF-1α by natural product small-molecules that inhibits cellular 
bioenergetic pathways  
Inhibition of HIF-1 activation is a valid and attractive antitumor molecular target (Nagle 
and Zhou, 2011). Efforts to discover clinically useful natural product or synthetic small-
molecules that target HIF-1 or its downstream effectors (e.g., PDK1, LDH-A, and HK) have 
been undertaken by several antitumor drug discovery groups (Narita et al., 2009; Lin et al., 
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2008; Bobkova et al., 2010; Xu et al., 2009; Kalusmeyer et al., 2007; Ward et al., 2012; Vander 
Heiden et al., 2010). Natural product-derived small-molecules that have been shown to inhibit 
the cellular bioenergetic pathways (glycolysis and mitochondrial ETC) and affect HIF-1 activity, 
will be briefly discussed. In an effort to discover chemically and mechanistically novel HIF-1 
inhibitors, the molecular-targeted antitumor drug discovery group at the University of 
Mississippi has screened more than 60,000 natural product-rich extracts from plants and marine 
invertebrates (NCI Open Repository Program) in a T47D human breast tumor cell-based reporter 
assay system. A number of the HIF-1α inhibitors recently identified by this group are molecules 
that interfere with mitochondrial complex I or uncouple oxidative phosphorylation (Mohammed 
et al., 2004; Liu et al., 2009a; Mao et al., 2009; Liu et al., 2009b; Coothankandaswamy et al., 
2010; Morgan et al., 2010; Du et al., 2010; Du et al., 2011; Mahdi et al., 2011, Li et al., 2011). 
The first compound that was identified to inhibit mitochondrial respiration by this group was 
laurenditerpenol (7) (Mohammed et al., 2004). This algal-derived diterpene-type compound 
potently (IC50 0.4 µM) inhibited hypoxic (1% O2) HIF-1 activation in a human breast tumor 
T47D cell-based luciferase reporter assay system. Laurenditerpenol inhibits mitochondrial 
complex I in isolated mouse liver mitochondria (Mohammed et al., 2004). Subsequently, the 
marine sponge-derived compound furospongolide (8) inhibited hypoxia-induced HIF-1 (IC50 2.9 
µM, T47D) activation by suppressing cellular respiration at mitochondrial complex I (Liu et al., 
2008). The plant metabolite 4'-O-methylalpinumisoflavone (9) was the first mitochondrial 
inhibitor identified by this group from Lonchocarpus glabrescens Benth. (Fabaceae), and was 
reported to inhibit hypoxic HIF-1 activation (IC50 0.6 µM) by simultaneous inhibition of 
mitochondrial complex I and mammalian protein translation (Liu et al., 2009a). Numerous other 
natural product small-molecules that inhibited mitochondrial complex I in cell-based assays were 
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identified by the Nagle/Zhou group. These mitochondriotoxic compounds from plants and 
marine invertebrates preferentially abolished HIF-1 activation under hypoxic conditions. These 
include mycalenitrile-6 (10) (Mao et al., 2009), mycalenitrile-7 (11) (Mao et al., 2009), caulerpin 
(12) (Liu et al., 2009b), manassantin A (13) (Hossain et al., 2005), manassantin B (14) (Hodges 
et al., 2004), 4-O-methylsaucerneol (15) (Hossain et al., 2005), thyrsiferol (16) (Mahdi et al., 
2011),  mycothiazole (17) (Morgan et al., 2010), 10-hydroxyglaucanetin (18) 
(Coothankandaswamy et al., 2010), annonacin (19) (Coothankandaswamy et al., 2010), 
annonacin A (20) (Coothankandaswamy et al., 2010), skimmiarepin A (21) (Li et al., 2011) and 
skimmiarepin C (22) (Li et al., 2011) (Figures 1.4 – 1.5). Among these, 13 and 14 were the most 
potent complex I inhibitors (IC50 0.003 µM) discovered by this group. Skimmiarepin A (21) 
inhibits the initiation and elongation steps of protein translation in T47D and MDA-MB-231 
breast cancer cells by eIF2α and eEF2 hyperphosphorylation in a mitochondrial complex I 
inhibition-dependent manner (Li et al., 2011). Hypoxia-induced and iron chelator-induced HIF-1 
activation is inhibited by protonophoric compounds or uncouplers of oxidative phosphorylation. 
Fifteen isoprenylated dihydroxycoumarins that inhibit HIF-1 by this mechanism were identified 
(Du et al., 2011). Among these, mammea E/BB [IC50 0.96 µM, 1% O2, 16 h, T47D] (23), 
mammea F/BA [IC50 1.72 µM, 1% O2, 16 h, T47D] (24), and mammea F/BB1 [IC50 2.23 µM, 1% 
O2, 16 h, T47D] (25) were the most potent ones (Du et al., 2011) (Figure 1.7). The mechanisms 
for HIF-1 inhibition by uncouplers are not clearly understood. 
Apart from mitochondrial inhibitors, glycolysis inhibitors, such as 2-deoxy-D-glucose 
[2DG] (26) and sodium iodoacetate (27) (Figure 1.7), inhibit HIF-1α protein accumulation in 
response to hypoxia (0.1% O2) in HT-1080 human fibrosarcoma cells (Staab et al., 2007). 
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Glycolysis inhibitors also produced a dose-dependent decrease of HIF-1α accumulation in 
hypoxic (< 0.1% O2) HEK293 cells (Zhou et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Natural products that inhibit mitochondrial complex I and thereby inhibit HIF-1 
activation. 
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Figure 1.6 Natural products that inhibit mitochondrial complex I and thereby inhibit HIF-1 
activation. 
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Figure 1.7 Natural products that uncouple oxidative phosphorylation and thereby inhibit HIF-1 
activation. 
 
 
                                                        
 
Figure 1.8 Small-molecules that inhibit HIF-1 via inhibition of glycolysis. 
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1.2 Cellular bioenergetic pathways 
1.2.1 Glycolysis 
 Mammalian cells generate energy required for cellular reactions by catabolizing glucose 
(Lehninger et al., 2005). This process known as glycolysis occurs by a cascade of enzymatic 
reactions. Because glucose is a highly hydrophilic molecule, specialized glucose transporters 
(GLUTs) are required for cellular glucose uptake. The glycolytic reactions can be grouped into 
two phases: (a) the reactions that use ATP or the preparatory phase and (b) the reactions that 
generate ATP or the payoff phase. The preparatory phase consists of five reactions that convert 
one hexose molecule (glucose) into two triose molecules (glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate). Together, these reactions consume two molecules of ATP. Each 
glyceraldehyde-3-phosphate molecule is then converted to pyruvate by another series of 
reactions, generating two ATP molecules (Lehninger et al., 2005) (Figure 1.9). 
The first step towards glucose oxidation is entrapment of the glucose molecule by 
phosphorylation (Lehninger et al., 2005; Munoz-Pinedo et al., 2012). The enzyme hexokinase 
catalyzes the conversion of glucose to glucose-6-phosphate. Glucose-6-phosphate is then 
converted by hexosephosphate isomerase to F6P. Fructose-6-phosphate can subsequently be 
phosphorylated either at position-1 or position-2, generating either F1,6BP or F2,6BP. The 
conversion of F6P to F1,6BP is the first committed step in glycolysis. The F2,6BP molecule 
generated in this step is not further processed by the glycolytic pathway. Rather, F2,6BP is used 
by PPP to generate nucleic acid precursors. However, F2,6BP plays a critical role in glycolysis 
regulation, by potently activating PFK. The enzyme PFK catalyzes the conversion of F6P to 
F1,6BP.  Thus, increased F2,6BP levels can maintain a high cellular glycolysis rate. The F1,6BP 
is cleaved by aldolase to generate one molecule of glyceraldehyde-3-phosphate and one molecule 
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of dihydroxyacetone phosphate. Subsequently, the dihydroxyacetone phosphate molecule is 
converted to glyceraldehyde-3-phosphate by triosephosphate isomerase. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) converts glyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate with generation of NADH from NAD+. Pyruvate is generated from 1,3-
bisphosphoglycerate in four steps, generating two ATP molecules. Depending on the oxygen 
availability and/or pathological state of the cell, the pyruvate is either transported to the 
mitochondria where it enters the TCA cycle (after conversion to acetyl-CoA); or it can be 
converted into lactate (Figure 1.9) (Lehninger et al., 2005; Munoz-Pinedo et al., 2012). 
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Figure 1.9 The glycolysis pathway and its inhibitors. (Munoz-Pinedo, C. et al. Cell Death Dis. 
2012, 3, e248.) Glut: Glucose transporter; MCT: monocarboxylate transporter; G6P: Glucose-6-
phosphate; F6P: fructose-6-phosphate; F1,6BP: fructose-1,6-bisphosphate; F2,6BP: fructose-2,6-
bisphosphate; DHAP: dihydroxyacetone phosphate; GA3P: Glyceraldehyde-3-phosphate; 1,3-
BPG: 1,3-bisphosphoglycerate; 3-PGA: 3-phosphoglycerate; 2-PG: 2-phosphoglycerate; PEP: 
phosphoenolpyruvate; HK: hexokinase; PGI: phosphoglucoisomerase; PFK: 
phosphofructokinase; TPI: triose phosphate isomerase; GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase; PGK: phosphoglycerate kinase; PGAM: phosphoglycerate mutase; ENO1: 
enolase 1; PK: pyruvate kinase; LDH: lactate dehydrogenase; 2-DG: 2-deoxy-D-Glucose; LND: 
lonidamine; 3BrPA: 3-bromopyruvate, KA: koningic Acid; TLN-232 is a synthetic cyclic 
heptapeptide which targets PK; DCA: dichloroacetate 
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1.2.2 Oxidative phosphorylation 
 
 Transfer of an electron pair to either complex I or complex II of the respiratory chain 
initiate the process of oxidative phosphorylation. Complex I (NADH:ubiquinone oxidoreductase 
or NADH dehydrogenase) is one of the entry points into the electron transport chain (Lehninger 
et al., 2005; Nicholls and Ferguson, 2002; Suski et al., 2011). Complex I is a large ‘L’ shaped, 
membrane bound enzyme complex that contains 45 subunits eight of which are iron-sulfur 
proteins. Complex I is comprised of a peripheral portion that extends to the mitochondrial matrix 
(cytoplasm in case of bacteria) and a membrane-embedded component (Lehninger et al., 2005; 
Nicholls and Ferguson, 2002).  The NADH molecules generated during glycolysis or from the 
TCA cycle interact with the peripheral arm of complex I and transfers electrons to the subunit 
that possesses flavin mononucleotide as a prosthetic group. Subsequently, the electrons are 
transferred through eight iron-sulfur proteins and ultimately delivered to ubiquinone (Q) by the 
N2 iron-sulfur cluster. Complete reduction of ubiquinone is mediated through formation of an 
ubisemiquinone molecule, since the N2 iron-sulfur cluster delivers the electron pair in two steps. 
During this process of electron movement, four protons are extruded in the intramembrane space, 
resulting in a proton pumping stoichiometry of 4H+/2e−. The ubiquinol molecule shuttles the 
electrons to complex III (ubiquinone:cytochrome c oxidoreductase or cytochrome bc1 complex) 
by diffusion through the mitochondrial inner membrane lipid bilayer. Mitochondrial complex I 
inhibitors like rotenone (2) and piericidin A (28) (Figure 1.11) inhibit the transfer of electrons 
from the iron-sulfur proteins to ubiquinone. 
 Three other enzymes may reduce ubiquinone and initiate oxidative phosphorylation 
(Lehninger et al., 2005; Nicholls and Ferguson, 2002). Mitochondrial complex II (succinate 
dehydrogenase) oxidizes succinate to fumarate and transfers two electrons to ubiquinone. 
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Electrons from succinate are rapidly transferred through flavin adenine dinucleotide (FAD) and 
three iron-sulfur proteins, before they are accepted by ubiquinone. No proton translocation takes 
place during mitochondrial complex II electron movement. 
 Apart from complexes I and II, electrons can be donated to ubiquinone by electron-
transferring flavoproteins (ETF): ubiquinone oxidoreductase and s,n-glycerophosphate 
dehydrogenase (Lehninger et al., 2005; Nicholls and Ferguson, 2002). Both of these contain one 
FAD and one iron-sulfur cluster, and are attached to the inner mitochondrial membrane. 
However, the former is attached to the matrix side of the mitochondria, while the latter is 
attached to the cytosolic side. The ubiquinol molecules generated in complexes I and II or in 
either of these proteins, translocate to complex III. 
 The cytochrome bc1 complex known as complex III (ubiquinol:cytochrome c 
oxidoreductase) oxidizes the reduced ubiquinol through the Q cycle (previously described, 
Figure 1.3) (Lehninger et al., 2005; Nicholls and Ferguson, 2002). Complex III structural 
features involved in the electron transfer process include cytochrome b, cytochrome c1, and the 
Rieske protein (iron-sulfur protein). The final electron acceptor in this step is the single-electron 
carrier cytochrome c, which shuttles the electrons to complex IV (cytochrome c oxidase). During 
the electron transfer process, two protons per electron (or 4H+ per 2e−) are extruded into the 
intermembrane space. 
 Mitochondrial complex IV carries out oxygen reduction, the final step of the electron 
transport process (Lehninger et al., 2005; Nicholls and Ferguson, 2002). Cytochrome c initially 
transfers an electron to one of the copper centers (CuA); the electron is subsequently transferred 
through cytochrome a, cytochrome a3, and a second copper center (CuB), in that order, before it 
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is accepted by the molecular oxygen. Translocation of one proton to the intermembrane space 
occurs for each electron transported through complex IV.  
 The protonmotive force generated by extrusion of protons into the intermembrane space 
is utilized by the mammalian F0F1-ATP synthase enzyme to generate ATP (Lehninger et al., 
2005; Nicholls and Ferguson, 2002; Suski et al., 2011). This enzyme channels the passive 
reentry of protons into the mitochondrial matrix and couples the process of energy generation 
with the electron transport. For every three protons reentering the mitochondrial matrix, one ATP 
molecule is generated and released into the matrix. In the absence of sufficient protonmotive 
force, F0F1-ATP synthase enzyme acts as an ATPase and pumps protons into the intermembrane 
space in order to maintain the protonmotive force. Since the phosphorylation of ADP is coupled 
to oxygen reduction, this process is known as oxidative phosphorylation (Figure 1.10). 
 
 
Figure 1.10 Mitochondrial electron transport chain and oxidative phosphorylation. Reproduced 
with permission from Dr. Dale G. Nagle (Nagle and Zhou, 2010).
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1.3 Natural product mitochondriotoxic small molecules  
 
Though mitochondrial inhibitors are valuable antitumor leads, exposure to 
mitochondriotoxic agents may lead to idiosyncratic toxicity. Over the past decade, it has become 
increasingly apparent that some of the FDA approved drugs have unexpected toxicity because of 
their effects on the mitochondria. The role of mitochondrial impairment in drug toxicity has 
gained considerable attention (Dykens and Will, 2007). Aerobically poised tissues with a high 
mitochondrial dependence, and tissues exposed to high drug concentrations (e.g., liver) are 
commonly affected by drug-induced mitochondrial dysfunction (Wallace, 2008; Labbe et al., 
2008). The most common manifestation of drug-induced mitochondrial impairment is 
hepatotoxicity (Sanchez et al., 2006). Other major symptoms include cardiotoxicity, 
nephrotoxicity, neuropathy, skeletal myopathy, retinopathy, ototoxicity, hepatic steatosis, and 
hematotoxicity (Haller and Benowitz, 2000; Gabardi et al., 2007; Palmer et al., 2003). Typically, 
chronic use of these drugs leads to mitochondria-mediated toxicity, because a threshold level of 
cellular mitochondrial dysfunction is required to trigger cell collapse and tissue injury (Scatena 
et al., 2007). However, high doses of certain drugs [e.g., acetaminophen] are capable of inflicting 
acute liver injury and hepatic failure (Chun et al., 2009). 
Every year, numerous new drug applications are denied, and a small percentage (2 – 3%) 
of clinically approved drugs is withdrawn from the market due to adverse effects. Most drugs 
with FDA Black Box Warnings for hepatotoxicity and cardiotoxicity are known mitochondrial 
poisons (Dykens and Will, 2007). 
Apart from the clinically approved drugs, many small-molecule natural products have 
been reported to cause mitochondrial dysfunction in experimental settings (Nagle and Zhou, 
2012). The most common mechanisms for mitochondrial dysfunction following an exposure to 
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drugs or natural phytohemicals/environmental toxins are: (a) inhibition of oxidative 
phosphorylation and (b) uncoupling of oxidative phosphorylation (Scatena et al. 2007). 
Inhibition of oxidative phosphorylation may occur at any of the electron transport chain 
(ETC) protein complexes (complexes I to IV) or at the F0F1-ATP synthase (aka complex V). 
Mitochondrial ETC complex I (NADH-ubiquinone oxidoreductase) is the most common target 
of small-molecule inhibitors (Degli Esposti, 1998). The simplistic structural feature for complex 
I inhibition is a cyclic head and a hydrophobic tail (Degli Esposti, 1998; Wallace, 2008). More 
than 60 classes of compounds have demonstrated complex I inhibitory activity (Wallace, 2008). 
The previously discussed group of natural products 2 and 7 – 22, inhibit mitochondrial complex I 
and subsequently inhibit HIF-1 activation. Natural products that inhibit complex I can be broadly 
categorized into six groups; (a) rotenoids, (b) piericidins, (c) annonaceous acetogenins, (d) 
antibiotics, (e) vanilloids, and (f) miscellaneous plant products (Degli Esposti, 1998). This 
classification is somewhat arbitrary, and according to this classification most of the earlier 
mentioned complex I inhibitors fall into the rotenoid, acetogenin, and miscellaneous categories.  
 Among the natural products, rotenone (2) was isolated from a variety of plants from the 
Fabaceae family (Jiang et al., 2012; Kamal and Mathur, 2010; Liu et al., 2009a; Mai et al., 2010; 
Cao et al., 2004). Rotenone is a well-studied complex I inhibitor that is the prototype for the 
rotenoid class of mitochondrial inhibitors. Rotenone is used as a natural insecticide, fish toxin 
and it is routinely used as a pharmacological/molecular probe in mitochondrial mechanistic 
studies (Radad et al., 2006; Liu et al., 2009a). Deguelin (29) (Figure 1.11) is another rotenoid 
that is produced by the African terrestrial plant Mundulea sericea (Willd.) A. Chev. 
(Leguminosae). Deguelin is a potent complex I inhibitor that is used as a pesticide (Clark, 1931).  
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Piericidin A (28) is a Streptomyces sp.-derived antibiotic that inhibits mammalian and 
bacterial NADH:ubiquinone oxidoreductase (Tamura et al., 1963). It is believed to inhibit 
ubiquinone reduction by preventing access of ubiquinone to the ubiquinone-binding site 
(Friedrich et al., 1994).  
 Annonaceous acetogenins are a group of natural product small-molecules, which are 
isolated from plants belonging to the family Annonaceae. The complex I inhibitory properties of 
acetogenins have been widely studied (McLaughlin, 2008). They have been shown to inhibit 
complex I at nanomolar concentrations, in various experimental models that include bovine heart 
mitochondria, bovine submitochondrial particles, and human cell lines. More than 350 
anonaceous acetogenins from 37 species have been identified from 1982 to 1998 (Alali et al., 
1999). Some of the representative compounds from this group include bullatacin (30), uvaricin 
(31), diepomuricanin B (32), and muconin (33) (McLaughlin, 2008; Alali et al., 1999).  
 Structurally diverse compounds from higher plants have also been shown to inhibit 
mitochondrial complex I. Many plant alkaloids are known mitochondrial toxins. The plant 
alkaloid berberine (34), inhibits complex I in rat skeletal muscle cells (IC50 15 µM) (Turner et 
al., 2008). The opium alkaloid papaverine (35) inhibits state 3 respiration at complex I in isolated 
mouse-brain mitochondria (IC50 6.45 µM) (Morikawa et al., 1996). Another group of 
phytochemicals which has shown to interfere with mitochondrial complex I activity are the 
flavonoids. Some of the flavonoids that inhibit complex I enzymatic activity include quercetin 
(36), kaempferol (37), and apigenin (38) (Lagoa et al., 2011).  
 Several antibiotics specifically inhibit mitochondrial complex I, these include phenoxan 
(39), thiangazole (40), aureothin (41), and cochlioquinone B (42) (Friedrich et al., 1994; Lim et 
al., 1996). Cinnamaldehyde (43) (Usta et al., 2002), acrolein (44) (Sun et al., 2006), eugenol (45) 
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(Usta et al., 2002; Cotmore et al., 1979), 2',4'-dihidroxy-5'-(1'''-dimethylallyl)-6-
prenylpinocembrin (6PP, 46) (Elingold et al., 2008), and 4,20-dideoxyphorbol-12,13-
bis(isobutyrate) (47) disrupt complex I activity (Betancur-Galvis et al., 2003). Apart from 
complex I inhibition, 44 and 45 inhibit complex II and uncouple oxidative phosphorylation, 
respectively (Sun et al., 2006; Cotmore et al., 1979).  
 Specific complex II (succinate dehydrogenase) inhibition by xenobiotics is uncommon 
relative to the inhibition of other complexes. Chloramphenicol succinate (48) (Ambekar et al., 
2004), surangin B (49) (Deng and Nicholson, 2005), siccanin (50) (Mogi et al., 2009), and 
doxorubicin (51) (Marcillat, 1989) inhibit complex II activity. Acrolein and surangin B have 
been shown to inhibit other respiratory complexes too (Sun et al., 2006; Deng and Nicholson, 
2005). 
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Figure 1.11 Natural products that inhibit mitochondrial complex I (NADH:ubiquinone 
oxidoreductase). 
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Figure 1.12 Natural products that inhibit mitochondrial complex I (NADH:ubiquinone 
oxidoreductase). 
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Figure 1.13 Natural products that inhibit mitochondrial complex II (succinate dehydrogenase). 
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Mitochondrial complex III (cytochrome bc1-complex, ubiquinol:cytochrome c 
oxidoreductase) is a major site for inhibition by small-molecules (Thierbach and Reichenbach, 
1981; Von Jagow et al., 1986; Bell et al., 2007; Brandt et al., 1988). Inhibition of complex III 
often produces significant toxicity. Hence, molecules that inhibit complex III are devoid of 
clinical utility. Natural product-derived quinol antagonists, such as myxothiazol (4) (Thierbach 
and Reichenbach, 1981), strobilurin A (52) (Von Jagow et al., 1986), stigmatellin (5) (Bell et al., 
2007), and oudemansin (53) (Brandt et al., 1988), inhibit complex III at the Qo site by blocking 
the oxidation of ubiquinol to ubiquinone. Compounds that contain a 6-hydroxyquinone moiety 
inhibit the transfer of electron between the Rieske protein and cytochrome c1 (Von Jagow and 
Link 1986). 
The complex III inhibitor, antimycin A (6), blocks electron transfer at the Qi center 
(Chandel et al., 1998). Together with funiculosin (54), the Qi center inhibitors comprise a third 
group of the complex III inhibitors (Von Jagow and Link, 1986). However, certain complex III 
inhibitors, such as myxothiazol (4) and stigmatellin (5) also inhibit complex I at higher 
concentrations (Degli Esposti et al., 1993). Sorgoleone (55), a benzoquinone derivative, inhibits 
plant mitochondria at complex III (Rasmussen et al., 1992). Rubratoxin B (56) (Hayes, 1976), 
lamellarin D (57) (Ballot et al., 2010), and polyalthidin (58) (Zafra-Polo et al., 1996) also inhibit 
complex III. 
 Natural product complex IV inhibitors are rare. The xanthone α-mangostin (59) inhibits 
mitochondrial complex IV and reduces oxygen consumption rates under state 3 respiration 
conditions. However, 59 increases state 4 respiration most likely by uncoupling oxidative 
phosphorylation (Martinez-Abundis et al., 2010). Cyanides or azides are used to inhibit complex 
IV in mitochondrial mechanistic studies. 
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Figure 1.14 Natural products that inhibit mitochondrial complex III (coenzyme Q:cytochrome c 
oxidoreductase) (52 – 58) and complex IV (cytochrome c oxidase) (59). 
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 The F0F1-ATP synthase generates ATP in the mitochondria and is also known as complex 
V. Several antibiotics potently inhibit this enzyme. Some of the macrolide natural products that 
inhibit F0F1-ATP synthase are apoptolidin (60) (Salomon et al., 2001), the oligomycins 
(oligomycin A, 61) (Linnett and Beechey, 1979), aurovertin B (62) (Gledhill and Walker, 2006), 
venturicidin A (63) (Matsuno-Yagi and Hatefi, 1993), ossamycin (64), and cytovaricin (65) 
(Salomon et al., 2000). Polyphenols bind to and inhibit mammalian F0F1-ATP synthase. Notable 
polyphenols that inhibit the enzymatic activity are resveratrol (66), piceatannol (67), quercetin 
(36), and epigallocatechin gallate (68) (Gledhill et al., 2007). Cruentaren A (69), a benzolactone, 
has been reported to inhibit F0F1-ATP synthase at low nanomolar concentrations by binding to 
the catalytic F1-subunit of the enzyme (Kunze et al., 2007). 
Protonophores uncouple oxidative phosphorylation by shuttling protons directly across 
the mitochondrial inner membrane to the mitochondrial matrix, and dissipate the mitochondrial 
membrane potential (Kessler et al., 1977). Thereby, uncouplers disrupt ATP synthesis by 
preventing proton channeling through the F0F1-ATP synthase. In order to maintain the 
mitochondrial membrane potential, the F0F1-ATP synthase starts hydrolyzing ATP and pumping 
protons into the intermembrane space, which can leads to cellular ATP depletion, and subsequent 
cytotoxicity (Das, 1998). 
 Usnic acid (70) is a popular lichen-derived dietary weight-loss supplement in the US 
(Sanchez et al., 2006). Usnic acid and the other lichen metabolite, vulpinic acid (71), potently 
uncouple isolated mice-liver mitochondria (Abo-Khatwa et al., 1996). Steviobiosides are natural 
product small-molecules from Stevia rebaudiana (Bertoni) (Asteraceae) that are used as natural 
sweeteners (Goyal et al., 2010). Isosteviol (72), obtained by stevioside acid hydrolysis, potently 
uncouples oxidative phosphorylation (Kelmer Bracht et al., 1985). Natural products, such as 
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rottlerin (73) (Soltoff, 2001), juglone (74) (Sailing et al., 2011), Δ9-tetrahydrocannabinol (75) 
(Sarafian et al., 2003), ferulenol (76) (Nadia et al., 2009), desaspidin (77) (Runeberg, 1962), and 
ochratoxin (78) (Wei et al., 1985), uncouple mitochondrial oxidative phosphorylation. Recently 
the three isocoumarins paepalantine (79), paepalantine-8,8'-dimer (80), and vioxanthin (81) that 
are produced by Paepalanthus bromelioides (Silveira) (Eriocaulaceae) have been identified as 
mitochondrial uncouplers (Calgaro-Helena et al., 2006). 
 Apart from purified compounds with well-defined mechanisms of action, several plant-
derived extracts and dietary supplement products disrupt mitochondrial electron transport or 
uncouple oxidative phosphorylation. The extract of Phyllanthus urinaria Linn. (Euphorbaceae) 
has been shown to exert a biphasic effect on isolated rat-liver mitochondria. Phyllanthus urinaria 
extract was reported to stimulate state 4 respiration but inhibits state 3 respiration at 500 µg/mL 
(Chudapongse et al., 2010). An extract of Cynara scolymus Linn.  (Asteraceae) was reported to 
inhibit more than one mitochondrial respiratory complex (Juzyszyn et al., 2010). Interestingly, a 
mixture of β-carotene cleavage products inhibited mitochondrial respiration (Siems et al., 2002). 
It was proposed that the inhibition of adenine nucleotide transporter was responsible for this 
effect. 
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Figure 1.15 Natural product small-molecules that inhibit mitochondrial F0F1-ATP synthase. 
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Figure 1.16 Natural product small-molecules that inhibit mitochondrial F0F1-ATP synthase. 
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Figure 1.17 Natural product small-molecules that uncouple oxidative phosphorylation. 
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1.4 Conclusions 
 
The contemporary oncology drug discovery process is increasingly focusing toward 
molecular-targeted approaches. Identification of molecular targets and HTS lead generation are 
at the core of this process. Molecular-targeted drug discovery approach has found only limited 
success in the generation of new therapeutic agents (e.g., tamoxifen, Gleevec®, and Velcade®). In 
order to increase the success rate of molecular-targeted antitumor drug discovery, the selection of 
a valid molecular target, a robust assay system and an appropriate endpoint are essential. 
Hypoxia-inducible factor-1 is a valid antitumor target in oncology research. Agents that inhibit 
HIF-1 are currently in clinical trials (e.g., topotecan, EZN-2968, and dutasteride). Natural 
products are extensively used in current antitumor therapies. Efforts to develop clinically useful 
HIF-1 inhibitors from natural products are underway (Onnis et al., 2009). 
As a transcription factor, HIF-1 controls expression of genes that modulate cellular 
metabolism and bioenergetics. It has been hypothesized that HIF-1 induces aerobic glycolysis by 
actively downregulating mitochondrial oxidative metabolism and upregulating glycolytic 
enzyme activities. Tumor cell metabolism, especially glycolysis, is an emerging target for 
antitumor therapy. In addition, mitochondria-targeted agents are also being evaluated as possible 
antitumor leads. Indeed, disruption of cellular bioenergetics by mitochondrial ETC inhibitors, 
uncouplers, and glycolysis inhibitors suppress HIF-1 activation. The inhibition of HIF-1 makes 
tumor cells more susceptible to the existing chemotherapy (Song et al., 2006; Chang et al., 2006; 
Moeller et al., 2005; Schwartz et al., 2009). In spite of the association between enhanced 
glycolytic metabolism and poor prognosis/advanced disease stage, there has only been limited 
effort to discover glycolysis inhibitors. 
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Mitochondrial inhibitors can be valuable antitumor leads, but toxic effects from off-target 
mitochondrial ETC inhibition may be observed in healthy individuals. This is exemplified by the 
fact that several clinically approved drugs (e.g., troglitazone and cerivastatin) (Dykens and Will, 
2007) have been withdrawn from the market due to their off-target mitochondrial effects. The 
possibility of idiosyncratic adverse effects from botanical dietary supplements may be 
underestimated relative to synthetic drugs, especially because natural products are becoming 
more recognized as a major source of mitochondrial toxins. Identification of mitochondrial 
toxins from botanical dietary supplements can facilitate better understanding the mechanisms 
responsible for the adverse effects associated with botanical dietary supplement (BDS) products 
and the possible withdrawal of potentially toxic supplements from the market. 
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CHAPTER II 
COMPARATIVE EVALUATION OF CHROMATOGRAPHIC MEDIA IN 
MOLECULAR-TARGETED ANTITUMOR DRUG DISCOVERY 
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2.1 Overview 
2.1.1 Introduction 
 Natural products and natural product-rich extracts have been extensively used for 
medicinal purposes in traditional medicinal systems worldwide (Harvey, 2008). Numerous 
natural product-based drugs have become available in the clinic for disease treatment and 
management over the past 30 years (Newman and Cragg, 2012). Most preliminary drug 
discovery efforts screen natural product-rich extracts or purified compounds for specific 
bioactivities in vitro. Once an extract is identified as an ‘active’ or a hit in the molecular-targeted 
bioassay, the extract is subjected to chromatographic separation to isolate the molecules 
responsible for the bioactivity.  Chromatographic separation can be chemistry-guided or 
bioassay-guided. In the chemistry-guided approach, compounds are isolated in a bioactivity-
blind manner. In the bioassay-guided isolation approach, the fractions are generated and 
evaluated in the molecular-targeted bioassay and only the active fractions are subjected for 
further purification. In both cases, suitable normal or reversed-phase chromatographic media or 
size-exclusion resins (Si gel, diol, C8, C18, Sephadex®LH-20) are used to fractionate the bioactive 
chemical constituents to pure form. The synthetic polymer-based medium DiaionTM HP20SS 
(cross-linked polystyrenic matrix) is an alternative to Si gel or more expensive bonded-phase 
media and size-exclusion resins. A common problem in the natural products drug discovery 
process is poor sample recovery or/and the loss of bioactivity of fraction(s) subsequent to the 
chromatographic separation process. Hence, selection of appropriate chromatographic media for 
each fractionation or purification step is critical for the successful isolation of bioactive 
compounds. However, no report is available that directly evaluates and compares these various 
chromatographic media used for natural product drug discovery. 
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 Hypoxia-inducible factor-1 (HIF-1) has emerged as an important molecular target for 
antitumor drug discovery (Semenza, 2008). A cell-based reporter assay was used to examine a 
library of extracts from the NCI’s Open Repository.  Bioassay-guided isolation had been 
hampered by the prevalence of biologically active, yet chromatographically unstable, extract 
components.  For a comparative evaluation of the chromatographic media, an array of 
chemically diverse extracts was selected as a representative test panel.  Diaion® HP20SS was 
evaluated side-by-side with normal-phase media for the loss of recovery due to irreversible 
binding. Additional recovery by EtOAc and other non-polar solvents added to a typical HP20SS 
elution system was examined. Various solvent fractions from a single column were pooled and 
subjected for TLC to observe any major chemical alterations. Chemical profiles of the individual 
solvent fractions including the final EtOAc elute from HP20SS were examined by TLC. The 
HIF-1 inhibitory activities of the recombined extracts were compared side-by-side with the 
activities of the original extracts to assess the impact of various chromatographic media on the 
HIF-1 inhibitory activity of natural product-rich extracts. 
 
2.1.2 Evaluation of natural products for drug discovery 
 The success of natural products as a source of chemically and mechanistically novel drug 
leads has been unparalleled. In the last three decades, 34% of small-molecules approved by the 
FDA to be used therapeutically were either natural products or were directly derived from them 
(Newman and Cragg, 2012). However, with the invention of high-throughput screening (HTS) 
technologies, the pharmaceutical industry has lost interest in natural products in a shift toward 
the screening of synthetic pure compound libraries as a primary source of new drug leads 
(McChesney et al., 2007). This decline in interest in natural products stems from the much more 
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resource and time intensive nature of traditional extract testing and isolation efforts when 
compared to the rapid HTS and identification of the ‘hits’ from the synthetic pure compound 
libraries. Dereplication of nuisance, ubiquitously active, or previously known compounds present 
in the extracts and potential new molecule structure elucidation problems present major 
challenges with natural product-based drug discovery efforts. Moreover, varying active principle 
potency and abundance in the extracts can add another level of complexity that leads to false 
positives or negatives (Koehn, 2008). Technological advances have helped to promote the 
development of new approaches to overcome some of these challenges. Recent improvements in 
the NMR spectroscopic and mass spectrometric methods have simplified minute sample natural 
product structural elucidation. Advances in screening technologies, such as the quantitative high-
throughput screening (qHTS) approach, is currently used to minimize the generation of false 
positives and negatives (Inglese et al., 2006). However, the generation of chemically diverse 
drug-like screening libraries still remains a limiting step for the success of many drug discovery 
programs (Koehn, 2008). To improve natural product screening library acceptability, 
prefractionated, semipurified and purified natural product libraries are slowly replacing the 
traditional extract-based sample libraries (Bugni et al., 2008a). Both pure compound libraries 
and extract-based libraries are being generated by the National Institutes of Health (NIH) at the 
National Cancer Institute (NCI), but the pharmaceutical industry has shifted away from the use 
of the extracts to focus only on the purified compounds (NIH Molecular Libraries Program: 
pathways to discovery, website accessed on 03/11/2012; Newman and Nagle, personal 
communication, 2008). 
 The University of Mississippi (UM), Department of Pharmacognosy’s Molecular-
Targeted Antitumor Discovery Group runs a HIF-targeted drug discovery program. Hypoxia-
57 
 
inducible factor-1 has been identified as an important potential molecular target in treatment of 
solid tumors (Semenza, 2008). Solid tumors often outgrow the blood vessels that supply them 
with essential oxygen and nutrients. This creates a low oxygen or ‘hypoxic’ environment within 
the tumor mass. Tumor-hypoxia causes activation of an oxygen-sensitive heterodimeric 
transcription factor HIF-1 constituted by an α and a β subunit. Though HIF-1α protein is 
constitutively expressed in the cytosolic compartment of cells, it is rapidly degraded by the 26S 
proteosome with a short half-life (approximately 5 min) under the normoxic conditions (Ke and 
Costa, 2006). However, hypoxic conditions prevent the oxygen-dependent degradation of HIF-
1α and cause HIF-1α stabilization. Stabilized HIF-1α subunit translocates into the nucleus, forms 
a complex with HIF-1β and transcriptionally regulates more than 100 genes that produce an 
overall effect that helps the tumor cells to adapt and survive under hypoxic stress (Sememza and 
Wang, 1992; Semenza, 2008). Activated HIF-1 has been associated with increased 
aggressiveness and resistance to both chemotherapeutic agents and radiation therapy (Tatum et 
al., 2006). To date, there is no approved therapeutic agent that specifically target HIF-1 for 
treatment of cancer. Considerable efforts are underway to discover clinically useful HIF-1 
inhibitors (Onnis et al., 2009). In our laboratory, over 60,000 extracts from the NCI Open 
repository of marine invertebrates and higher plants were evaluated for their abilities to inhibit 
hypoxia-induced HIF-1 activation in a cell-based reporter assay (a molecular-targeted assay for 
antitumor drug discovery). The hits were prioritized and then subjected to confirmatory assays 
and a dereplication process before subjecting them to bioassay-guided isolation. 
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2.1.3 Selection of chromatographic media for bioassay-guided isolation and natural 
products stability studies 
Traditionally a chemistry-based phytochemical approach was used to fractionate, isolate 
and purify the bioactive compounds from natural sources. However, bioassay-guided 
fractionation has found favor as laboratories shifted to an emphasis on the modern molecular-
targeted drug discovery. Following biological evaluation, active extracts are initially fractionated 
into 5-10 fractions which have distinctly different chemical compositions as determined by TLC. 
These fractions are dried and dissolved in an assay-compatible solvent and evaluated in the 
original bioassay system. The steps are repeated until purified compounds are identified that are 
responsible for the observed bioactivity. The bioassay-guided approach has the advantage of 
ignoring the inactive fractions or compound, in favor of active constituents. Appropriate assay 
design can differentiate the cytotoxic compounds from the ‘active’ compounds and increase the 
hit rate with reduced effort. The selection of chromatographic media is a critical step for a 
successful bioassay-guided isolation of active compounds. Exposure to inappropriate 
chromatographic media can cause catalytic degradation or irreversible binding of the compounds 
to the solid phase. This can lead to a loss of bioactivity or the production of artifactual 
compounds. In a bioassay-guided isolation process, inappropriate medium selection in any one of 
the fractionation steps can result in partial or complete loss of bioactivity in the subsequent 
fractions. Routinely used chromatographic media can be broadly classified into normal-phased or 
bonded normal-phased (Si gel, diol), styrene-divinylbenzene polymers and bonded reversed-
phases (C8, C18, phenyl-hexyl). Inexpensive Si gel is often used for initial fractionation of 
extracts by normal-phase separation (Linington et al., 2007). However, Si gel irreversibly binds 
certain natural products and promotes the acid-catalyzed rearrangement or degradation of others. 
59 
 
To overcome this problem, Si gel is often substituted with C8, C18, phenyl-hexyl or diol bonded-
phase media. Among these, C8, C18, and phenyl-hexyl are used for reversed-phase separation and 
provide versatility in the separation process. Diol bonded-phase media is used as a chemically 
less reactive alternative for normal-phase separations where Si gel-like elution properties are 
required. However, large scale usage of these bonded-phase media is often limited by their 
relatively high cost. Diaion HP20SS is a synthetic styrene-divinylbenzene polymer used for 
reversed-phase like separation. It is less reactive, reusable and has emerged as a possible 
substitute for Si gel for mass use (Bugni et al., 2008b). Though HP20SS is more expensive than 
Si gel, it is much more economical than the bonded-phase materials and suitable for repeated 
use. Diaion HP20SS provides an aromatic surface on which aromatic molecules are adsorbed by 
Van der Waal’s forces (Shimizu, 2005). Sephadex® LH-20 is another chromatographic medium 
which is often used in natural product isolation. It is a hydroxypropylated dextran and works 
through gel permeation mechanisms (Seidel, 2005). Our HIF-1 bioassay-guided natural product 
isolation efforts were found to be severely hampered by the loss of bioactivity following routine 
fractionation protocols with Si gel. A variety of chromatographic media are used in the field of 
natural product drug discovery. However, these media have not been subjected to side-by-side 
comparison studies for their advantages/disadvantages in natural product based drug discovery 
efforts. Our objective of this study was to (a) characterize the elution profile of HP20SS; (b) 
compare the potential of various chromatographic media for irreversible binding of natural 
products present in plant extracts; and (c) examine the potential of these alternative media to 
reduce the loss of bioactivity in a typical reporter-based molecular-targeted (HIF-1) bioassay. 
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2.2 Materials and methods 
2.2.1 General Experimental Procedures 
 The TLCs were performed using Merck Si60F254 or Si60RP18F254 plates, visualized under 
UV at 254 nm and heated after spraying with a 10% H2SO4 solution in EtOH. The solvents were 
purchased from Fisher Scientific unless otherwise specified. The Si gel (32-63 μM) was 
purchased from Selecto Scientific and HP20SS ((Diaion 75 -100 μM, Supelco), Diol (50 µM, 
Discovery® Supelco) and Sephadex LH-20 was purchased from Sigma. 
 
2.2.2 Preparation of columns 
 Miniature columns of Si gel, HP20SS, Diol, and Sephadex LH-20, were prepared by 
packing the pasture pipettes (Corning) with each respective chromatographic medium. Each 
column was 7.5 cm long with 0.55 cm internal diameter. The Si gel and diol were activated 
before elution by heating at 110°C for 30 min and then cooling to room temperature immediately 
before packing the columns. The HP20SS columns were washed with EtOAc and then with 
MeOH  prior to the elution of the extracts. 
 
2.2.3 Preparation and elution of extracts 
 Punica granatum L. (Puniaceae) freeze-dried juice, Vaccinium macrocarpon A. 
(Ericaceae) spray-dried juice, P. granatum, Aspalathus linearis (Burm. F) Dahlg. (Fabaceae), 
and Cyclopia intermedia L. (Fabaceae) extracts were kindly provided by Dr. Daneel Ferreira, 
(University of Mississippi, Department of Pharmacognosy). Curcuma longa L. (Zingiberaceae) 
powder (McCormik) was purchased from local store and extracted with several volumes of 
EtOH (500 mL) at 24 hour intervals by maceration at room temperature until the supernatant was 
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almost colorless.   Podophyllum peltatum L. (Berberidaceae) root materials were collected from 
Oxford, Mississippi in the US and stored at -80°C and air dried at 40°C. Dried roots and 
rhizomes of P. peltatum were crushed in a mortar and pestle and extracted with EtOH (500 mL) 
at room temperature by several macerations at 24 hour intervals until the extract was almost 
colorless. Saururus cernuus sec-butanol/water partitionate was prepared previously by Dr. 
Chowdhury Faiz Hossain (Hossain et al., 2005). Briefly, S. cernuus underground parts were 
extracted with CH2Cl2 and MeOH and combined. The combined extract was dissolved in CHCl3 
and partitioned with water. Then the water residue was partitioned with sec-butanol to obtain the 
sec-butanol/water partitionate. Commercially available Asimina triloba dietary supplement 
capsules (Nature’s Sunshine) were purchased and the capsule contents were extracted with 
several volumes of 500 mL CH2Cl2 at room temperature by maceration till the supernatant was 
colorless. The solvent was replaced every 24 hours and the extract was used for the subsequent 
experiments. Citrus reticulata B. (Rutaceae) fruits were purchased from local store and the peels 
were air dried. The dried fruit peels were extracted with several volumes of EtOH until the 
supernatant was almost colorless. The C. reticulata EtOH-extract was used for subsequent 
experiments. All the extracts were dried and stored at -20 °C freezer. 
The dried extracts were first weighed accurately to one-tenth of a milligram in small vials 
and dissolved in EtOH at a concentration of 200 mg/mL. Because not all the extracts were 
completely soluble in EtOH, the partially soluble extracts were first dissolved in a small amount 
of a water-EtOH (50:50) mixture and then diluted with EtOH to get the target concentration. The 
columns were loaded with the stock solution (30 mg, 150 µL). As controls, identical volumes 
(150 µL) of the stock solutions were placed directly in pre-weighed vials and were dried (n = 3). 
These served as controls for the losses in recovery due to sample handling and in the TLC 
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analysis. For the Sephadex LH-20 columns, C. longa and C. reticulata extracts were dissolved in 
MeOH, filtered, and no significant extract residues remained on the filter papers. The columns 
were loaded with the MeOH soluble portions (150 µL). The extracts were allowed to sit on top 
of the columns for 30-45 min, and overnight for the diol columns.  The Si gel columns were 
eluted successively with hexanes (2 mL), EtOAc (5 mL), MeOH (5 mL) and water (2 mL), while 
the HP20SS columns were eluted successively with 50% MeOH-water (2 mL), MeOH (5 mL), 
EtOAc (5 mL) and hexanes (2 mL). Step gradients (100:0, 75:25, 50:50, 25:75, 0:100; 6 mL 
each) of water in isopropanol were applied for the elution of C. longa, C. reticulata and S. 
cernuus extracts. The combined dry weights of these fractions were used to calculate the total 
extract recoveries. Because solvent systems were unable to completely elute C. reticulata and C. 
longa from the columns (apparent yellow color on the columns, but the sample recovery loss was 
not statistically significant), we repeated the elution using a water-acetone step gradient in 
identical manner as the water-isopropanol system. Step gradients of hexanes-dichloromethane 
(9:1; 6 mL), dichloromethane-EtOAc (20:1; 6 mL), EtOAc (6 mL), EtOAc-MeOH (5:1; 6 mL) 
and MeOH (6 mL) were used to elute diol columns. Sephadex LH-20 columns were eluted with 
MeOH.  
 
2.2.4 Tumor cell culture and cell-based HIF-1 reporter assay 
 Human breast tumor T47D cells were purchased from ATCC and were maintained in 
Dulbecco’s Modified Eagle’s Mediun (DMEM) and Ham’s F-12 (1:1) media containing 2.5 mM 
L-glutamine (Mediatech). The medium was supplemented with fetal bovine serum (FBS, 10% 
v/v final concentration, Hyclone), penicillin (50 units/mL) and streptomycin (50 μg/mL) 
(pen/strep) (BioWhittaker). Exponentially grown T47D cells were transfected with the pTK-
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HRE3-luc reporter by electroporation using an ECM830 square wave electroporation system 
(BTX Inc) at 140 V for 70 ms (1 pulse). The transfected cells were plated at 3 x 104 cells per 
well into 96-well plates in a volume of 100 µL of DMEM/F12 medium supplemented with 10% 
FBS and antibiotics. After 24 h, the test compounds were diluted (2x final concentration) in 
DMEM/F12 medium with antibiotics, added in a volume of 100 µL per well, and the incubation 
continued for another 30 min at 37 °C. The cells were exposed to hypoxic (1% O2, 5% CO2, 94% 
N2) or normoxic (5% CO2, 95% air) conditions or hypoxia mimetic (1,10-phenanthroline, 10 
µM, Sigma) at 37 °C for 16 h. Hypoxic conditions were achieved by incubationg the cells in a 
humidified chamber (Billups-Rothenberg) that was purged with a hypoxic gas mixture (1% O2, 
5% CO2, 94% N2). The cells were then lysed using a lysis buffer (1%Triton X-100, 1 mM CaCl2, 
and 1 mM MgCl2 in 1 x phosphate buffered saline pH7.4) and luciferase activities determined 
following manufacturer’s instructions (Promega) using a microplate reader (Biotek).  The 
following formula was used to calculate the % inhibition data: 
% inhibition = (1 - luminescencetreated/luminescenceinduced) x 100 
Extracts for bioassay were prepared as stock solutions in DMSO and the final concentration of 
solvent was less than 0.5% (v/v) in all assays. 
 
2.2.5 Statistical Analysis  
Data was compared using the Student’s t test, one-way ANOVA and Bonferroni post hoc 
analyses (GraphPad Prism 5.0).  Differences were considered significant when p < 0.05. 
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2.3 Results and discussion 
2.3.1 Effects of chromatographic media and elution protocols on extract recovery  
 Ten natural product-rich extract samples from terrestrial plants, with chemically different 
HIF-1 inhibitory constituents were selected for evaluating the effects of chromatographic media 
on natural product metabolite recovery and HIF-1 inhibitory activity (Table 2.1).  
Natural product-rich mixtures Active constituents 
Pomegranate - Punica granatum( Punicaceae) extract Flavonoids, anthocyanins, tannins 
(Seeram et. al., 2006) 
Pomegranate juice - P.granatum juice  Flavonoids, anthocyanins (Seeram et. 
al., 2006) 
Cranberry – Vaccinium macrocarpon (Ericaceae) 
freeze-dried juice 
Polyphenols (Neto, 2007) 
Rooibos - Aspalathus linearis (Fabaceae) extract Flavonoids (Bramati et al., 2002)
Honeybush - Cyclopia intermedia (Fabaceae) extract Flavonoid glycosides (Kamara et al., 
2003) 
Tangerine - Citrus reticulata (Rutaceae) extract Flavonoid glycosides (Khan et al., 
2010) 
Turmeric - Curcuma longa (Zingiberaceae) extract Curcuminoids (Roth et al., 1998)
Lizard’s tail - Saururus cernuus (Saururaceae) sec-
butanol partitionate 
Sesquineolignans, dineolignans (Rao 
and Rao, 1990) 
Paw paw - Asimina triloba (Annonaceae) extract Annonaceous acetogenins 
(Coothankandaswamy et al., 2010) 
Mayapple - Podophyllum peltatum (Berberidaceae)  Lignans (Moraes et al., 2002)
 
Table 2.1 Selected extracts for comparative evaluation of chromatographic media 
 
Among the ten extract samples examined, V.  macrocarpon juice and extracts of A. 
triloba, and P. granatum showed a significant level of irreversible sample loss on Si gel columns 
when eluted with typically used solvent systems [hexanes, EtOAc, MeOH, and water for Si gel 
and MeOH-water (1:1), MeOH, EtOAc and hexanes for HP20ss] (Figure 2.1).  
65 
 
 
0
25
50
75
100
125
%
 R
ec
ov
er
y
 
 
Figure 2.1 Recovery of extracts (30 mg; 150 µL stock solution) from various columns (     
HP20SS,      Si Gel) after elution with water-MeOH, MeOH, EtOAC and hexanes; (i) V. 
macrocarpon; (ii) A. triloba; (iii) P. granatum. Stock solutions (150 µL) was directly placed in a 
vial and dried (n = 3). The dried material served as sample recovery controls (     ). Data shown 
are average + standard deviation from three separate columns (n = 3). One-way ANOVA with 
Bonferroni post hoc test were applied to analyze the data using GraphPad Prism 5.0; Differences 
between data sets were considered statistically significant when p < 0.05 (* p < 0.05, ** p < 
0.01). 
 
Drastic losses in the masses of C. longa, C. reticulata and S. cernuus extracts were 
observed (approx 50%, data not shown) on both HP20SS and Si gel. Rather than irreversible 
binding, this suggested that these columns were insufficiently eluted by the initial solvent 
systems. Hence a water-isopropanol step gradient system was used to completely elute the C. 
longa, C. reticulata and S. cernuus extracts from the HP20SS columns. The weights of the 
combined water-isopropanol gradient fractions were used to calculate total recovery. This is 
particularly noteworthy that the use of the water-isopropanol gradient alone was unable to 
completely elute the C. longa and C. reticulata extracts from the HP20SS columns. A non-polar 
solvent such as EtOAc was required for significantly improve column recovery. The water-
isopropanol gradient system has been reported for natural product library production by the 
Ireland group (Bugni et al., 2008a; Bugni et al., 2008b) at the University of Utah and the Orjala 
group at the University of Illinois at Chicago to elute cyanobacterial extracts from HP20SS 
**
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**
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columns (Sturdy et al., 2010). In the case of C. longa the total sample recovery was significantly 
increased (p = 0.0015) when a final EtOAc elution step was added to the typically used MeOH 
solvent system; while when compared with water-isopropanol gradient system alone, the 
increase in the total recovery with a final EtOAc elution step was marginally significant (p = 
0.0527). The recovery of A. triloba, and C. reticulata extracts also showed significant 
improvement following final elution with EtOAc (Figure 2.2). Previously reported water-acetone 
gradients (Boonlarppradab and Faulkner, 2007) completely eluted of C. longa extract from the 
HP20SS columns. 
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Figure 2.2 Eluting HP20SS column with non-polar solvent such as EtOAc can increase extract 
recovery. (i) Curcuma longa extract recovery using a water-MeOH system inclusive (     ) or 
exclusive (    ) of EtOAc elution (p = 0.0015); (ii) Curcuma longa extract recovery using a water-
IPA system inclusive or exclusive of EtOAc elution (p = 0.0527); (iii) Asimina triloba extract 
recovery using a water-MeOH system inclusive or exclusive of EtOAc elution (p = 0.0009); (iv) 
Citrus reticulata extract recovery using a water-MeOH system inclusive or exclusive EtOAc 
elution (p = 0.0036).  Data shown are average + standard deviation from three separate columns 
(n = 3). Student’s paired t-test (two-tailed) was used to compare the data using GraphPad Prism 
5.0; Differences between data sets were considered statistically significant when p < 0.05 (** p < 
0.01, *** p < 0.001). 
** **
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The Si gel elute of the P. peltatum extract showed a noticeable change in its chemical 
composition as observed by analysis of its TLC profile (Figure 2.3A). The C. reticulata (Figure 
2.3B) and C. longa (Figure 2.3C) extract TLC profiles indicated that considerable loss on the 
HP20SS columns can occur unless the media is subjected to further elution with a non-polar 
solvent such as EtOAc. 
 
 
 
Figure 2.3A TLC analysis of the Podophyllum peltatum extract exposed to elution with various 
chromatographic media. Notable chemical alterations in (Blue arrow) and active phytochemicals 
retained in EtOAc eluent (solid circle); 1 – Podophyllum extract, 2 – Combined Podophyllum 
fractions from a Si gel column, 3 – Combined water-MeOH fractions of Podophyllum from a 
HP20SS column and 4 – EtOAc wash of Podophyllum  from a HP20SS columns after water-
MeOH elution. C18 reversed-phase TLC eluted with 60% MeOH in water; Pigments = 
“bracketed” spots, UV254-absorbing compounds = “dotted circles” and 10% ethanolic sulphuric 
acid-charred compounds = “arrows”. 
 
 
1 2 3 4
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Figure 2.3B TLC analysis of the Citrus reticulata extract and fractions exposed to elution with 
various chromatographic media. 1 – C. reticulata extract, 2 – Combined C. reticulata fractions 
from a Si gel column, 3 – Water fraction of C. reticulata extract from a HP20SS column, 4 – 
Isopropanol-water (1:3) fraction of C. reticulata extract from a HP20SS column, 5 – 
Isopropanol-water (1:1) fraction of C. reticulata extract from a HP20SS column, 6 – Ipropanol-
water fraction (3:1) of C. reticulata extract from a HP20SS column, 7 – Isopropanol fraction of 
C. reticulata extract from a HP20SS column and 8 – EtOAc wash after isopropanol-water elution 
of C. reticulata extract from a HP20SS column; active phytochemicals retained in EtOAc eluent 
(solid circle); Si gel normal phase TLC eluted with hexanes:EtOAc (1:1). Pigments = 
“bracketed” spots, UV254-absorbing compounds = “dotted circles” and 10% ethanolic sulphuric 
acid-charred compounds = “arrows”. 
 
1 2 3 4 5 6 7 8 
69 
 
 
 
Figure 2.3C TLC analysis of the Curcuma longa extract and fractions exposed to elution with 
various chromatographic media.   1 – C. longa  extract, 2 – Combined C. longa fractions from a 
Si gel column, 3 – Isopropanol-water(1:3) fraction of C. longa extract from a HP20SS column, 4 
– Isopropanol-water (1:1) fraction of C. longa extract from a HP20SS column, 5 – Isopropanol-
water (3:1) fraction of C. longa extract from a HP20SS column, 6 – Isopropanol fraction of C. 
longa extract and 7 – EtOAc wash of C. longa extract from a HP20SS column after isopropanol-
water elution; active phytochemicals retained in EtOAc eluent (solid circle); Si gel normal-
phased TLC eluted with hexanes:EtOAc (1:1).  Pigments = “bracketed” spots, UV254-absorbing 
compounds = “dotted circles” and 10% ethanolic sulphuric acid-charred compounds = “arrows”. 
 
The extracts of C. longa, C. reticulata and S. cernuus were subjected to elution on diol, a 
chromatographic medium used by Dr. Gustafson (National Cancer Institute) for generating 
natural product libraries, to evaluate its elution properties (Gustafson and Nagle, personal 
communication, 2008). Of the three extracts, C. reticulata showed a significant loss of recovery 
on diol. The elution profiles of C. longa and C. reticulata extract MeOH soluble portions were 
evaluated on Sephadex LH-20. Citrus reticulata extract also showed a significant loss of 
recovery from Sephadex LH-20 (Figure 2.4).  
1 2 3 4 5 6 7
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Figure 2.4 Total recovery of C. reticulata extract from various chromatographic columns.   (i – 
Control, ii – HP20SS, iii – Si Gel, iv – Diol, v – Sephadex LH-20) Data shown are average + 
standard deviation (n = 3) and was analyzed by one-way ANOVA with Bonferroni post hoc test; 
using GraphPad Prism 5.0; Differences between data sets were considered statistically significant 
when p < 0.05 (* p < 0.05, ** p < 0.01). 
 
These results clearly indicate the potential of Si gel, relative to other chromatographic 
media, to cause an irreversible binding or chemical alteration of the plant extract chemical 
constituents. Use of Si gel as a chromatographic medium for fractionation of extracts obtained 
from terrestrial or marine organisms with an unknown chemical profile can result in a loss of 
potential chemical diversity, sample quantity or produce corresponding experimental artifacts. 
Although the alternative media evaluated such as diol-bonded phase and Sephadex LH-20 also 
caused observable losses in sample recovery that were elution protocol dependant, Si gel caused 
the greatest sample recovery loss. The water-isopropanol solvent systems used for the elution of 
HP20SS columns appear to be insufficient for the complete elution of extracts, especially for 
extracts with lipophilic constituents. Elution of HP20SS with non-polar solvents, such as EtOAc, 
prevents the loss of the intermediate to highly non-polar compounds. While certain drug 
discovery programs may choose to exclude these constituents because they may not serve as 
promising drug candidates due to their high lipophilicity, but they may serve as valuable 
*
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molecular probes or as potential ‘template’ molecules from which to construct potential drug 
candidates. Such considerations are of special importance in the generation of natural product-
rich extracts/fraction libraries. Another observation worth noting is that the use of non-polar 
solvents, such as EtOAc, cause elution of fine HP20SS particles during the separation process. 
However, this is preventable by first washing the HP20SS columns with EtOAc and then 
washing the column with MeOH. 
 
2.3.2 Effects of chromatographic media on extract HIF-1 inhibitory activity  
We examined whether exposure of the extracts to these chromatographic media affects 
extract bioactivities. The HIF-1 inhibitory activity of the extracts was evaluated using a 96-well 
plate-based method. Of the 10 extracts, A. triloba (0.5 µg/mL), C. reticulata (50 µg/mL), P. 
peltatum (50 µg/mL), S. cernuus (50 µg/mL), and C. longa (25 µg/mL) extracts inhibited HIF-1 
activity by > 50% (Figure 2.5) in the T47D cell-based HIF-1 reporter assay. Other extracts were 
inactive. However, the P. peltatum extract was excluded from further evaluation because it was 
highly unstable and decomposed during storage. The HIF-1 inhibitory activity of these extracts 
was not secondary to cytotoxic effects (cytotoxicity < 25%). In addition, a review of literature 
indicated that some of these extracts contain known HIF-1 inhibitors and it is unlikely that these 
extracts interfere with the luciferase assay system (Coothankandaswamy et al., 2010; Hodges et 
al., 2004; Choi et al., 2006). 
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Figure 2.5 Inhibiton of physiological hypoxia (1% O2) and 1,10-phenanthroline-induced HIF-1 
activation by active extracts. Data shown are average + standard deviation from single 
experiment assayed in triplicate.  
 
  
When C. reticulata and C. longa extracts were eluted through HP20SS medium, 
considerable active materials remained on the column until ultimately eluted with EtOAc. The 
EtOAc eluted material inhibited both hypoxia-induced (1% O2) and 1,10-phenanthroline (10 
µM)-induced HIF-1 activation at 50 µg/mL (suppression of cell viability  < 25%, data not 
shown) (Figure 2.6).  
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Figure 2.6 Inhibition of HIF-1 activity under physiological hypoxia (1% O2) and 1,10-
phenanthroline-induced HIF-1 activation by Citrus reticulata and Curcuma longa EtOAc eluates 
(50 µg/mL) from HP20SS columns. Data shown are average + standard deviation from one 
representative experiment in triplicate.  
 
All fractions obtained from each extract/column combination were recombined and 
evaluated for HIF-1 inhibitory activity to assess the impact of each media exposure on the 
extracts’ total bioactivity. Under physiological hypoxic conditions (1% O2), reconstituted C. 
longa extract samples from the HP20SS, Si gel, and diol columns were significantly less active 
relative to the original extract (Figure 2.7A). Under chemical hypoxia (1,10-phenanthroline, 10 
µM), reconstituted C. longa extract samples from both Si gel and HP20SS columns exhibited 
significantly lower activities (Figure 2.7B). For the reconstituted extract samples eluted from the 
Sephadex LH-20 and diol columns, there was no difference in activity when compared with the 
original extract. The inhibitory activity towards 1,10-phenanthroline-induced HIF-1 activation by  
the Si gel eluted C. reticulata pooled material was markedly reduced (Figure 2.7C). In all cases 
suppression of cell viability was ≤ 25% (data not shown). 
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Figure 2.7A Inhibition of physiological hypoxia-induced HIF-1 activation by recombined 
Curcuma longa eluates (25 µg/mL) [i – Control, ii – HP20SS, iii – Si Gel, iv – Diol, v – 
Sephadex LH-20]. The stock solution used to load the columns were placed in dried vials in 
identical volumes (n = 3). The HIF-1 inhibitory activity of the dried material served as control. 
Data represent average + standard deviation from one representative experiment in triplicate. 
Data was analyzed by one-way ANOVA with Bonferroni post hoc test; Differences between data 
sets were considered statistically significant when p < 0.05. (* p < 0.05, ** p < 0.01). 
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Figure 2.7B Inhibition of 1,10-phenanthroline-induced HIF-1 activation by recombined  
Curcuma longa eluates (25 µg/mL) [i – Control, ii – HP20SS, iii – Si Gel, iv – Diol, v – 
Sephadex LH-20]. The stock solution used to load the columns were placed in dried vials in 
identical volumes (n = 3). The HIF-1 inhibitory activity of the dried material served as control. 
Data represent average + standard deviation from one representative experiment in triplicate. 
Data was analyzed by one-way ANOVA with Bonferroni post hoc test; Differences between data 
sets were considered statistically significant when p < 0.05. (** p <0.01, *** p < 0.001). 
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Figure 2.7C Inhibition of 1,10-phenanthroline-induced HIF-1 activation by recombined Citrus 
reticulata eluates (50 µg/mL) [1 – Control, 2 – HP20SS, 3 – Si Gel, 4 – Diol, 5 – Sephadex LH-
20]. The stock solution used to load the columns were placed in dried vials in identical volumes 
(n = 3). The HIF-1 inhibitory activity of the dried material served as control. Data represent 
average + standard deviation from one representative experiment in triplicate. Data was analyzed 
by one-way ANOVA with Bonferroni post hoc test; Differences between data sets were 
considered statistically significant when p < 0.05. (*** p < 0.001). 
 
Both the original and reconstituted S. cernuus and A. triloba extracts selectively inhibit 
hypoxia-induced HIF-1 activation (1% O2). The S. cernuus extract lost activity upon Si gel 
elution. Similar loss was not observed upon HP20SS elution. The reconstituted A. triloba extract 
lost considerable HIF-1 inhibitory activity when eluted through HP20SS but retained its activity 
when eluted through Si gel (Figure 2.8A and 2.8B). The suppression of cell viability by S. 
cernuus and A. triloba column eluates was ≤ 20% in all cases (data not shown). 
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Figure 2.8A Inhibition of physiological hypoxia-induced HIF-1 activation by recombined 
Asimina triloba eluates (0.05 µg/mL) [i – Control, ii – HP20SS, iii – Si Gel]. The stock solution 
used to load the columns were placed in dried vials in identical volumes (n = 3). The HIF-1 
inhibitory activity of the dried material served as control. Data represent average + standard 
deviation from one representative experiment in triplicate. Data was analyzed by one-way 
ANOVA with Bonferroni post hoc test; Differences between data sets were considered 
statistically significant when p < 0.05. (*** p < 0.001). 
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Figure 2.8B Inhibition of physiological hypoxia-induced HIF-1 activation by recombined 
Saururus cernuus eluates (3.125 µg/mL) [i – Control, ii – HP20SS, iii – Si Gel]. The stock 
solution used to load the columns were placed in dried vials in identical volumes (n = 3). The 
HIF-1 inhibitory activity of the dried material served as control. Data represent average + 
standard deviation from one representative experiment in triplicate. Data was analyzed by one-
way ANOVA with Bonferroni post hoc test; Differences between data sets were considered 
statistically significant when p < 0.05 (* p <0.05). 
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Many laboratories identify molecular-targeted antitumor natural products through the use 
of bio-assay guided isolation approach. Because bioassay-guided fractionation relies on the 
bioactivity of extracts and subsequent fractions, loss of activity due to inappropriate 
chromatographic media selection, can significantly impact the drug discovery outcome. Three of 
the four extracts that inhibited HIF-1 activation, exhibited a significant loss of bioactivity when 
subjected to Si gel-based chromatographic methods. For C. longa extract, no loss in sample mass 
recovery was detected upon HP20SS or Diol elution, while considerable loss in bioactivity was 
observed. Only the extracts of A. triloba and C. longa lost significant HIF-1 inhibitory activity 
upon HP20SS elution relative to the original extracts. Moreover, neither extract showed 
significant mass loss upon HP20SS elution but A. triloba lost mass upon Si gel elution. Because 
A. triloba extract contains unsaturated, lipophilic active acetogenin constituents, it is possible 
that its active constituents bind to the aromatic skeleton of HP20SS by π-bonding. Because these 
extremely potent acetogenins are relatively minor extract components, the overall loss of sample 
mass was not statistically significant. Such sample losses can be prevented by eluting HP20SS 
with a highly non-polar solvent such as CH2Cl2 or hexanes. Although the loss of bioactivity upon 
elution through Si gel was apparent for some extracts, HP20SS elution may also cause 
significant losses in bioactivity. Hence, chromatographic media selection should prioritize 
alternatives to Si gel when possible, but the specific elution protocol when the HP20SS medium 
is selected should be carefully considered. Unless the aim of the separation is to include a 
“defattening” step to remove lipophilic compounds, HP20SS elution protocols must include a 
final non-polar wash with EtOAc, CH2Cl2 or other lipophilic solvent to ensure a more complete 
elution of sample than that may be obtained with commonly used aqueous-MeOH or aqueous-
isopropanol gradients. However, HP20SS columns must be prewashed with EtOAc and 
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equilibrated with MeOH to avoid elution of small HP20SS particles when the elution protocol 
involves a final non-polar solvent wash. 
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CHAPTER III 
DEVELOPMENT OF A BIOENERGETICS-BASED SCREEN FOR IDENTIFICATION 
OF SMALL-MOLECULE GLYCOLYSIS INHIBITORS 
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3.1 Overview 
3.1.1 Introduction 
 Tumor cells produce lactate as an end product of glucose catabolism in the presence of 
adequate oxygen. This phenomenon is known as ‘aerobic glycolysis’ (Gatenby and Gillies, 
2004). Tumor cells with a high rate of aerobic glycolysis are usually associated with poor 
prognosis, malignant aggressiveness, and resistance to standard therapeutic regimens (Mason et 
al., 2010; Wolf et al., 2011; Zhou et al., 2010; Pitroda et al., 2009; Klawitter et al., 2009). 
Aerobic glycolysis is less efficient in producing adenosine triphosphate (ATP) compared to 
oxidative phosphorylation (OxPhos).  However, it is hypothesized that generating energy 
through the glycolytic pathway constitutes an advantageous metabolic environment for 
unrestricted cell proliferation and tumor growth (Vander Heiden et al., 2009; Kroemer and 
Pouyssegur, 2008; Brand and Hermfisse, 1997). Metabolic targeting of tumors has been in the 
limelight for several decades (Papandreou et al., 2011). Inhibitors of the enzymes required for 
aerobic glycolysis are currently being explored for their therapeutic potential (Scatena et al., 
2008). Small-molecules that target aerobic glycolysis, such as 2-deoxy-D-glucose (2) and 
lonidamine (3) (Figure 3.1B), have undergone clinical evaluation for the treatment of refractory 
tumors (ClinicalTrials.gov, website accessed on 04/03/2012; Di Cosimo et al., 2003). 
Natural products from plants and marine organisms have been widely investigated as a 
potential source of new anticancer agents (Newman and Cragg, 2012). Natural products that 
target the mitochondria have been explored as a class of potential antitumor therapeutic agents 
(Wolvetang et al., 1994) and screening methods have been developed to identify mitochondrial 
inhibitors (Lin et al., 2008). However, there have been limited efforts to discover small-molecule 
inhibitors of aerobic glycolysis from natural sources (Kitagawa et al., 2011). 
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More than 10,000 lipid extracts from the National Cancer Institute’s (NCI) Open 
Repository of higher plants and marine invertebrates were examined to identifyr inhibitors of 
aerobic glycolysis (glycolysis inhibitors) from natural sources (hit rate 0.72%). The extract of 
Moronobea coccinea Aubl. (Clusiaceae) was ‘active’ in our screening assay. Polyprenylated 
benzophenone derivatives (PBDs), which had been previously isolated from the plant, were 
initially hypothesized to be responsible for its glycolysis inhibitory activity (Marti et al., 2009). 
A wide spectrum of activities including cytotoxic, antimicrobial, antioxidant, and anti-
inflammatory activities have been attributed to prenylated benzophenones isolated from the 
plants belonging to the family Clusiaceae (Acuna et al., 2009). Bioassay-guided isolation and 
structure elucidation led us to the discovery of moronone (1), a PBD with a new carbon skeleton. 
In this report, we describe the development of an assay system to screen for glycolysis inhibitors 
and the discovery of a protonophoric benzophenone derivative. The well studied protonophore 2-
[{4-(trifluoromethoxy)phenyl}hydrazinylidene]propanedinitrile (4)[FCCP] was also found to be 
active in our assay system. It was concluded that the protonophoric compounds or extracts 
containing protonophoric components are possible nuiscance compounds and needs to be 
dereplicated in order to successfully discover the glycolysis inhibitors. 
 
 
 
 
 
 
Figure 3.1A Structure of FCCP (4) and proposed structure of moronone (1)
 
FCCP (4) 
 
Moronone (1) 
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3.1.2 Cancer cell metabolism and bioenergetics  
 Normal mammalian cells generate ATP by metabolizing glucose through two 
complementary cellular pathways, i.e., glycolysis and OxPhos. Under aerobic conditions, the 
cellular glycolytic flux is limited. However, under anaerobic conditions, the lack of oxygen 
inhibits mitochondrial OxPhos, and pyruvate generated in the glycolytic pathway is converted to 
lactate in the cytosol (Kim and Dang, 2006). Hence, for non-malignant cells under anaerobic 
conditions, glycolysis is the major supplier of cellular ATP, while under aerobic conditions the 
ATP demands of the same cells are mainly met by ATP synthesized by OxPhos. 
 This bioenergetic homeostasis is altered in tumors. In tumor cells, the glycolytic flux is 
high, even in the presence of adequate oxygen. Increased glucose uptake, increased production of 
lactate from pyruvate and lower OxPhos by tumor cells, even under aerobic conditions, are 
collectively considered to be one of the hallmarks of cancer (Yeung et al., 2008). This 
phenomenon was first reported in the early twentieth century by Otto Warburg (Warburg, 1956), 
and is currently termed as the ‘Warbug effect’ or aerobic glycolysis.  A previous study estimated 
that 40-75% of cellular ATP production is generated by aerobic glycolysis (Mathupala et al., 
2010). However, a newer study has challenged the paradigm that aerobic glycolysis is the 
universally predominant ATP supplier for tumor cells (Zu and Guppy, 2004). This study 
indicates that the extent of ATP contribution by aerobic glycolysis can be cell line and tumor 
type-dependent. In some tumor cell lines, mitochondrial OxPhos has been known to contribute 
50-97% of cellular ATP generation (Moreno-Sanchez et al., 2009). Although aerobic glycolysis 
may not be the predominant energy generating pathway in all tumor cells, enhanced cellular 
glycolytic metabolism is often associated with poor prognosis, aggressiveness, and 
chemotherapy resistance (Mason et al., 2010; Wolf et al., 2011; Zhou et al., 2010; Pitroda et al., 
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2009; Klawitter et al., 2009).  Hypoxic conditions in tumor masses are hypothesized to be a key 
mediator of cellular dependence on glycolysis. Hypoxic conditions activate HIF-1 and induce 
more than 100 HIF-1-regulated genes in tumor cells, including multiple glycolytic enzymes (Ke 
and Costa, 2006). Specific isoforms of several glycolytic enzymes induced by HIF-1 (hexokinase 
II, phosphofructokinase-1 and lactate dehydrogenase isoform A) contribute to the glycolytic 
tumor cell phenotype. A major redistribution of hexokinase II (HKII), one of the four isoforms of 
the enzyme hexokinase, from the cytosol to the outer mitochondrial membrane occurs in tumor 
cells (Nakashima et al., 1986). The binding of HKII to the voltage-dependent anion channels 
(VDAC) on the mitochondrial outer membrane is believed to give the glycolytic enzyme 
preferential access to mitochondrial ATP. This preferential access to ATP enhances the catalytic 
activity of the enzyme (Arora and Pedersen, 1988). This binding of HKII to VDAC also may 
disable the activation of the mitochondria-mediated apoptotic pathway via Bax, a pro-apoptotic 
Bcl-2 family protein (Pastorino et al., 2002). Aerobic glycolysis is inefficient from the 
bioenergetics perspective, since the net ATP gain/mole of glucose in this process is 17–18 fold 
less than that of OxPhos. However, the predominantly glycolytic metabolism is hypothesized to 
create a pro-proliferation and pro-survival environment for tumor cells. Rapidly dividing cells in 
living tissues undergo similar metabolic rearrangements (Vander Haiden et al., 2009; Wang et 
al., 1976; Almeida et al., 2010; Herrero-Mendez et al., 2009; Colombo et al., 2010). As the cells 
rapidly multiply, they require biosynthetic building blocks such as amino acids, nucleic acids and 
lipids. Certain glycolytic intermediates, such as glucose-6-phosphate, can be utilized by pentose 
phosphate pathway to generate some of the components required for continuous cell division 
(Barger and Plas, 2010). In addition, evidence suggests that lactate is used as a substrate for 
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OxPhos, and a possible symbiotic relationship exists between the hypoxic and oxygenated cells 
in solid tumors (Sonveaux et al., 2008). 
 
3.1.3 The glycolytic pathway as an antitumor target 
 Selective tumor cell targeting is the single most important objective in antitumor drug 
discovery. Cancer researchers aim to identify the genetic, biochemical and structural differences 
between malignant cell and non-malignant cells. Enhanced tumor cell glucose consumption and 
increased dependence on the glycolytic pathway for ATP synthesis can be exploited to 
selectively target tumor cells. Indeed, inhibition of aerobic glycolysis has emerged as one of the 
potential adjuvant therapies to treat various solid tumors (Rodriguez-Enriquez et al., 2009; 
Cheng et al., 2012). Targeting glycolysis in tumor cells can potentially interfere with the 
intracellular signaling that stimulate uncontrolled proliferation, as well as enhance the efficacy of 
the conventional antitumor regimens (Scatena et al., 2008; Cheng et al., 2012). In addition, ATP 
depletion due to the inhibition of glycolysis can lead to the circumvention of multidrug resistance 
mechanisms (Nakano et al., 2011). Because tumore cells are more dependent on glycolysis for 
their energy needs, proliferation and survival, a comparatively small perturbation of the 
glycolytic pathway is expected to have higher impact on tumor cells relative to normal cells and 
thus result in a selective tumor cell targeting. 
 The enzyme hexokinase catalyzes the first step of glycolysis, i.e., phosphorylation of 
glucose. To date, this enzyme has been the most common target for the discovery of agents that 
inhibit aerobic glycolysis. Compounds that result in a decrease in hexokinase enzymatic activity, 
such as 2-deoxy-D-glucose (2) [2-DG] and lonidamine (3) (Figure 3.1B), have undergone clinical 
evaluation for the treatment of advanced malignancies, both as monotherapies and in 
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combination with other chemotherapeutic agents (ClinicalTrials.gov, website accessed on 
04/03/2012; Di Cosimo et al., 2003). The phase II clinical trial of 2-DG for advanced prostate 
cancer was terminated due to slow patient accrual (ClinicalTrials.gov, website accessed on 
07/03/2012). However, a phase I clinical trial found that administering 2-DG in combination 
with taxol is feasible and safe (Raez et al., 2005). In preclinical studies, 3-bromopyruvate (5) 
[another HKII inhibitor] has shown promising results against hepatocellular carcinoma (Ko and 
Pedersen, 2001; Ko et al., 2004). However, 3-bromopyruvate (5) is reported to inhibit 
mitochondrial respiration and to have non-selective thiol-alkylating effects (Shoshan, 2012). 
Inhibition of HKII by 3-bromopyruvate (5) might be non-specific and only partly responsible for 
its demonstrated activity. Gossypol [AT-101] (6), a promiscuous inhibitor of glycolytic enzymes 
including glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Scatena et al., 2008) and 
lactate dehydrogenase (LDH) (Granchi et al., 2011), is currently being evaluated in multiple 
clinical trials as a treatment option for aggressive tumor phenotypes, such as glioblastoma 
multiforme (ClinicalTrials.gov, website accessed on 07/06/2012). Pyruvate kinase, the enzyme 
that converts phosphoenolpyruvate to pyruvate, has been identified as another plausible 
molecular target in the glycolysis pathway. Cancer cells overexpress the specific pyruvate kinase 
isoform PKM2, which is usually detected in early fetal tissues (Christofk et al., 2008). A seven 
amino acid peptide known as CAP-232/TLN-232 (7) targets PKM2, and recently underwent a 
phase II clinical trial for the treatment of metastatic renal cell carcinoma (ClinicalTrials.gov, 
website accessed on 07/07/2012). Lactate dehydrogenase isoform A (LDH-A) is another 
glycolytic enzyme that is overexpressed in tumor cells. It catalyzes the conversion of pyruvate to 
lactate. Tumor cell-specific LDH-A upregulation suggests that LDH-A may be a potential target 
to suppress aerobic glycolysis (Granchi et al., 2011). Inhibitors for almost all the enzymes 
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involved in the glycolytic process have been reported (Scatena et al., 2008). However, a 
clinically useful aerobic glycolysis inhibitor is yet to be discovered. Inhibitors of parasitic 
glycolysis have been evaluated for their therapeutic (anti-infetive) potential (Coley et al., 2011; 
Rosenthal, 2003; Sharlow et al., 2010), but drug discovery efforts to identify inhibitors of 
aerobic glycolysis have been limited. Only one study that describe glycolysis inhibitor screening 
using a cell-based assay has recently been published (Kitagawa et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1B Small-molecule glycolysis inhibitors. 
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3.1.4 Benzophenones as bioactive natural products 
 Small-molecule natural products have been the single most successful source for 
antitumor drug discovery (Newman and Cragg, 2012). Apart from the clinically successful 
natural product-derived drugs, natural product-derived small-molecules that exhibit interesting 
bioactivities are widely used as both pharmacological and molecular probes. Benzophenones are 
a class of compounds that have demonstrated a broad spectrum of bioactivities (Acuna et al., 
2009). Approximately 150 known benzophenones from 13 different families have been isolated. 
More than 50% of these compounds are found in members of the Clusia, Garcinia and 
Hypericum genera from the family Clusiaceae. The core of a benzophenone type molecule is 
composed of a 13-carbon skeleton (Figure 3.2) which is later modified with substituent additions 
and subsequent cyclizations. Benzophenones are thought to be biosynthetically derived from the 
shikimate and mevalonate pathways. Benzophenones can be broadly classified into two 
categories: a) basic benzophenones and b) polyprenylated benzophenone derivatives (PBDs).  
 
 
 
 
 
Figure 3.2 Core structure of benzophenones. 
 
Prenylation of benzophenones occurs mainly on the B ring, and the prenyl units often 
undergo cyclization leading to bi-, tri- and tetracyclic molecules.  Only four compounds have 
been reported with prenylation on the A ring (cudraphenones A–D, 8–11) (Baggett et al., 2005). 
Cytotoxic, antimicrobial, antiviral and antioxidant activities have been attributed to 
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effects of HIV infection in human T-lymphoblastoid CEM-SS cells in vitro (EC50 1–23 µg/ mL), 
but were also toxic to the host cells (IC50 50–82 µg/ mL) (Gustafson et al., 1992; Fuller et al., 
1999a). Other known anti-HIV benzophenones include laxifloranone (18) (Bokesch et al., 1999), 
vismiaphenone D (19) (Fuller et al., 1999b), and garciosaphenone A (20) (Rukachaisirikul et al., 
2003). 
Numerous benzophenones have shown broad spectrum antibacterial, antifungal and 
antiprotozoal activities. Some prominent antibacterial benzophenones include: 7-epiclusianone 
(21), garcinol (22), guttiferone I (23), isogarcinol (24), microsphaerins A-D (25–28), 
nemorosone (29), isoxanthochymol (30) and xanthochymol (31). Among these, isoxanthochymol 
(30), isogarcinol (24), xanthochymol (31), microsphaerins A-D (25–28) and garcinol (22) are 
active against MRSA. Antiplasmodial activity was observed with coccinones A-E (32–36), 7-
epigarcinol (37), 7-epiisogarcinol (38), garcinol (22), isogarcinol (24), while 3-geranyl-2, 4, 6-
trihydroxybenzophenone (39), and pestalachlorides A–C (40–42) demonstrateded antifungal 
activity.  Trypanosidal and leishmanicidal activities were also reported for a number of 
benzophenone compounds (Acuna et al., 2009).  
In addition to the antiviral and antimicrobial activities, guttiferones A (12), E (16), G, 
(43), H (44), I (23), J (45), K (46), L (47), curdaphenones A–D (8–11), garcinol (22), isogarcinol 
(24), hyperibone K (48) and L (49), xanthochymol (31), isoxanthochymol (30) and nemorosone 
(29) showed broad spectrum cytotoxic effects against numerous cell lines derived from colon, 
breast, ovarian, oral, cervical, lung, prostate and hepatocellular carcinomas (Acuna et al., 2009). 
These PBDs have been shown to (a) induce cell cycle arrest and apoptosis; (b) bind and inhibit 
tubulin disassembly during cell division; (c) activate caspase-3; and (d) inhibit enzymatic activity 
of histone acetyl transferase, proteases and kinases (Acuna et al., 2009). However, this type of 
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broad spectrum inhibition may be indicative of nonspecific suppression of cell viability or the 
targeting of a central pathway that affects many cellular reactions. 
The keto-enol equilibria within PBD structures are essential for their bioactivity, and the 
compounds devoid of this functional group are drastically less active. Guttiferones A-F (12–17) 
have been shown to be active in HIV-inhibitory assay in vitro. However, isoxanthochymol (30), 
a cyclized derivative of guttiferone E (16), which was missing the enol functionality, was 
inactive (Gustafson et al., 1992). 
A recent study showed that nemorosone (29), a strong antiplasmodial and cytotoxic 
benzophenone, potently uncoupled mitochondria and depleted intracellular ATP levels in HepG2 
cells. The keto-enol tautomerism had been shown to be responsible for the protonophoric activity 
of nemorosone (29) (Pardo-Andreu et al., 2011). Uncoupling of oxidative phosphorylation owing 
to the enolic functionality present in the benzophenone compounds can explain the broad 
spectrum of the antimicrobial and cytotoxic activity of this class of compounds. 
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Figure 3.3 Bioactive polyprenylated benzophenone derivatives (PBDs). 
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Figure 3.4 Bioactive polyprenylated benzophenone derivatives (PBDs). 
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Figure 3.5 Bioactive polyprenylated benzophenone derivatives (PBDs). 
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Figure 3.6 Bioactive polyprenylated benzophenone derivatives (PBDs).
 
Pestalachloride A (40) Pestalachloride B (41) 
 
Pestalachloride (42) 
 
Guttiferone G (43) 
O
OH
O
O
H
HO
OH
Guttiferone H (44) 
O O
OH
OH
O
Guttiferone J (45) 
 
Guttiferone K (46) 
Guttiferone L (47) 
Hyperibone K (48) 
O O
OO
Hyperibone L (49) 
94 
 
3.2 Materials and methods 
3.2.1 General experimental procedures 
 A Varian 50 Bio spectrophotometer was used to record UV spectrum and IR spectrum 
was obtained by a Bruker Tensor 27 Genesis Series FTIR. Bruker AMX-NMR 
spectrophotometers operating at 400 MHz for 1H and 100 MHz for 13C were used to record the 
NMR spectra. Moronone (1) was dissolved in pyridine-d5 (Sigma) to record the NMR spectra, 
and solvent resonances were used as internal references [8.74 (s) for 1H and 150.35 (t) for 13C]. 
A Bruker Daltonic micro TOF fitted with an Agilent 1100 series HPLC and an electrospray 
ionization source was used to obtain the HRESIMS. Merck Si60F254 or Si60RP18F254 (Sorbent 
Technologies) were used to obtain TLC. Ethanolic sulfuric acid (10% H2SO4 in EtOH) was used 
as visualizing agent. The TLC plates were first observed under UV at 254 nm, and sprayed with 
the visualizing agent, followed by heating. HPLC was performed on a Waters system equipped 
with a 600 controller and a 2998 photodiode array detector. Semi-preparative HPLC column 
(Phenomenex Luna RP-18, 5 μm, 250 × 10.00 mm) was employed for isolation. Solvents and 
formic acid for HPLC were purchased from Fisher unless specified otherwise. The purity of the 
compound was judged on the percentage of the integrated signal at UV 220 nm. The compound 
submitted for bioassay was at least 95% pure as judged by this method. 
 
3.2.2. Plant material 
 Moronobea coccinea Aubl. (Clusiaceae) stem woods were collected from British Guyana 
(October 21, 1991) and identified by Dr. S. Tiwari (New York Botanical Gardens, Bronx, NY). 
A voucher specimen was deposited at the Smithsonian Institution National Museum of Natural 
History, Washington, DC, and a collection number 0CKF0401 was assigned to the sample. 
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3.2.3 Extraction and isolation 
 The plant material was extracted with CH2Cl2-MeOH (1:1). The extract was vacuum-
dried and stored at -20 °C in the NCI repository at the Frederick Cancer Research and 
Development Center (Frederick, Maryland). An NCI Open Repository Sample number, 
N063783, was assigned to the extract. The extract (3.0 g) showed enhanced suppression of cell 
viability in a MDA-MB-231 cell-based viability assay under a glycolysis-dependent condition 
compared to regular culture conditions. The extract was eluted through Sephadex LH-20 to 
prepare preliminary fractions. Seven fractions were obtained using step gradients of CH2Cl2-
MeOH (1:1), CH2Cl2-MeOH (1:2), and MeOH. The second fraction (373.1 mg), eluted with 
CH2Cl2-MeOH (1:1) at 1 column volume, was active in the glycolysis inhibitor screening assay. 
The active fraction was subjected to Si gel column chromatography using step gradients of 
hexanes-EtOAc (6:1, 4:1, 2:1, 1:1, 0:1). The column was washed with MeOH. Eight sub-
fractions were obtained; the second fraction (112.2 mg), eluted with hexanes-EtOAc (6:1), being 
active in the glycolysis inhibitor screening assay. TLC of the active fraction showed a UV-active 
yellow char, indicating that it might be similar to the PBDs previously isolated from this plant 
(Marti et al., 2011). The active fraction was dissolved in MeOH and centrifuged. Subsequently, 
the supernatant was filtered and subjected to semi-preparative isolation (Phenomenex Luna RP-
18, 5 μm, 250 × 10 mm) using acetonitrile : formic acid (0.1% ) [87:13]. This reversed-phase 
separation produced the pure compound moronone (83.5 mg, 2.78% yield).  The purity of the 
compound was determined by the percentage of the integrated signal at UV 220 nm and the 
compound was at least 95% pure as judged by this method. 
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3.2.4 Moronone (1) 
 Dark brown oil; optically inactive; UV (MeOH) λmax (log ε) 237 (4.29), 281 (4.04), 351 
(4.39) nm; IR (NaCl block) νmax 3510, 2968, 2918, 1642, 1566, 1504, 1446, 1384, 1316, 1220, 
1105, 1066 cm-1; 1H NMR and 13C NMR data, see Table 1; HRESIMS m/z 525.2997 [M+Na]+ 
(calcd. for C33H42O4Na, 525.2981). 
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3.2.5 Tumor cell culture 
 Human breast tumor T47D and MDA-MB-231 cells were purchased from American type 
culture collection (ATCC). These cells were maintained in the Roswell Park Memorial Insitute 
1640 medium containing 2 mM L-glutamine (Mediatech). The medium was supplemented with 
fetal bovine serum [FBS, 10% v/v final concentration, Hyclone] and a mixture of penicillin (50 
units/mL final concentration) and streptomycin (50 μg/mL final concentration) (pen/strep) 
(Lonza). 
 
3.2.6 Glycolysis inhibitor screening assay 
 MDA-MB-231 cells were plated at 3 x 104 cells per well into 96-well plates in a volume 
of 100 µL RPMI 1640 medium supplemented with FBS and penicillin/streptomycin (pen/strep) 
as described in the previous section. After 24 h, extracts or test compounds were diluted with the 
serum free RPMI 1640 medium with pen/strep (2x final concentration) and added in a volume of 
100 µL per well. The final concentration of each extract was 20 µg/mL. The cells were treated 
with extracts in the presence or absence of rotenone (0.1 µM) and incubated at 37 °C under 
normoxic conditions (95% air, 5% CO2) for 48 h. At the end of the specified incubation period, 
cell viability was measured using the sulforhodamine B method (Skehan et al., 1990). The cell 
viability was measured for each extract Extracts with a differential cytotoxicity index of ≥ 1.5 
that exerted ≥ 45% cytotoxicity in the presence of rotenone (0.1 µM), were considered ‘active’. 
The differential cytotoxicity index was calculated using the following formula: 
                                                                 cytotoxicity in the presence of rotenone (0.1 µM) 
                                                                       cytotoxicity in the absence of rotenone 
 
 
Differential cytotoxicity index = 
99 
 
The Z-factor for each plate was calculated by the following formula: 
                      3 x standard deviation [2-DG or (2-DG + rotenone)] – 3 x standard deviation media  
                                          Mean [2-DG or (2-DG + rotenone)] – Mean media control 
 
3.2.7 Cell viability assay by the sulforhodamine B method 
 MDA-MB-231 cells were plated at 3 x 104 cells per well into 96-well plates in a volume 
of 100 µL of RPMI1640 medium supplemented with FBS (10% v/v final concentration) and 
pen/strep. After 24 h, each test compound was diluted with the serum free DMEM/F12 medium 
with pen/strep (2x final concentration) and added in a volume of 100 µL per well, and the 
incubation continued for another 2 days or 6 days at 37 °C (95% air, 5% CO2). For the 6-day 
exposure study, the conditioned media were replaced after 3 days with fresh culture media that 
contained test compounds. Following a 2- or 6-day incubation period, the cells were fixed by 
replacing 100 µL of conditioned medium with 100 µL trichloroacetic acid solution (20% w/v in 
1x PBS, pH 7.4) per well. Following incubation at 4 °C for 1 h, the supernatant was removed, 
and the cells were washed with tap water (4x) and air dried. A sulforhodamine B solution (0.4% 
w/v, in 1% actetic acid) was added in a volume of 100 µL per well and incubated at room 
temperature for 10 min. The stained cells were washed with 1% acetic acid (4x) and air dried. 
The dye was eluted by adding 200 µL of Trizma® base (10 mM) per well and incubating for 10 
min at room temperature. The plates were gently shaken for 2–3 min, and absorbance was 
measured at 490 nm and background absorbance at 630 nm, on a BioTek Synergy plate reader. 
The ΔOD values were used for subsequent data analysis and were calculated by subtracting the 
background absorbance from the absorbance at 490 nm. The following formula was used to 
calculate the percentage inhibition data: 
% inhibition = (1 - ΔODtreated/ΔODcontrol) x 100 
Z-factor = 1 -  
100 
 
3.2.8 Cellular respiration assay 
 The effects of compound on MDA-MB-231 or T47D cellular oxygen consumption were 
measured by a Clarke-type electrode system (Oxytherm, Hansatech). To determine the effect of 
1 on cellular respiration, 5 × 106 T47D or MDA-MB-231 cells were added to the chamber of an 
Oxytherm Clark-type electrode system (Hansatech), containing 1 mL of DMEM/F-12 medium 
(JRH) (equilibrated to 37 °C) free of serum and antibiotics. Glucose (17.5 mM) in the DMEM/F-
12 medium served as the major metabolic substrate. Once the base-line respiration had been 
established (for a 12 min interval), 1 dissolved in DMSO was injected into the chamber 1–2 min 
after the establishment of steady-state respiration, using a 10-μL syringe (Hamilton). The data 
were presented as “Respiration rate relative to untreated control” and was calculated using the 
following formula: 
                                                                                              oxygen consumption rate compound 
                                                                                              oxygen consumption rate control 
   
The mitochondrial uncoupler FCCP (Sigma) was used as a positive control. For mechanistic 
studies, state 4 respiration was initiated by the addition of oligomycin (1 µM, Sigma). Following 
subsequent addition of either FCCP or 1, the effects of each compound on state 4 respiration 
were determined by monitoring the rates of cellular oxygen consumption. 
 
3.2.9 Mitochondrial membrane potential assay 
 MDA-MB-231 and T47D cells were plated into four-well Lab-Tek II coverglass 
chambers (Nunc) at a density of 1 x 105 cells per well and incubated at 37 °C. Following 
overnight incubation, the conditioned media were replaced with a buffer which contained TES 
(20 mM), pH 7.3, NaCl (150 mM), KCl (5 mM), CaCl2 (1.3 mM), MgCl2 (1.3 mM), glucose (5 
Respiration rate relative to untreated control = 100 x 
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mM), Na2SO4 (1.2 mM), KH2PO4 (0.4 mM), BSA (0.3% w/v), and tetramethylrhodamine 
methylester (TMRM+) (2 nM). The cells were incubated with the membrane potential-dependent 
dye TMRM+ [Molecular Probe] at 37 °C for 2 h, for equilibration of the dye across the 
membrane. At the end of incubation, test compounds were added, and incubation continued for 
another 30 min. Live cell imaging was performed with an Axiovert 200M epifluorescence 
microscope (Zeiss). 
 
3.2.10 Glucose uptake and lactate secretion assays 
 MDA-MB-231 cells were plated at 3 x 104 cells per well into 96-well plates in a volume 
of 100 µL RPMI 1640 medium supplemented with FBS and pen/strep as described in the 
previous section. After 24 h, test compounds were diluted with serum free RPMI 1640 medium 
with pen/strep (2x final concentration) and added in a volume of 100 µL per well. The cells were 
incubated at 37 °C under normoxic conditions (95% air 5% CO2) for 24, 48 or 72 h. The levels 
of glucose and lactate in the conditioned media samples were measured spectrophotometrically 
using enzymatic assays. To determine glucose level in the conditioned media samples, 6 µL of 
the conditioned media were added to 194 µL of reaction buffer that contained triethanolamine 
(100 mM, pH 7.3), MgCl2 (7 mM), ATP (2 mM), nicotinamide adenine dinucleotide phosphate 
(NADP+, 2 mM), hexokinase (1 unit/mL) and glucose-6-phosphate dehydrogenase (1 unit/mL). 
After an 8 min incubation at the room temperature, the absorbance was measured at 340 nm on a 
BioTek Synergy plate reader. Distilled deionized (dd) water and the glucose free RPMI 1640 
medium were used as the blanks. The average reading from the media wells (used as the blank 
reading) was subtracted from the sample readings. The average reading from the water wells 
(used as the blank reading) was subtracted from the standard wells. A glucose stock solution of 
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30 mM in dd water was diluted with dd water to achieve the final concentration of 1.25, 2.5, 5, 6, 
10, 15, 20 and 30 mM. This set of glucose standards was used to generate the standard curve. 
Glucose concentrations of the conditioned media samples were determined from the standard 
curve.  
To determine lactate concentration in the conditioned media, 8 µL of conditioned media 
was added to 192 µL of reaction buffer composed of glycylglycine (100 mM, pH 8.0), glutamate 
(100 mM), nicotinamide adenine dinucleotide (NAD+, 1mM), lactate dehydrogenase (LDH,        
1 unit/mL), and glutamate/pyruvate transaminase (1 unit/mL). After 1 h incubation at room 
temperature, fluorescence was measured at an excitation wavelength of 340 nm and an emission 
wavelength of 460 nm, on a BioTek Synergy plate reader. Distilled deionized water and the 
RPMI 1640 medium supplemented with FBS and pen/strep were used as the blanks. The average 
reading from the media wells (used as the blank reading) was subtracted from the sample 
readings. The average reading from the water wells (used as the blank reading) was subtracted 
from the standard wells. A lactate stock solution of 20 mM in dd water was diluted with dd water 
to achieve the final concentration of 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20 mM. This set of lactate 
standards was used to generate the standard curve. Lactate concentrations in the conditioned 
media samples were determined from the standard curve. Enzymes, NAD+ and NADP+ were 
purchased from Calzyme, and other reagentss were purchased from Sigma. The test compounds 
may produce cytotoxic effects and affect the net glucose uptake or lactate production. Hence the 
net glucose uptake or lactate production was normalized to protein concentrations. Following 
extraction of the cellular proteins with M-PER (Pierce), in presence of protease inhibitor cocktail 
(Sigma; 1:10 dilution), the protein concentrations were determined using a Micro BCA assay kit 
(Pierce, manufacturer’s instructions). 
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3.2.11 Statistical analysis 
 The cytotoxicity data for FCCP and 1 were analyzed using two-way ANOVA, followed 
by Bonferroni post hoc analyses (GraphPad Prism 5). The glucose and lactate concentration data 
was analyzed using one-way ANOVA, followed by Dunnett’s post hoc analysis for each time 
point. Differences between the data sets were considered significant when p < 0.05. 
 
3.3 Results and discussion 
3.3.1 Development of the bioenergetics-based screening system for the identification of 
glycolysis inhibitors 
For the identification of the inhibitors of aerobic glycolysis, MDA-MB-231, a well 
characterized triple negative human breast cancer cell line was used as the in vitro experimental 
model. This cell line was selected for its glycolytic, aggressive, and hormone refractory 
phenotype that resembles tumor tissues in advanced state of malignancy (Robey et al., 2008). At 
the concentration of 0.1 µM rotenone exerts maximal mitochondrial complex I inhibition (Liu et 
al., 2009) but exhibits only marginal cell proliferation/viability suppression in MDA-MB-231 
cells. In breast and colon tumor cells, the simultaneous inhibition of glycolysis and OxPhos 
displays enhanced cytotoxicity than either of them alone (Cheng et al., 2012; Fath et al., 2009). 
Hence, it was hypothesized that the potential glycolysis inhibitors can be identified by enhanced 
suppression of MDA-MB-231 cell viability in the presence of OxPhos inhibitors. Rotenone (50, 
Figure 3.8A) and 2-deoxy-D-glucose (2-DG, 2) were selected as prototypical OxPhos and 
glycolysis inhibitors, respectively. We evaluated the concentration-dependent effects of 2-DG (1 
to 30 mM, in half log increments) and rotenone (0.001 to 0.1 µM, in half-log increments) on 
MDA-MB-231 cell viability. Cell viability was measured by the sulforhodamine B method after 
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48 h of compound treatment at 37 °C (Skehan et al., 1990). Combinations of rotenone and 2-DG 
at different concentrations were also evaluated. Rotenone enhanced the cytotoxic effects of 2-DG 
at lower concentrations (1 and 3 mM). A the concentrations of 10 and 30 mM, 2-DG was 
cytotoxic and rotenone did not further enhance the cytotoxicity of 2-DG (Figure 3.8B).  
 
 
 
 
 
 
Figure 3.8A Structure of rotenone (50) and kolanone (51) 
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Figure 3.8B Effects of rotenone and 2-DG combinations on MDA-MB-231 cell viability. MDA-
MB-231 cells were treated with 2-DG [( ) 1 mM, ( ) 3 mM, ( ) 10 mM, ( ) 30 mM], and 
cycloheximide [( ) 100 µM], in the presence or absence of rotenone [( ) 0.0, 0.001, 0.003, 
0.01, 0.03, and 0.1 µM] for 48 h under normoxia (37 °C, 95% air, 5% CO2). Cell viability was 
measured by the sulforhodamine B method. Data shown are average ± standard deviation from 
three independent experiments performed in duplicate. 
 
%
 In
hi
bi
tio
n 
of
 C
el
l V
ia
bi
lit
y 
Rotenone (µM) 
0.001 0.003 0.01 0.03 0.1 0 
Kolanone (51) 
 
Rotenone (50) 
105 
 
Concentration of MDA-MB-231 cells with rotenone (0.1 µM) and 2-DG (3 mM) exerted 
a ~2.5-fold increase in cytotoxicity, in comparison to the additive effects of rotenone and 2-DG 
(Figure 3.9A). The mitochondrial respiration inhibitor antimycin (1 µM) and an F1F0-ATPase 
inhibitor oligomycin (1 µM) were also evaluated in combination with 2-DG for their effects on 
the MDA_MB-231 cells. These agents produced results similar to those observed with rotenone 
(data not shown). To confirm that the cytotoxicity-enhancing effect of rotenone is specific to the 
glycolysis inhibitor 2-DG, we also evaluated a protein synthesis inhibitor, cycloheximide (100 
µM). There was no additive or synergistic effects of rotenone on the suppression of MDA-MB-
231 cell viability by cycloheximide (Figure 3.9A). 
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Figure 3.9A Effect of rotenone on 2-deoxy-D-glucose (2-DG) cytotoxicity. MDA-MB-231 cells 
were treated with 2-DG (3 mM) and cycloheximide (100 µM) in the presence (or absence) of 
rotenone (0.1 µM) and incubated for 48 h under normoxic conditions (37 °C, 95% air, 5% CO2). 
Cell viability was measured by the sulforhodamine B method. Data shown are average + 
standard deviation from three independent experiments performed in duplicate (n = 6). [i (2-DG), 
ii (rotenone), iii (2-DG + rotenone), iv (cycloheximide), v (cycloheximide + rotenone)] The “*” 
denotes statistical significance (p < 0.05) when compared with cytotoxicity of either 2-DG or 
rotenone. 
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enhancement of the cytotoxicity of 2-DG (3 mM). This rotenone concentration was used to force 
the cells to survive under glycolysis-dependent conditions. The combination of a mitochondrial 
inhibitor and a glycolysis inhibitor was significantly more cytotoxic than either one alone. For 
this reason, we used the aforementioned system as the primary screening assay for the discovery 
of natural product-based inhibitors of glycolysis. We evaluated the NCI’s Open Repository of 
higher plant and marine invertebrate extracts for aerobic glycolysis inhibitory activities. A total 
of 10,648 samples (121 plates, 88 samples/plate) were evaluated in this bioenergetics-based 
cytotoxicity assay, and cell viability was measured 48 h post sample treatment (20 µg/mL) in the 
presence (plate #1) or absence (plate #2) of rotenone (0.1 µM), using the sulforhodamine B 
method (Figure 3.9B). For plate #1, media and 2-DG (3 mM) in the presence of rotenone (0.1 
µM) were used as the negative and positive control, respectively, while for plate #2, media and 
2-DG (3 mM) were used as the negative and positive control, respectively. The controls were 
plated in triplicate (n = 3) in each plate. The ‘Z-factor’ was calculated for individual plates. 
While the mean Z-factor from 121 screened plates for media control relative to the 2-DG + 
rotenone combination was 0.856 (Figure 3.9C), the Z-factors for media control vs. 2-DG alone 
(plate #2) were highly variable. This variation may be due to the low cytotoxic effect of 2-DG (3 
mM). The extracts (20 µg/mL) with a differential cytotoxicity index of ≥ 1.5 [cytotoxicity in the 
presence of rotenone (0.1 µM)/cytotoxicity in absence of rotenone (0.1 µM)], that showed ≥ 45% 
inhibition of cell viability in the presence of rotenone (0.1 µM), were selected for further 
evaluation (highly potent glycolysis inhibitors may not be selected in this assay system as they 
may completely block the glycolytic pathway, prevent the substrate availability to the 
mitochondria, and produce toxicity irrespective of the presence of rotenone). The 77 hits 
identified in the primary assay (0.72% hit rate) were prioritized according to their potency and 
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differential cytotoxicity index, and the top 23 extracts were subjected to reconfirmation. The 
active extracts (20 µg/mL) were reevaluated in triplicate using the primary assay system. Seven 
of the 23 extracts were active in the confirmatory assay.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9B A schematic diagram of the assay system for the identification of glycolysis 
inhibitors. 
Incubate at 37 °C, 48 h, Normoxia 
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Figure 3.9C Frequency distribution of calculated Z-factors between media control and 2-DG (3 
mM) + rotenone (0.1 µM). The dotted line indicates the average Z-factor (0.856) from all the 
plates screened. 
 
 
 
3.3.2. Moronone (1) structural elucidation  
 
Species identification of the active extracts and additional extract material for chemical 
studies were obtained from the NCI repository. Bioassay-guided isolation of a  Moronobea 
coccinea plant extract resulted in the identification of a new, active compound that was named 
moronone (1) (Figure 3.10). The HREISMS data of 1 showed a pseudomolecular ion (m/z) at 
525.2997 [M + Na]+, suggesting a molecular formula of C33H42O4. This formula indicated that 
the structure contained 13 hydrogen deficiency indices. The UV spectrum showed absorptions at 
237, 281, and 351 nm indicating the presence of a conjugated benzophenone chromophore (1,3-
dicarbonyl system) (Hussain et al., 1982). The IR spectrum supported the presence of an α, β-
conjugated carbonyl group (1642 cm-1) and a hydroxy group (3510 cm-1) in 1. NMR spectra of 1 
(Figure 3.11–3.12) contained resonances for a benzophenone group [δH 7.84 (2H, d, J = 7.2 Hz, 
H-9, 13), 7.46 (3H, overlapped, H-10, 11, 12); δC 198.0 (C-7), 142.0 (C-8), 132.1 (C-11), 130.0 
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(C-9, 13), 129.1 (C-10, 12)] and two geranyl moieties [δH 5.51 (2H, t, J = 7.2 Hz, H-2', 2''), 5.17 
(2H, t, J = 6.4 Hz, H-6', 6''), 3.02 (4H, overlapped, H2-1', 1''), 2.15 (4H, overlapped, H2-5', 5''), 
2.07 (4H, overlapped, H2-4', 4''), 1.79 (6H, s, H3-10',10''), 1.66 (6H, s, H3-8',8''), 1.56 (6H, s, H3-
9', 9''); δC 139.5 (C-3', 3''), 132.6 (C-7', 7''), 125.9 (C-6', 6''), 120.8 (C-2', 2''), 41.4 (C-4', 4''), 39.3 
(1', 1''), 28.2 (C-5', 5''), 27.0 (C-8', 8''), 19.0 (C-9', 9''), 17.9 (C-10', 10''], which were assigned on 
the basis of HSQC (Figure 3.13) and HMBC experiments (Figure 3.14). In addition, one 
carbonyl (δC 190.2), one quaternary carbon (δC 60.2) and four olefinic (δC 196.3, 109.9, 184.6, 
100.4) resonances were observed in the 13C NMR spectrum of 1. According to the hydrogen 
deficiency indices, the structure was deduced to contain an additional ring. Accordingly, six 
additional carbons were attributed to an α, β-conjugated cyclohexenone moiety as proposed in 
Figure 3.10 (partial structure C1–C6). The NMR data of partial structure C1–C13 was comparable 
to that of kolanone (51) (Hussain et al., 1982) (Figure 3.8A), except that an additional proton 
singlet (δH 6.15) was present in the 1H NMR spectra of 1. The position of this singlet proton was 
located at C-6, as confirmed by the HMBC correlations between H-6 (δH 6.15) and C-1 (δC 
190.2), C-5 (184.6), C-2 (109.5), C-4 (60.2). The connection of two geranyl groups to C-4 in the 
partial structure C1–C13 was established on the basis of HMBC correlations between H-1' and C-
3, C-4, C-5, C-1'', and between H-1'' and C-3, C-4, C-5, C-1'. The observation of NOESY 
correlation (Figure 3.16) between H-2'/2'' (δH 5.51) and H-4'/4'' (δH 2.07) suggested E-
configurations of the Δ2',3' and Δ2'',3'' double bonds. Therefore, the structure of moronone was 
determined to be 1 (Figure 3.10). 
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Figure 3.10 Structure and selected HMBC, 1H-1H COSY, and NOESY of moronone (1). 
Moronone (1) 
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Position δC, type δH (J in Hz) HMBC 
1 190.2, C   
2 109.5, C   
3 196.3, C   
4   60.2, C   
5 184.6, C   
6 100.4, CH 6.15, s 1, 2, 4, 5 
7 198.0, C   
8 142.0, C   
9 130.0, CH 7.84, d (7.2) 7, 8, 10, 11, 13 
10 129.1, CH 7.47, overlapped 8, 9, 11, 12 
11 132.1, CH 7.47, overlapped 9, 10, 12, 13 
12 129.1, CH 7.47, overlapped 8, 10, 11, 13 
13 130.0, CH 7.84, d (7.2) 7, 8, 9, 11, 12 
1'   39.3, CH2 3.02, overlapped 3, 4, 5, 2', 3', 1'' 
2' 120.8, CH 5.51, t (7.2) 4, 3', 4', 10' 
3' 139.5, C   
4'   41.4, CH2 2.07, overlapped 2', 3', 5', 6', 10' 
5'   28.2, CH2 2.15, overlapped 3', 4', 6', 7' 
6' 125.9, CH 5.17, t (6.4) 4', 5', 8', 9' 
7' 132.6, C   
8'   27.0, CH3 1.66, s 6', 7', 9' 
9'   19.0, CH3 1.56, s 6', 7', 8' 
10'   17.9, CH3 1.79, s 2', 3', 4' 
1''   39.3, CH2 3.02, overlapped 3, 4, 5, 2'', 3'', 1' 
2'' 120.8, CH 5.51, t (7.2) 4, 3'', 4'', 10'' 
3'' 139.5, C   
4''   41.4, CH2 2.07, overlapped 2'', 3'', 5'', 6'', 10'' 
5''   28.2, CH2 2.15, overlapped 3'', 4'', 6'', 7'' 
6'' 125.9, CH 5.17, t (6.4) 4'', 5'', 8'', 9'' 
7'' 132.6, C   
8''   27.0, CH3 1.66, s 6'', 7'', 9'' 
9''   19.0, CH3 1.56, s 6'', 7'', 8'' 
10''   17.9, CH3 1.79, s 2'', 3'', 4'' 
OH  8.85, br s  
 
Table 3.1 NMR spectroscopic data for 1 at 400 MHz (1H) and 100 MHz (13C) in pyridine-d5. 
Carbon (13C) assignments were assigned from HSQC data.  
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3.3.3 Bioactivity of moronone (1) 
In order to confirm the glycolysis inhibitory effect of 1, glucose uptake and lactate 
production by MDA-MB-231 cells were measured in the presence of 1 (1, 3, 10 and 30 µM) after 
24, 48 and 72 h. Moronone (1) significantly increased cellular glucose uptake at the 
concentrations of 10 and 30 µM, at all the time points, with a corresponding increase in lactate 
production (Table 3.2). This was suggestive of a stimulatory effect on the glycolytic pathway 
instead of a glycolysis inhibitory effect. When cells were treated with a well-known 
mitochondrial uncoupler FCCP (0.1, 0.3, 1 and 3 µM), similar changes to cellular glucose uptake 
and lactate production was observed at the concentrations of 1 and 3 µM. Rotenone (0.1 µM) 
enhanced the cellular glucose uptake and lactate production at all the time points. The 
observation that FCCP stimulate glycolysis is consistent with an earlier report of glycolysis 
stimulation in mammalian tumor cells by uncouplers (Sturdik et al., 1986). 
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Based on the observations that 1 contains two geranyl moieties and keto-enolic 
functionalities in the structure, and stimulate cellular glucose uptake and lactate production, it 
was hypothesized that 1 might penetrate the mitochondrial membrane and act as a protonophore. 
Hence, we evaluated 1 in MDA-MB-231 and T47D cell-based mitochondrial respiration assays 
(Liu et al. 2009). Moronone (1) exerted a biphasic effect on cellular oxygen consumption in both 
MDA-MB-231 and T47D cells. At lower concentrations (0.1, 0.3, and 1 µM), 1 increased 
cellular oxygen consumption. A decline in the respiration rate was observed at a higher 
concentration (3 µM) (Figure 3.17A). When the prototypical uncoupler FCCP was added to both 
cell lines at increasing concentrations (0.03, 0.1 0.3 and 1 µM), a similar change was observed 
on cellular oxygen consumption. The magnitude of the enhancement of the relative respiration 
rate was higher in MDA-MB-231, compared to that of T47D. This phenomenon might be 
explained by a lower baseline oxygen consumption rate in MDA-MB-231 cells compared to that 
of T47D cells (Li et al., 2011). In order to eliminate possible effects of 1 on ATP turnover, and 
determine if 1 acts as a protonophore (increases cellular oxygen consumption), we evaluated the 
effect of 1 on cellular respiration in the presence of an F0F1-ATPase inhibitor oligomycin. 
Inhibition of F0F1-ATPase by oligomycin increases the mitochondrial membrane potential by 
preventing proton re-entry into the mitochondrial matrix, which in turn inhibits electron transfer 
through the respiratory chain. Protonophores, such as FCCP, release the inhibition of respiration 
by translocating protons to the mitochondrial matrix through the inner mitochondrial membrane. 
Moronone (1) and FCCP each overcame oligomycin exerted inhibition on cellular oxygen 
consumption in MDA-MB-231 (Figure 3.17B, 3.17C) and T47D cells (data not shown), and 
accelerated oligomycin-induced state 4 respiration. 
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Figure 3.17A Concentration-response effects of 1 and FCCP on cellular respiration in T47D and 
MDA-MB-231 cells. Moronone was tested at 0.1, 0.3, 1 and 3 µM, while FCCP was tested at 0.3 
µM in T47D cells and at 0.03, 0.1, 0.3 and 1 µM in MDA-MB-231 cells. Oxygen consumption 
rates were recorded before and after treatments and the data were presented as relative 
respiration rates. Data shown are average + standard deviation from three independent 
experiments (n = 3). 
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Figure 3.17B Accelaration of state 4 respiration initiated by oligomycin (1 µM) in MDA-MB-
231 cells by moronone (1 µM) 
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Figure 3.17C Accelaration of state 4 respiration initiated by oligomycin (1 µM) in MDA-MB-
231 cells by FCCP (0.3 µM). 
 
In order to confirm the protonophoric activity of 1 and to exclude enhanced substrate 
oxidation as the cause of an increase in the relative respiration rate, we evaluated the effect of 1 
on mitochondrial membrane potential in MDA-MB-231 and T47D cells. A cationic, fluorescent 
dye, TMRM+, was used to assess mitochondrial membrane potential. Owing to its cationic 
charge, TMRM+ accumulates into the mitochondrial matrix under the normal mitochondrial 
membrane potential, and stains the mitochondria. Protonophores, such as FCCP, dissipate 
mitochondrial membrane potential and cause diffusion of the TMRM+ dye, which results in 
reduction of the fluorescent dye intensity. Moronone (1) decreased mitochondrial membrane 
potential significantly in MDA-MB-231, which supported the protonophoric nature of this 
compound (Figure 3.18). 
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Figure 3.18 Dissipation of mitochondrial membrane potential by 1 and FCCP. MDA-MB-231 
(upper panel) and T47D (lower panel) cells were incubated with 2 nM TMRM+ for 2 h. The cells 
were treated with either 1 (1 µM) or FCCP (1 µM) for 30 min, and the cells were imaged with an 
Axiovert 200 M epifluorescent microscope. Images representative of each condition are shown 
above. 
 
Since bioassay-guided fractionation of the active extract led us to the isolation of 1 that 
acts as a protonophore, we decided to evaluate the effect of the uncoupler standard FCCP in our 
assay system. MDA-MB-231 cells were treated with either FCCP or 1, in the presence (or 
absence) of a mitochondrial inhibitor, such as rotenone. Rotenone (0.1 µM) significantly 
enhanced the cytotoxic effect of both FCCP and 1 on the normoxic MDA-MB-231 cells under 
normoxia (Figure 3.19).  
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Figure 3.19 Differential suppression of MDA-MB-231cell viability by moronone and FCCP in 
the presence (or absence) of rotenone. MDA-MB-231 cells were treated with moronone [1, 3, 10, 
and 30 µM] or FCCP [0.1, 0.3, 1 and 3 µM], with (or without) rotenone and incubated for 48 h 
under normoxic conditions (37 °C, 95% air, 5% CO2). Data shown are average + standard 
deviation from two independent experiments assayed in triplicate [i (rotenone), ii (2-DG), iii (2-
DG + Rotenone), iv (FCCP), v (FCCP + Rotenone), vi (moronone), vii (moronone + rotenone)]. 
The “*” denotes statistical significance (p < 0.05) when compared with cytotoxicity in the 
absence of rotenone. 
 
The results indicate that, mitochondrial respiration inhibitors enhance the 
cytostatic/cytotoxic effects of mitochondrial uncouplers, similar to those reported for glycolysis 
inhibitors. The concentration that produced optimum uncoupling in the cell-based respiration 
assay was lower than the concentration at which FCCP (1 µM) and moronone (10 µM) produced 
optimum differential cytotoxicity [≥45% cytotoxicity in the presence of rotenone (0.1 µM) with 
a differential index of ≥ 1.5].  
The glucose analog 2-DG inhibits glycolysis by indirectly decreasing enzymatic 
hexokinase (an enzyme that catalyzes the intracellular glucose phosphorylation) activity. Clinical 
2-DG monotherapy phase I trials was successful; however, the phase II clinical trial was 
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terminated due to slow patient enrollment (ClinicalTrials.gov, website accessed on 04/03/2012). 
Inhibition of aerobic glycolysis by small molecules is a promising approach to treat advanced 
stages of cancer (Scatena et al., 2008); hence, the discovery of natural product-derived small-
molecules that inhibit aerobic glycolysis more potently than 2-DG is a critical step towards 
finding an effective agent for cancer therapy. The stem wood extract of Moronobea coccinea 
showed a differential cytotoxicity index of 1.5 ( ≥ 45% cytotoxicity in the presence of rotenone) 
in the initial screening assay. Bioassay-guided fractionation of Moronobea coccinea led to the 
isolation of polyprenylated benzophenone derivative moronone (1). Rotenone, FCCP, and 1 
stimulated cellular glucose uptake and enhanced lactate secretion, in a concentration and time-
dependent manner. Moronone uncoupled mitochondrial respiratory chain in both the cellular 
respiration assay and the mitochondrial membrane potential assay. When evaluated in the 
primary screening system, an increased cytotoxicity was observed for both FCCP and 1 in the 
presence of rotenone. The observed differential suppression of cell viability under glycolysis-
dependent conditions by either FCCP or 1 might be due to glucose deprivation and subsequent 
ATP depletion. Further investigations are needed to reveal the actual mechanism. It has been 
reported that the combination of a mitochondrial respiratory chain inhibitor and a mitochondrial 
uncoupler stimulate cellular sugar uptake, depletion of cellular ATP levels (due to ATP 
hydrolysis by the F1F0-ATPase), and suppression of cell viability in mammalian cells. 
Oligomycin, an F1F0-ATPase inhibitor, protected the cells from the cytotoxic effect (Nieminen et 
al., 1994). Alternatively, one school of thought contends that, under normoxic conditions, the 
presence of an uncoupler with a mitochondrial complex I inhibitor lead to enhanced superoxide 
production, which cause enhanced cytotoxicity (Cadenas and Han, 2007). The protonophoric 
nature of some polyprenylated benzophenone analogs may possibly explain general 
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antimicrobial, cytotoxic and some other activities exhibited by these analogs. In this bioassay 
system, the mitochondrial uncouplers tend to mimic the effect of glycolysis inhibitors on MDA-
MB-231 cell viability under glycolysis-dependent conditions. In order to discover inhibitors of 
aerobic glycolysis by using this system, one must rapidly dereplicate the mitochondrial 
uncouplers from specific glycolysis inhibitors. A tumor cell-based respiration assay may be 
employed to dereplicate extracts with protonophoric properties, after primary screening and 
identification of the hits. Alternatively, rotenone may be substituted with oligomycin in order to 
prevent experimental artifact resulting from ATP hydrolysis by F0F1-ATPase.  
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presence of mitochondrial inhibitors. 
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4.1 Overview 
4.1.1 Introduction 
 Only recently has the potential for drug-induced mitochondrial dysfunction become 
recognized to significantly limit pharmaceutical development, and has forced the withdrawal of 
major drugs used to treat diabetes [troglitazone (1)] and hyperlipidemia [cerivastatin (2)].  Nearly 
half of the drugs with hepatoxicity and cardiovacular toxicity-associated FDA Black Box 
Warnings are known to interfere with mitochondrial function (Dykens and Will, 2007). These 
safety issues highlight the critical importance of employing measures to assess the potential 
mitochondrial toxicity of new drug leads early in the drug development process. While the 
pharmaceutical industry has only recently begun to recognize and test for the potential 
mitochondrial liability of new therapeutic agents, similar efforts have not been applied to the 
plethora of phytochemicals in botanical dietary supplement (BDS) products. As an initial 
exploratory study, extracts from more than 350 species of plants and other organisms used in 
traditional Chinese, Ayurvedic, and Western Herbal Medicine were evaluated for their ability to 
disrupt mitochondrial function. 
 Extracts from 24 different plant species suppressed mitochondrial respiration in 
mammalian cells. The extracts from five species uncoupled oxidative phosphorylation. Several 
species that were identified in our assays [i.e., Glycyrrhiza glabra L. (Fabaceae), Chenopodium 
botrys L. (Amaranthaceae), Larrea tridentata (Sessé & Moc. ex DC.) Coville (Zygophyllaceae), 
and Tripterygium wilfordii Hook.f. (Celastraceae)], contain compounds that interfere with 
mitochondrial function (Pardini et al., 1973; Monzote et al., 2009; Su et al., 2007). Extracts of 
Caulophyllum thalictroides (L.) Michx. (Berberidaceae) and Commiphora wightii (Arn.) 
Bhandari (Burseraceae) contain components that can disrupt mitochondrial function and 
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potentially produce idiosyncratic mitochondria-mediated toxicities. The three blue cohosh (C. 
thalictroides) saponins, cauloside A (3), saponin PE (4), and cauloside C (5) were preliminarily 
identified as potential mitochondriotoxic components using a cell-based HIF-1 reporter gene 
assay. In addition to permeabilizing the plasma membrane, these saponins disrupt mitochondrial 
function in the Clarke-type electrode-based cellular respiration assay by permeabilizing 
mitochondrial membranes. Sesamin (6) and guggulsterol III (7) from guggul (C. wightii) extract 
preferentially inhibited hypoxia-induced HIF-1 activation, and disrupted mitochondrial complex 
I. Further investigation of guggul compounds is required because the extract was more active 
than the samples of pure compounds evaluated. Our results indicate the presence of 
mitochondriotoxic substances in popular dietary supplements and the need for systematic 
investigation of BDS products to identify the components that disrupt mitochondrial function. 
 
4.1.2 General mechanisms of mitochondria-mediated toxicity 
The term ‘toxicity’ means the harm caused to a living being by chemical, physical or 
biological agents (Society of Toxicology, accessed on 05/04/2012). Toxicity is often the end 
result of a cascade of events initiated by the initial exposure of an organism to toxic agents. 
Toxins elicit a wide variety of toxic effects ranging from nonlethal biochemical dysfunction to 
massive tissue/organ injury and even death of the organism (Society of Toxicology, accessed on 
05/04/2012). Based on the pathological effects induced by the toxins, toxicity can be broadly 
categorized into the following: (a) cell death/tissue injury; (b) altered phenotype/function; (c) 
immunological hypersensitivity; and (d) cancer (Liebler and Guengerich, 2005). Among these, 
the most prevalent toxic response is the cell death/tissue injury. 
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Mitochondria are double membrane-bound cellular organelles which synthesize ATP via 
oxidative phosphorylation to provide energy for cellular reactions. Apart from meeting the 
cellular energy demand, mitochondria also regulate a number of pathways critical for cellular 
homeostasis and specialized metabolic processes such as fatty acid β-oxidation and the Kreb’s 
cycle (Eaton et al., 1996; Alberts et al., 2002). Certain biosynthetic processes, such as heme and 
urea syntheses, partially occur in the mitochondrial matrix (Fontenay et al., 2006; Mori et al., 
1983). Additionally, mitochondria play a key role in resulting cellular injury or cell death (Green 
and Kroemer, 2004). Mitochondrial content may vary widely depending on cell type. Cells with 
high ATP turnover contain more mitochondria than cells with low ATP turnover. It is 
hypothesized that cells have some functional mitochondrial reserve capacity; and when 
mitochondrial damage exceeds a certain threshold, cells initiate the process of either apoptotic or 
necrotic cell death (Jones et al., 2010). When cellular injury or cell death is widespread in a 
particular tissue or organ, it results in tissue or organ toxicity, such as cardiotoxicity, 
neurotoxicity, nephrotoxicity and hepatotoxicity. 
Cell death pathways can be broadly categorized into the following, based on the 
molecular mechanisms: (a) apoptosis; (b) necrosis; (c) autophagy; and (d) mitotic catastrophe 
(Kroemer et al., 2007). Mitochondria are involved in effecting cell death through all four 
pathways. However, we will mainly focus on apoptosis and necrosis, as these are the most 
relevant pathways in drug/chemical-induced toxicity.   
Apoptotic or programmed cell death is mediated by either of the two major pathways: (a) 
the extrinsic or death receptor pathway and (b) the intrinsic or mitochondrial pathway. Both 
pathways can be further divided into initiation, integration, and execution stages (Kroemer et al., 
2007; Jin and El-Deiry, 2005).  Extracellular ligands bind to the cell surface death receptors 
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[tumor necrosis factor (TNF) receptor-1, Fas, and TRAIL receptors-1 and -2] to initiate the 
extrinsic apoptotic pathway. Following ligation, the death receptors undergo oligomerization, 
forming a death-inducing signaling complex (DISC). The DISC contains Fas-associated death 
domain (FADD) and an initiator caspase (i.e., caspase-8). Caspase-8 in the DISC undergoes 
autoactivation, leading to the activation of executioner caspases (i.e., caspase-3, -6 and -7) 
(Ashkenazi and Dixit, 1998). Activated caspase-8 cleaves and activates Bid, a proapoptotic Bcl-2 
family protein, which results in mitochondrial membrane permeabilization. Activated 
executioner caspases (caspase-3, -6 and -7) cleave specific cellular substrates, resulting in 
apoptotic cell death (Kroemer et al., 2007).  
The intrinsic apoptotic pathway is the predominant apoptotic pathway in mammalian 
cells (Green and Kroemer, 2004). This pathway is initiated by diverse intracellular signals, such 
as damaged cellular organelles or DNA, and/or toxic substances. Permeabilization of the 
mitochondrial outer membrane occurs in response to intracellular apoptotic stimuli, and 
cytochrome c is released from the mitochondrial intermembrane space to cytosol (Kroemer et al., 
2007). The presence of cytochrome c in cytosol activates caspase-9 via formation of the 
apoptosome [a multiprotein complex that consists oligomerized apoptotic protease activating 
factor-1 (Apaf-1)] (Cain et al., 2002). Following activation, caspase-9 cleaves, and activates 
procaspase-3, -6, and -7, resulting in apoptotic cell death. Irrespective of the pathway involved, 
apoptotic cell death is characterized by cell shrinkage, nuclear pyknosis, karyorhexis and 
phosphatidylserine exposure to the extracellular environment. During apoptosis, apoptotic bodies 
are formed and cleared phagocytically without producing an inflammatory reaction (Elmore, 
2007).  
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Necrosis, on the other hand, usually results from a highly intense toxicological insult. 
Necrosis is typically accompanied with oncosis, including mitochondrial swelling and eventual 
mitochondrial and cell membrane rupture. Spillage of cytosolic content into the extracellular 
space results in inflammatory responses (Kroemer et al., 2007; Robertson and Orrenius, 2002).  
Mitochondria also play an important role in cell death via necrosis. Opening of a 
mitochondrial membrane permeability transition pore (mPTP) is often associated with necrosis. 
Opening of mPTP dissipates the mitochondrial membrane potential (ΔΨm), disrupts the 
intracellular electrochemical and pH gradients, and results in mitochondrial and cellular 
swelling. Eventually, cellular and mitochondrial lyses occur due to increased osmotic pressure 
(Gregus, 2008). Some of the key factors that determine whether a cell will undergo necrosis or 
apoptosis in response to a toxicant include the toxin concentration, exposure time, and 
intracellular ATP concentration. High toxin concentrations, prolonged exposure period and 
intracellular ATP depletion usually lead to necrotic cell death (Kroemer et al., 1998). In spite of 
the differences in the molecular mechanisms, mitochondrial dysfunction is often the final 
common step that leads to cellular death. 
 
4.1.3 Drug or small-molecule-induced mitochondrial toxicity  
From the discussion in the introduction section, it is obvious that both clinically approved 
drugs and natural products, may potentially cause mitochondrial dysfunction. However, natural 
products are commonly thought to be free of adverse effects, compared to clinically approved 
drugs. Hence, the rigorous scrutiny that is mandatory for clinically approved drugs are not 
applied for over-the-counter (OTC) natural products. Several drugs, such as troglitazone (1) and 
cerivastatin (2) (Figure 4.1), have been withdrawn from the market for their mitochondrial 
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liabilities. Similarly, the mitochondrial toxins in natural product dietary supplements should be 
identified and a regulatory standard comparable to clinically approved drugs should be set for 
OTC natural products with mitochondrial toxins. 
  
 
 
 
 
 
Figure 4.1 Examples of clinically approved drugs withdrawn from the market due to 
mitochondrial toxicity. 
 
4.1.4 Saponin glycoside toxicity 
 Saponins are ubiquitous plant secondary metabolites with surfactant properties (Sparg et 
al., 2004). Multiple dietary supplements containing saponin glycosides for various indications 
are currently marketed in the US (Avula et al., 2011; Kozlova et al., 2011; Yeh et al., 2003). A 
number of biological properties have been attributed to this class of compounds, with hemolytic 
or membrane permeabilizing activity being the most prominent (Francis et al., 2002). Based on 
the sapogenin (aglycone) structure, saponins are categorized into two broad classes: (a) steroidal 
saponins [e.g., diosgenin (8)] and (b) triterpenoid saponins [e.g., oleanolic acid (9)]. Owing to 
their surfactant properties, saponins interact with the lipid bilayers of cellular membranes and 
alter their permeability by irreversibly forming pores. Mechanistically, they are hypothesized to 
sequester cholesterol from membranes (Melzig et al., 2001). Alternatively, saponins are 
proposed to interact with the aquaporins on the cell surface, resulting in unregulated water 
 
(1) (2) 
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transport inside cells and subsequent hemolysis (Gauthier et al., 2009). Following parenteral 
administration, saponins show high levels of toxicity in animals. Holothurin A (10), a sea 
cucumber-derived saponin, had an LD50 of 0.75 mg/kg in mice upon intravenous administration. 
Due to their poor oral bioavailability, saponins are significantly less toxic upon oral ingestion 
(LD50 50-1000 mg/kg). Aberrant salivation, vomiting, diarrhea, loss of appetite and paralysis 
have been reported after saponin intoxication (Hostettmann et al., 1995). Lethal doses of 
saponins have been shown to cause liver necrosis, as well as bleeding in alveoli and other vessel 
walls (Hostettmann et al., 1995). However, conflicting results were reported in regard to the 
correlation of the hemolytic/surfactant activity and saponin toxicity profiles (Wang et al., 2007a; 
Böttger et al., 2012). Saponins permeabilize respiratory membranes of cold-blooded animals and 
have been reported to be highly toxic to frogs, fish, and mollusks. Saponins exert cytotoxic 
effects on a variety of human tumor cell lines (Hostettmann et al., 1995). It has been proposed 
that cellular internalization is required for steroidal saponin glycoside cytotoxicity (Wang et al., 
2007b). Release of cytochrome c from mitochondria was observed while investigating the 
mechanism of cytotoxic activity by avicins, a group of plant saponins. The cytochrome c release 
by avicins resulted from direct mitochondrial membrane permeabilization (Haridas et al., 2001; 
Lemeshko et al., 2006). Another plant saponin OSW-1 (11) has been reported to permeabilize 
mitochondrial membrane and activate calcium-dependent apoptosis in both leukemia and 
pancreatic cancer cells (Zhou et al., 2005). Numerous saponins have been reported to affect a 
number of cellular pathways that result in cytotoxicity (Man et al., 2010; Podolak et al., 2010). 
However, it is unclear whether the effect observed on the cellular signaling is secondary to a 
toxic mitochondrial insult. In addition, most cytotoxicity studies do not report whether the effect 
of the saponins are selective to tumor cell lines, relative to their effects on normal cells. The 
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potential for saponin selectivity toward tumor cells and a possible correlation between 
mitochondrial membrane permeabilization and general saponin cytotoxicity warrants further 
investigation. 
 The potential of mitochondrial toxicity from BDS has not been well characterized. One of 
the major challenges for identification of BDS-induced mitochondrial toxicity is that these 
dietary supplements are often consumed in conjunction with clinically approved drugs, which 
have off-target effects on the mitochondria. In addition, consumption of BDS is perceived as safe 
and often goes unreported. From the earlier discussions, it is apparent that natural products are a 
rich source for mitochondrial toxins and they impair mitochondrial functioning in the same way 
as synthetic compounds or clinically approved drugs. The presence of mitochondriotoxic 
substances in BDS may pose a potential health hazard and the characterization of these 
molecules is necessary to better understand, and potentially prevent, idiosyncratic adverse 
reactions. 
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Figure 4.2 Examples of sapogenins and saponins.
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4.2 Materials and methods 
4.2.1 Acqusition of extracts and pure compounds 
 Among 46 active extracts blue cohosh and guggul extracts and the purified compounds 
from blue cohosh [N-methylcytisine (12), cauloside H (13), cauloside D (14), cauloside B (15), 
cauloside G (16), leonticin D (17), cauloside A (3), saponin PE (4), cauloside C (5), and 
ciwujianoside A1 (18) (Figures 4.3 – 4.4)] and guggul [(13E,17E,21E)-8-hydroxypolypodo-
13,17,21-trien-3-one (19), (13E,17E,21E)-polypodo-13,17,21-trien-3,8-diol (20), sesamin (6), Z-
guggulsterone (21), E-guggulsterone (22), guggulsterol III (7), and (20S)-20-acetoxy-4-
pregnene-3,16-dione (23) (Figures 4.5A)] were further investigated. These extracts and 
compounds were kindly provided by Dr. Ikhlas A. Khan (National Center for Natural Products 
Research, University of Mississippi). The extracts and purified compounds were dissolved in 
either DMSO or isopropanol and 10 mM stock solutions of each were prepared. 
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Figure 4.3 Purified blue cohosh compounds that were evaluated for mitochondrial toxicity. 
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Figure 4.4 Purified blue cohosh compounds that were evaluated for mitochondrial toxicity. 
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Figure 4.5A Purified guggul compounds that were evaluated for mitochondrial toxicity. 
 
 
 
 
 
 
 
Figure 4.5B Prototypical mitochondrial inhibitors and uncoupler.
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4.2.2 Tumor cell culture and HIF-1 reporter assay 
 Human breast tumor T47D cells (ATCC) were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) and Ham’s F-12 (1:1) media with 2.5 mM L-gultamine (Mediatech), 
supplemented with fetal bovine serum (10% v/v final concentration, Hyclone) and penicillin (50 
units/mL) and streptomycin (50 μg/mL) (pen/strep, BioWhittaker). Exponentially grown T47D 
cells were transfected with the pTK-HRE3-luc reporter by electroporation using an ECM830 
square wave electroporation system (BTX Inc) at 140 V for 70 ms (1 pulse). The transfected 
cells were plated at 3 x 104 cells per well in a volume of 100 µL of FBS (10% v/v final 
concentration) and antibiotics supplemented DMEM/F12 medium, into 96-well plates, and was 
incubated under normoxic conditions (5% CO2, 95% air, 37 °C) for overnight. After 24 h, each 
test compound was diluted (2x final concentration) in serum free DMEM/F12 medium with 
antibiotics and added in a volume of 100 µL per well. Following the addition of the test 
compounds, the incubation continued at 37 °C for an additional 30 min. Subsequently, the cells 
were exposed to hypoxic (1% O2, 5% CO2, 94% N2) or normoxic (5% CO2, 95% air) or iron 
chelator-induced hypoxia-mimetic conditions (10 µM 1,10-phenanthroline, Sigma, 5% CO2, 
95% air) at 37 °C for 16 h. The cells were then lysed, and luciferase activities were determined 
according to manufacturer’s instructions (Promega) using a microplate reader (Biotek).  The 
following formula was used to calculate the percentage inhibition data: 
% inhibition = (1 - luminescencetreated/luminescenceinduced) x 100 
Extracts and compounds for bioassay were prepared as stock solutions in DMSO (or 
isopropanol) and the final concentration of solvent was less than 0.5% (v/v) in all HIF-1 reporter 
assays. 
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4.2.3 Cellular respiration assay 
 Human T47D or Hep3B cells (5 × 106) suspended in 100 µL of 1x phosphate-buffered 
saline (PBS), pH 7.4  (Fisher Scientific) were added to the chamber of an Oxytherm Clark 
electrode system (Hansatech) containing 900 µL of DMEM/F-12 medium (JRH) free of serum 
and antibiotics (equilibrated to 30 °C). Glucose (17.5 mM) in the DMEM/F-12 media served as 
the metabolic substrate. Steady state base-line respiration was established (for a 10-min interval) 
by recording the oxygen consumption of untreated cells. Subsequently, compounds dissolved in 
DMSO (or isopropanol) were injected into the chamber using a 10-μL syringe (Hamilton). For 
the compounds that initially stimulated cellular oxygen consumption, the average oxygen 
consumption rates were measured for a one-minute window 30, 115 and 295 seconds after each 
addition. For the compounds that inhibited oxygen consumption, the average rate was recorded 
for a one-minute window 2 min after each addition. For mechanistic studies, the cells were 
suspended in a buffer that contained 20 mM HEPES, pH 7.3, 120 mM KCl, 2 mM KH2PO4, 2 
mM MgCl2 and 1 mM EGTA [ethylene glycol bis(2-aminoethyl ether)-N,N,N’,N’-tetraacetic 
acid], in place of the DMEM/F-12 medium. Plasma membranes were selectively permeabilized 
with digitonin (4 μM) so that the substrates available to the mitochondria could be manipulated. 
The buffer was supplemented with the following substrates that provide electrons to different 
complexes within the mitochondrial respiratory chain: 5 mM sodium pyruvate and 5 mM sodium 
malate (complex I), 5 mM sodium succinate dibasic hexahydrate (complex II), and 5 mM L-
ascorbic acid plus 0.2 mM TMPD (N,N,N′,N′-tetramethyl-p-phenylenediamine) (complex IV). 
The prototypical complex I and III inhibitors rotenone (24) and antimycin A (25) (Figure 4.5B), 
respectively, were added from EtOH stock solutions to a final concentrations of 1 μM where 
indicated. All the chemicals were from Sigma, and the final concentration of solvent used in 
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assays was maintained at less than 0.1% (v/v). The data were presented as percentage inhibitions 
or relative respiration rates wherever appropriate and were calculated by the following formulas:  
                                                         oxygen consumption ratecompound 
                                                         oxygen consumption ratecontrol 
 
 
                                                                                               oxygen consumption ratecompound 
                                                                                               oxygen consumption ratecontrol 
 
4.2.4 Sulforhodamine B cell viability assay 
 Exponentially grown T47D or Hep3B cells were plated at 3 x 104 cells per well into 96-
well plates in a volume of 100 µL of DMEM/F12 medium supplemented with FBS (10% v/v 
final concentration) and antibiotics. After 24 h, each test compound was diluted (2x final 
concentration) in the serum free DMEM/F12 medium with antibiotics, added in a volume of 100 
µL per well, and incubated for an additional 2-day (or 6-day) period at 37 °C (95% air, 5% CO2). 
For the 6-day exposure study, the conditioned media were replaced after 3 days by fresh culture 
media that contained test compounds. Following a 2-day (or 6-day) incubation period, the cells 
were fixed by replacing 100 µL of culture medium with 100 µL trichloroacetic acid solution 
(20% w/v in 1x PBS, pH 7.4) per well. Following incubation at 4 °C for 1 h, the supernatant was 
removed, and the cells were washed with tap water (4x) and air-dried. A sulforhodamine B 
solution (0.4% w/v, in 1% actetic acid) was added in a volume of 100 µL per well and incubated 
at room temperature for 10 min. The stained cells were washed with 1% acetic acid (4x) and air-
dried. The dye was eluted by using 200 µL of Trizma® base (10 mM) per well and incubating for 
10 min at room temperature. The plates were gently shaken for 2 – 3 min, and absorbance was 
measured at 490 nm and background absorbance at 630 nm on a BioTek Synergy plate reader. 
The ΔOD values were used for subsequent data analysis and were calculated by subtracting the 
% Inhibition = 1 - x 100 
Respiration rate relative to untreated control = 100 x 
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background absorbance from the absorbance at 490 nm. The following formula was used to 
calculate the percentage inhibition: 
% inhibition = (1 - ΔODtreated/ΔODcontrol) x 100 
 
4.3 Results and discussion 
4.3.1 HIF-1 inhibitory activity of herbal dietary supplements due to suppression of 
mitochondrial electron transport chain 
 The evaluation of 352 extracts of botanical dietary supplement products was performed 
by Ms. Mahdi in the previously described T47D cell-based HIF-1 reporter assay. Transfected 
T47D cells (pTK-HRE3-Luc) were treated with the extracts (5 µg/mL) and then exposed to 
either hypoxic conditions (1% O2) or the iron chelator 1,10-phenanthroline (10 µM) to induce 
HIF-1 reporter activity. In this assay, mitochondrial ETC inhibitors typically more potently 
inhibit hypoxia-induced HIF-1 relative to their effect on iron chelator-induced HIF-1 activation 
(Coothankandaswamy et al., 2010). Protonophores demonstrate nonspecific inhibition of HIF-1 
induction irrespective of the inducing conditions (Du et al., 2010). Forty six extracts that 
displayed an activity profile similar to either a mitochondrial inhibitor or an uncoupler were 
reconfirmed in a cell-based respiration assay by Ms. Mahdi. Sixteen extracts strongly (> 50%) 
inhibited cellular respiration, while six extracts only weakly (25 – 50%) inhibited respiration.  
Five extracts increased cellular oxygen consumption, indicating that they may uncouple 
oxidative phosphorylation. Active extracts were reconfirmed and subjected for further 
phytochemical identification and dereplication studies. Among the active extracts, blue cohosh 
and guggul extracts were identified for further investigations. 
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4.3.2 Effects of herbal dietary supplement compounds on cellular respiration 
4.3.2.1 Blue Cohosh (Caulophyllum thalictroides) 
 The extract of blue cohosh [Caulophyllum thalictroides (L.) Michx. (Berberidaceae)] 
inhibited HIF-1 activity and its effects on cell respiration were reconfirmed in the oxygen 
consumption assay. Ten purified compounds from blue cohosh were obtained from Dr. Khan’s 
pure compound repository for further evaluation (Figures 4.3 – 4.4).  
The compounds were evaluated in the HIF-1 assay at multiple concentrations (1, 10 and 
30 µM) (Figures 4.6A – B). These concentrations were within the concentration range that was 
reported to be present in the commercial dietary supplements (Avula et al. 2011) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6A Inhibition of hypoxia-induced HIF-1 by blue cohosh pure compounds. Transfected 
(pTK-HRE3-luc) T47D cells were treated with compounds (1, 10 and 30 µM) and exposed to 
hypoxic (1% O2) conditions for 16 h. Data shown are average + standard deviation from single 
representative experiment performed in triplicate.  Absence of error bars due to identical 
readings for any data point is denoted by ‘*’. 
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Figure 4.6B Inhibition of 1,10-phenanthroline-induced HIF-1 by blue cohosh compounds. 
Transfected (pTK-HRE3-luc) T47D cells were treated with compounds (1, 10 and 30 µM) and 
exposed to 1,10-phenanthroline (10 µM) for 16 h. Data shown are average + standard deviation 
from single representative experiment performed in triplicate. Absence of error bars due to 
identical readings for any data point is denoted by ‘*’. 
 
Among the 10 compounds tested, cauloside A (3), Saponin PE (4), and cauloside C (5) 
demonstrated inhibition of both hypoxia, and 1,10-phenanthroline-induced HIF-1 activation. 
Because the HIF-1 activity profiles of 3, 4 and 5 were similar to mitochondrial protonophores, 
these compounds were further evaluated for their effects on cell respiration. The compounds 
exhibited a time and concentration-dependent biphasic effect on T47D (intact) cell oxygen 
consumption in the respiration assay (Figures 4.7A – C). The blue cohosh extract also showed 
similar a concentration-response effect on T47D cell respiration (Figure 4.7D). Saponin PE (4) 
most potently perturbed mitochondrial respiration. The solvent being DMSO (a well-
characterized solvent), possibility of any solvent effect was ruled out. 
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Figure 4.7A Concentration-response effect of cauloside A (3) on T47D respiration. Cauloside A 
(3) was tested at 5.6, 10.0, 17.8 and 30.0 µM. Oxygen consumption rates were recorded 30, 115 
and 295 seconds after each treatment and the data were presented as percentage inhibition of 
oxygen consumption rate compared to the average oxygen consumption rate of untreated T47D 
cells. Negative values indicate a relative stimulation of oxygen consumption. Data shown are 
average + deviation from the mean for the 5.6 µM data point from two independent experiments 
(n = 2) and average + standard deviation for the rest of the data points from three independent 
experiments (n = 3). 
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Figure 4.7B Concentration-response effect of saponin PE (4) on T47D cell respiration. Saponin 
PE (4) was tested at 5.6, 10.0, 17.8 and 30.0 µM. Oxygen consumption rates were recorded 30, 
115 and 295 seconds after each treatment and the data were presented as percentage inhibition of 
oxygen consumption rate compared to the average oxygen consumption rate of untreated T47D 
cells. Negative values indicate a relative stimulation of oxygen consumption. Data shown are 
average + standard deviation from three independent experiments (n = 3). 
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Figure 4.7C Concentration-response effect of cauloside C (5) on T47D cell respiration. 
Cauloside C (5) was tested at 5.6, 10.0, 17.8 and 30 µM. Oxygen consumption rates were 
recorded 30, 115 and 295 seconds after each treatment and the data were presented as percentage 
inhibition of oxygen consumption rate compared to the average oxygen consumption rate of 
untreated T47D cells. Negative values indicate a relative stimulation of oxygen consumption. 
Data shown are average + standard deviation from three independent experiments (n = 3). 
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Figure 4.7D Concentration-response effect of blue cohosh extract on T47D cell respiration. Blue 
cohosh extract was tested at 5.6, 10.0, 17.8 and 30.0 µg/mL. Oxygen consumption rates were 
recorded 30, 115 and 295 seconds after each treatment and the data were presented as percentage 
inhibition of oxygen consumption rate compared to the average oxygen consumption rate of 
untreated T47D cells. Negative values indicate a relative stimulation of oxygen consumption. 
Data shown are average + standard deviation from three independent experiments (n = 3). 
 
Hepatocyte mitochondrial impairment is one of the major reasons for drug-induced 
hepatotoxicity. The potential of 3, 4, 5 and the original extract to disrupt the hepatic 
mitochondrial respiration was evaluated in Hep3B (a human hepatocellular carcinoma cell line) 
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cell-based respiration assay, using intact Hep3B cells. Compounds 3 – 5 exerted time- and 
concentration-dependent biphasic effects on the Hep3B cell oxygen consumption similar to their 
effects on T47D cell respiration. However, Hep3B cells were more sensitive to the effects of the 
compounds, compared to the T47D cells (Figures 4.8A – D). Since Hep3B cells are of 
neoplasmic origin, these compounds needs to be further evaluated against primary hepatocytes or 
purified mammalian liver mitochondria to eliminate the possibility of tumor cell-selective 
toxicity. The magnitude of toxicity toward primary hepatocytes or purified mitochondria by 
these compounds will be indicative of the potential adverse effects in the healthy population. 
 
-100
-75
-50
-25
0
25
50
75
100
  5.6 M
   10 M
17.8 M
   30 M
%
 In
hi
bi
tio
n 
of
 c
el
lu
la
r
ox
yg
en
 c
on
su
m
pt
io
n
 
 
 
Figure 4.8A Concentration-response effect of cauloside A (3) on Hep3B cell respiration. 
Cauloside A (3) was tested at 5.6, 10.0, 17.8 and 30.0 µM. Oxygen consumption rates were 
recorded 30, 115 and 295 seconds after each treatment and the data were presented as percentage 
inhibition of oxygen consumption rate compared to the average oxygen consumption rate of 
untreated T47D cells. Negative values indicate a relative stimulation of oxygen consumption. 
Data shown are average + standard deviation from three independent experiments (n = 3). 
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Figure 4.8B Concentration-response effect of saponin PE (4) on Hep3B cell respiration. Saponin 
PE (4) was tested at 5.6, 10.0, 17.8 and 30.0 µM. Oxygen consumption rates were recorded 30, 
115 and 295 seconds after each treatment and the data were presented as percentage inhibition of 
oxygen consumption rate compared to the average oxygen consumption rate of untreated T47D 
cells. Negative values indicate a relative stimulation of oxygen consumption. Data shown are 
values obtained from a representative experiment (n = 1). 
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Figure 4.8C Concentration-response effect of cauloside C (5) on Hep3B cell respiration. 
Cauloside C (5) was tested at 5.6, 10.0, 17.8 and 30.0 µM. Oxygen consumption rates were 
recorded 30, 115 and 295 seconds after each treatment and the data were presented as percentage 
inhibition of oxygen consumption rate compared to the average oxygen consumption rate of 
untreated T47D cells. Negative values indicate a relative stimulation of oxygen consumption. 
Data shown are average + standard deviation from three independent experiments (n = 3). 
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Figure 4.8D Concentration-response effect of blue cohosh extract on Hep3B cell respiration. 
Blue cohosh extract was tested at 5.6, 10.0, 17.8 and 30.0 µg/mL. Oxygen consumption rates 
were recorded 30, 115 and 295 seconds after each treatment and the data were presented as 
percentage inhibition of oxygen consumption rate compared to the average oxygen consumption 
rate of untreated T47D cells. Negative values indicate a relative stimulation of oxygen 
consumption. Data shown are average + deviation from the mean from two independent 
experiments (n = 2). 
 
 The protonophore control 2-[{4-
(trifluoromethoxy)phenyl}hydrazinylidene]propanedinitrile (FCCP, 26, Figure 4.5B) [0.3 µM] 
stimulated oxygen consumption in both T47D and Hep3B cells; although the effect was greater 
in Hep3B cells, relative to the effect on T47D cells. However, 26 (0.3 µM) did not show a time-
dependent biphasic effect on cell respiration (Figure 4.9).  
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Figure 4.9 Effect of FCCP (26) on T47D and Hep3B cell respiration. Compound 26 was tested 
at 0.3 µM in both the cell lines. Oxygen consumption rates were recorded 30, 115 and 295 
seconds after each treatment and the data were presented as relative respiration rates. Positive 
values indicate a relative stimulation of oxygen consumption. Data shown are average + standard 
deviation from three independent experiments (n = 3). 
 
 Since 26 did not show a time-dependent biphasic response on cell respiration, it is 
unlikely that simple protonophoric activity is responsible for the observed effects of 3 – 5 on 
mitochondrial respiration. Structurally, these compounds are plant saponins and plant saponins 
are reported to interact with, and solubilize cell membranes (Wassler et al., 1987). Hence, we 
hypothesized that blue cohosh saponins disregulate cell respiration by permeabilizing the plasma 
and mitochondrial membranes. We further hypothesized that digitonin (27, Figure 4.2), a plant 
saponin commonly used in mechanistic mitochondrial studies, would exert similar a similar 
effect on cellular respiration. To selectively permeabilize the plasma membrane, we used a 
relatively low concentration of 27 (4 µM). Addition of 27 (4 µM) to intact cells did not alter 
oxygen consumption rates of the cells and did not permeabilize the mitochondrial membrane 
(data not shown). However, at elevated concentrations, 27 (17.8 and 30 µM) produced a time-
FCCP (26) (0.3 µM) 
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dependant biphasic effect on the cellular oxygen consumption similar to the effect observed with 
the blue cohosh saponins (Figure 4.10). 
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Figure 4.10 Concentration-response effect of digitonin (27) on T47D cell respiration. Digitonin 
(27) was tested at 10.0, 17.8 and 30.0 µM. Oxygen consumption rates were recorded 30, 115 and 
295 seconds after each treatment and the data were presented as percentage inhibition of oxygen 
consumption rate compared to the average oxygen consumption rate of untreated T47D cells. 
Negative values indicate a relative stimulation of oxygen consumption. Data shown are 
recording from a single experiment. 
 
 Dicarboxylic acids, and succinic acids, are Kreb’s cycle intermediates that serve as 
substrates for mitochondrial oxidation at mitochondrial and complex II. However, because 
succinate forms anion in solution, it cannot penetrate the plasma membrane. The mitochondrial 
inner membrane contains specialized transporters that transport succinate into the mitochondrial 
matrix. When added externally, succinate acts as a substrate for complex II and overcome 
mitochondrial complex I inhibitor-induced inhibition of cell respiration only when the plasma 
membrane is permeabilized. Digitonin (27) [4 µM] is routinely used to selectively permeabilize 
the plasma membrane. Selective plasma membrane permeabilization with 27 is performed in 
whole cell-based mitochondrial mechanistic studies to manipulate substrates at specific 
mitochondrial complexes. To assess whether blue cohosh saponins permeabilize the cellular 
Digitonin (27) (T47D) 
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membranes, we examined cauloside A (3) as a representative compound. In the presence of 3 (10 
µM), externally supplemented succinate (5 mM) restored T47D cell oxygen consumption in the 
presence of the complex I inhibitor rotenone (1 µM). However, at a reduced concentration, 3 (5.6 
µM) did not produce an observable membrane permeabilization effect (Figures 4.11A – C). 
These observations correlate with the previously observed effects of 3 on cell respiration. 
 
 
 
 
 
 
 
 
 
 
Figure 4.11A Effect of cauloside A (3) membrane permeabilization on T47D cell respiration. 
Cauloside A (3) was tested at 10 µM. Oxygen consumption rates were recorded after each 
treatment and the average oxygen consumption rate for each section are given in the parentheses. 
Data shown are recordings from a representative experiment (n = 1). 
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Figure 4.11B Effect of cauloside A (3) membrane permeabilization on T47D cell respiration. 
Cauloside A (3) was tested at 5.6 µM. Oxygen consumption rates were recorded after each 
treatment and the average oxygen consumption rate for each section are given in the parentheses. 
Data shown are recordings from a representative experiment (n = 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11C Effect of digitonin (27) membrane permeabilization on T47D cell respiration. 
Digitonin (27) was tested at 4 µM. Oxygen consumption rate was recorded after each treatment 
and the average oxygen consumption rate for each section are given in the parentheses. Data 
shown are recording from a representative experiment (n = 1). 
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 The results observed in Figures 4.11A – C support our hypothesis that 3 – 5 exert their 
effects on cellular oxygen consumption indirectly by permeabilizing cell membranes. The initial 
stimulation of cellular respiration is possibly due to the saponins disrupting the lipid packing of 
mitochondrial inner membrane leading to proton leak into the matrix. Exposure of mitochondrial 
inner membrane to the saponins for longer period of time possibly result in complete 
solubilization of the membrane causing complete disruption of oxidative phosphorylation and 
thus leads to time-dependent biphasic effects. These compounds are not selective mitochondrial 
inhibitors. However, when present in sufficient concentrations, they cause mitochondrial 
dysfunction due to their detergent-like properties. 
 
4.3.2.2 Ursolic and oleanolic acids 
 Lipophilic weak organic acids such as ursolic acid (28) have been previously reported to 
uncouple oxidative phosphorylation in isolated rat heart mitochondria (Liobikas et al., 2011). 
Oleanolic acid (9), a weak organic acid, is a regioisomer of ursolic acid. The oleanane-type 
saponins found in blue cohosh contain oleanolic acid or a modified oleanolic acid moiety as their 
core sapogenin. To rule out the potential for mitochondrial uncoupling caused by the free 
carboxylic group in the aglycone moiety, the effects of 9 on cell respiration was investigated. 
Oleanolic acid (up to 30 µM) did not exert any observable effects on cell respiration using intact 
T47D and Hep3B cells (data not shown). When 28 (0.03 – 30 µM) was examined at the 
concentrations within the range that was previously reported to uncouple oxidative 
phosphorylation, 28 did not affect respiration in either intact or digitonin-permeabilized T47D 
cells.  Similarly, 28 (0.03 – 30 µM) treatment did not affect Hep3B (intact) respiration (Figure 
4.12). These results contradict a previous report that 28 uncouples mitochondria (Liobikas et al., 
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2011).  Our results suggest that the inability of 28 to uncouple mitochondrial respiration may 
result from differences in the experimental models (intact/permeabilized cells vs. isolated 
mitochondria or the use of heart mitochondria vs. breast/liver cancer cells). 
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Figure 4.12 Concentration-response effects of ursolic acid (28) on intact (A) and digitonin-
permeabilized (B) T47D and intact Hep3B (C) cell respiration. Compound 28 was tested at 0.03 
– 30 µM in both the cell lines in half-log increments and FCCP (26) [0.3 µM] was used as a 
standard (S). Oxygen consumption rates were recorded after each treatment and the data were 
presented as percentage inhibition of oxygen consumption rates compared to the average oxygen 
consumption rate of untreated intact T47D and Hep3B cells. For the digitonin-permeabilized 
T47D cells digitonin (4 µM) was used to selectively permeabilize the plasma membrane and the 
percentage inhibition of oxygen consumption was calculated by comparing with the initial 
(untreated) oxygen consumption rates of the cells. Data are from a single representative 
experiment (n = 1). 
 
4.3.2.3 Guggul (Commiphora wightii) 
 The extract of guggul [Commiphora wightii (Arn.) Bhandari (Burseraceae)] was 
identified as a possible mitochondriotoxic herbal dietary supplement. Seven pure compounds 
from guggul gum resin were obtained from Dr. Khan’s pure compound repository (Figure 4.5A) 
and examined in the T47D cell-based HIF-1 reporter assay (Figures 4.13A – B).  
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Figure 4.13A Inhibition of hypoxia-induced HIF-1 by guggul compounds. Transfected (pTK-
HRE3-luc) T47D cells were treated with compounds (1, 10 and 30 µM) and exposed to hypoxia 
(1% O2) for 16 h. Data shown are average + standard deviation from a representative experiment 
performed in triplicate. Absence of error bars due to identical readings for any data point is 
denoted by ‘*’. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13B Inhibition of 1,10-phenanthroline-induced HIF-1 by guggul compounds. 
Transfected (pTK-HRE3-luc) T47D cells were treated with compounds (1, 10 and 30 µM) and 
exposed to 1,10-phenanthroline (10 µM) for 16 h. Data shown are average + standard deviation 
from a representative experiment performed in triplicate. 
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 Of the seven compound tested, compounds (13E,17E,21E)-8-hydroxypolypodo-13,17,21-
trien-3-one (19), sesamin (6), and guggulsterol III (7) showed increased potency against hypoxia-
induced HIF-1 activity relative to iron chelator-induced HIF-1, which suggested that they may 
inhibit mitochondrial respiration. These compounds were further evaluated in a T47D cell-based 
respiration assay. The concentration-response effects of these three compounds and the guggul 
extract (G) were determined. Among the three compounds 6 (30 µM) and 7 (10 µM) strongly 
suppressed cellular respiration while 19 was inactive (Figure 4.14). Compound 20 and 21 were 
weak (< 30% inhibition at 30 µM) suppressors of mitochondrial respiration (data not shown). 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Concentration-response effects of 19, 6, 7 and guggul extract (G) on the T47D cell 
respiration. Compound 19 was tested at 10 and 30 µM. Compound 6 was tested at 3, 10 and 30 
µM.  Compound 7 was tested at 1, 3, and 10 µM. Guggul extract (G) was tested at 10, 30 and 
100 µg/mL. Oxygen consumption rates were recorded after each treatment and the data were 
presented as percentage inhibition of oxygen consumption rates compared to the average oxygen 
consumption rate of untreated T47D cells. Data are average + deviation from the mean for 19, 6, 
and 7 from two independent experiments (n = 2), while for G data are from a single 
representative experiment (n = 1).  
 
0
20
40
60
80
100
%
 In
hi
bi
tio
n 
of
 c
el
lu
la
r
ox
yg
en
 c
on
su
m
pt
io
n
 
19 6 7 G
Concentration (µM)
160 
 
 Mechanistic studies were performed to identify the mitochondrial complex(es) targeted 
by the guggul compounds. In digitonin-permebilized cells, addition of exogenous succinate (5 
mM) restored cell respiration that had been inhibited by sesamin (6) and guggulsterol III (7). 
This indicates that these compounds selectively inhibit mitochondrial complex I (Figures 4.15A 
– B). 
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Figure 4.15A Sesamin (6) [30 µM] inhibits mitochondrial respiration by selectively targeting 
mitochondrial complex I. Exponentially cultured T47D cells (5 x 106) were permeabilized with 
digitonin (4 µM) and respiratory complex substrates and 6 (30 µM) were added sequentially as 
specified. Sesamin (6) [30 µM] did not affect complex II, III or IV. Data are from a 
representative experiment. 
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Figure 4.15B Guggulsterol III (7) [10 µM] inhibits mitochondrial respiration by targeting 
complex I. Exponentially cultured T47D cells (5 x 106) were permeabilized with digitonin (4 
µM) and respiratory complex substrates and 7 (10 µM) were added sequentially as specified. 
Guggulsterol III (7) [10 µM, did not affect complex II, III or IV. Data are from a representative 
experiment. 
 
 
 
4.3.3 Cytotoxicity of herbal dietary supplement compounds  
 
4.3.3.1 Blue Cohosh (Caulophyllum thalictroides)   
 The cytotoxic potential of cauloside A (3), saponin PE (4), cauloside C (5), cauloside B 
(15), and blue cohosh extract were evaluated in both 2-day and 6-day cell viability assays using 
the sulforhodamine B method. Both human breast tumor (T47D) and hepatocarcinoma (Hep3B) 
cells were used as experimental models. The purified blue cohosh saponins and the extract 
demonstrated potent cytotoxic activity in both cell lines (Figures 4.16A – E). The saponins and 
the extract were more toxic to Hep3B cells. This preferential cytotoxicity was consistent with the 
results obtained in respiration studies. The cytotoxicity also increased with extended cell 
exposure, as the IC50 values were significantly lower in the 6-day cell viability assay, relative to 
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the 2-day cell viability assay (Tables 4.1 and 4.2). We have observed this kind of activity profile 
with the compounds that interfere with mitochondrial function. The maximum solvent present in 
the assay was 1.1% v/v. The effect of solvent alone on cell viability was minimal (< 10%) even 
after 6 days of incubation. 
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Figure 4.16A Effect of blue cohosh compounds on Hep3B cell viability following short-term (48 
h) incubation. Exponentially cultured Hep3B cells were incubated for 48 h with the test 
compounds (3, 4, 5 and 15) and cell viability was measured using the sulforhodamine B method. 
Data shown here are average ± standard deviation from a representative experiment performed in 
triplicate. 
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Figure 4.16B Effect of blue cohosh compounds on Hep3B cell viability following prolonged (6-
day) incubation. Exponentially cultured Hep3B cells were incubated for 6 days with the test 
compounds (3, 4, 5 and 15) and cell viability was measured using the sulforhodamine B method. 
Data shown here are average ± standard deviation from a representative experiment performed in 
triplicate. 
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Figure 4.16C Effect of blue cohosh compounds on T47D cell viability following short-term (48 
h) incubation. Exponentially cultured T47D cells were incubated for 48 h with the test 
compounds (3, 4, 5 and 15) and cell viability was measured using the sulforhodamine B method. 
Data shown here are average ± standard deviation from a representative experiment performed in 
triplicate. 
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Figure 4.16D Effect of pure blue cohosh compounds on T47D cell viability following prolonged 
(6-day) incubation. Exponentially cultured T47D cells were incubated for 6 days with the test 
compounds (3, 4, 5 and 15) and cell viability was measured using the sulforhodamine B method. 
Data shown here are average ± standard deviation from a representative experiment performed in 
triplicate. 
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Figure 4.16E Effect of the blue cohosh extract on T47D and Hep3B cell viability following 2-
day and 6-day incubation periods. Exponentially grown T47D and Hep3B cells were incubated 
for 48 h or 6 days with blue cohosh extract and cell viability was measured using the 
sulforhodamine B method. Data shown here are average ± standard deviation from a 
representative experiment performed in triplicate. 
 
 
Compound/ 
Extract 
IC50 (95% CI) µM (or µg/mL*) 
T47D 
48 h 6 days 
3 12.98 (12.21 - 13.80) 11.52 (11.21 – 11.85) 
4 12.60 (12.23 - 12.99) 10.21 (10.08 – 10.35) 
5 30.07 (29.30 - 30.86) 25.60 (25.03 – 26.18) 
15 > 56 >56 
*Blue cohosh 
extract 55.61 (52.69 – 58.68) 32.03 (30.92 – 33.19) 
 
Table 4.1 IC50 values of 3, 4, 5, 15 and the blue cohosh extract on T47D cell 
proliferation/viability in a concentration-response study (2-day and 6-day). Data shown are from 
a representative experiment performed in triplicate. 
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Compound/ 
Extract 
IC50 (95% CI) µM (or µg/mL*) 
Hep3B 
48 h 6 days 
3 7.53 (7.11 – 7.98) 6.63 (6.41 – 6.87) 
4 7.00 (6.63 – 7.39) 3.45 (3.32 – 3.58) 
5 27.83 (22.31 – 34.72) 8.99 (8.46 – 9.56) 
15 41.49 (40.13 – 42.89) 30.44 (28.95 – 32.00) 
*Blue cohosh 
extract 30.77 (29.93 – 31.64) 24.66 (23.91 – 25.43) 
 
Table 4.2 IC50 values of 3, 4, 5, 15 and the blue cohosh extract in Hep3B cell 
proliferation/viability in a concentration-response study (2-day and 6-day). Data shown are from 
a representative experiment performed in triplicate. 
 
Oleanolic acid (9) was examined for its cytotoxic effect on T47D cells. Compound 9 (30 
µM) was mildly cytotoxic only in 6-day cell proliferation/viability assay (< 30% inhibition of 
cell viability at 30 µM). 
 
4.3.3.2 Guggul (Commiphora wightii) 
 Six pure compounds isolated from guggul were evaluated in the T47D cell 
proliferation/viability assay. The compounds and the guggul extract showed time- and 
concentration-dependent suppression of the T47D cell proliferation/viability (Figures 4.17A – 
C). Guggulsterol III (7) was the most potent among the compounds tested (IC50 values 13.8 µM 
and 3.38 µM, in 2-day and 6-day cell viability assays, respectively (Table 4.3). The guggul 
extract was more cytotoxic upon extended exposure, suggesting mitochondrial disruption may be 
responsible for the observed cytotoxicity. 
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Figure 4.17A Effect of guggul compounds on T47D cell viability following short-term (48 h) 
incubation. Exponentially cultured T47D cells were incubated for 48 h with the test compounds 
and cell viability was measured using the sulforhodamine B method. Data are average ± standard 
deviation from a representative experiment performed in triplicate. 
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Figure 4.17B Effect of guggul compounds on T47D cell viability following long-term (6-day) 
incubation. Exponentially cultured T47D cells were incubated for 6 days with the test 
compounds and cell viability was measured using the sulforhodamine B method. Data here are 
average ± standard deviation from a representative experiment performed in triplicate. 
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Figure 4.17C Effect of guggul extract on T47D cell viability following 2-day and 6-day 
incubation periods. Exponentially cultured T47D cells were incubated for either 48 h or 6 days 
with the guggul extract and cell viability was measured using the sulforhodamine B method. 
Data are average ± standard deviation from a representative experiment performed in triplicate 
. 
 
 
Compound/ 
Extract 
IC50 (95% CI) µM (µg/mL*) 
T47D 
48 h 6 days 
19 > 30 10.60 (9.69 – 11.61) 
20 28.75 (25.26 – 32.72) 9.28 (8.82 – 9.76) 
6 >30 22.15 (19.78 – 24.81) 
21 > 30 17.90 (16.88 – 18.99) 
22 > 30 10.12 (9.01 – 11.38) 
7 13.80 (12.13 – 15.70) 3.38 (3.06 – 3.73) 
*Guggul 
extract 49.33 (40.72 – 59.78) 5.75 (5.03 – 6.58) 
 
Table 4.3 Human breast cancer T47D cell proliferation/viability study. The IC50 values of 6, 7, 
19, 20, 21, 22 and the guggul extract on in a 2-day and 6-day exposure concentration-response 
study. Data are from a representative experiment performed in triplicate. 
 
 Mitochondria are important cellular organelles, mediating cell death (Green and 
Kroemer, 2004). Drug-induced toxicity is often mediated through the induction of mitochondrial 
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dysfunction and resulting cell death (Begriche et al., 2011). Botanical dietary supplements and 
herbal remedies are widely consumed for a variety of health conditions. They are often perceived 
as safe and devoid of adverse effects or toxicity due to their natural origin. However, toxicities 
due to botanical dietary supplement consumption have been reported (Stickel et al., 2011). The 
toxicities are often similar in nature to the toxicities observed with compounds that target the 
mitochondria (Frazier and Krueger, 2009). Mitochondriotoxic substances are common in nature 
and, while chemically undefined, botanical dietary supplements and other herbal remedies are 
likely to have a similar potential to induce mitochondrial dysfunction as clinically approved 
drugs or other synthetic molecules. Currently the data on the presence of possible 
mitochondriotoxic substances in the dietary supplements and their daily consumption, percentage 
yield, bioavailability, metabolism, and pharmacokinetics are unavailable. Hence, it is difficult to 
predict whether or not these compounds are in high enough concentrations to cause toxicity in 
vivo. Mitochondria play an important regulatory role in hypoxia-induced HIF-1 activation 
(Agani et al., 2000). Inhibition of the mitochondrial ETC strongly prevents activation and 
stabilization of hypoxia-induced HIF-1 relative to iron chelator-induced HIF-1 
(Coothankandaswamy et al., 2010). Uncoupling of oxidative phosphorylation abolishes HIF-1 
activation, regardless of the nature of the inducing stimulus (Du et al., 2010). Even though the 
class of mitochondrial inhibitors can be a valuable tool in antitumor therapy, these compounds 
can produce serious adverse effects in healthy individuals.  
A T47D cell-based HIF-1 reporter gene assay, in conjunction with an intact cell-based 
respiration assay, was used to preliminarily identify mitochondriotoxic extracts from plants used 
in botanical dietary supplement products. Over 350 botanical dietary supplement plant extracts 
from the National Center for Natural Products Research (NCNPR) repository were evaluated in a 
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human breast cancer T47D cell-based HIF-1 reporter gene assay. The extracts that preferentially 
inhibited hypoxia-induced HIF-1 activation were selected and reconfirmed in a T47D cell-based 
cell respiration assay. Blue cohosh and guggul extracts were identified as hits in the screening 
and confirmatory assays. Pure compounds previously isolated from blue cohosh and guggul were 
obtained from Dr. Ikhlas A. Khan’s pure compound repository. The saponin glycosides from 
blue cohosh [cauloside A (3), saponin PE (4), and cauloside C (5)] disrupted both hypoxia-
induced and 1,10-phenanthroline-induced HIF-1 activation. Saponins are amphiphylic in nature 
and are known to form pores in the lipid bilayer of cellular membranes. Further investigation 
revealed that HIF-1 inhibition and the biphasic effect on cellular oxygen consumption by these 
compounds and blue cohosh extract were due to the membrane disrupting properties of the 
saponins. Oleanolic acid (9), which is structurally similar to the aglycone part of the saponin 
glycosides, was inactive in the mitochondrial respiration assay. The presence of an additional 
hydroxy group on the aglycone core reduced the bioactivity of the saponins. The hepatocellular 
carcinoma cell line Hep3B was more sensitive to the saponins 3 – 5 relative to its effect on the 
breast cancer T47D cell line. This difference in sensitivity may result from differences in their 
membrane lipid composition, a concept that may warrant further study. The cytotoxicity of 
saponins in various tumor cell lines has been reported previously (Podolak et al., 2010). The blue 
cohosh extract and the blue cohosh pure compounds were cytotoxic to both T47D and Hep3B 
cells, with higher potency in Hep3B cells. It is particularly noteworthy that oleanolic acid (9) 
was inactive in the T47D-cell based cellular respiration and the viability assays indicate that the 
sugar moieties are essential for the activities. Since the overall tumor cell selectivity profile of 
these compounds are yet to be established, it is possible that mammalian hepatocytes could be 
similarly susceptible to the membrane disrupting activity of blue cohosh saponins and blue 
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cohosh extract. In that case, the potential for hepatotoxicity from consuming herbal remedies that 
contain blue cohosh is greater than previously estimated. Blue cohosh (Caulophyllum 
thalictroides) is a plant indigenous to North America that has a history of traditional use. As a 
dietary supplement it is used as an antispasmodic, emenagogue (menstrual flow stimulator), 
parturifacient (labor inducer) and abortifacient (Dugoua et al., 2008). In 1999, it was estimated 
that 64% of midwives in the US used blue cohosh as a labor-inducer (McFarlin et al., 1999). 
However, the safety profile and adverse effects of blue cohosh in pregnant women and neonates 
are unknown. Perinatal stroke, acute myocardial infarction, congestive heart failure, multiple 
organ injury and shock in neonates have been associated with consumption of blue cohosh 
tincture/dietary supplements (Dugoua et al., 2008). Such idiosyncratic toxicities may be 
explained by the plasma and mitochondrial membrane permeabilizing effects of saponin 
glycosides. Further monitoring and reporting of adverse effects due to blue cohosh consumption 
is required to better understand the toxic potential of this over-the-counter dietary supplement. 
 Guggul gum resin is a popular dietary supplement used for its hypolipidemic and anti-
inflammatory effects (Shishodia et al., 2008). Sporadic cases of guggul-associated hepatotoxicity 
had been reported (Yellapu et al., 2011; Grieco et al., 2009). However, this work is the first to 
report that guggul extract and purified guggul gum resin compounds act as mitochondrial ETC 
inhibitors. Sesamin (6) and 7 both inhibit mitochondrial complex I in cellular respiration assays 
in a concentration-dependent manner. Guggulsterol III (7) was more potent than 6. Compound 
19 was inactive in the mitochondrial respiration assay although it preferentially suppressed 
hypoxia-induced HIF-1 activation. Other compounds (i.e, 20 and 21) were weak inhibitors (< 
30% inhibition at 20 µM, data not shown) of T47D cell respiration. The potency of guggul 
extract to suppress mitochondrial respiration cannot be fully explained by the activity of these 
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two compounds. It is possible that other known or unreported, compounds present in the guggul 
extract contribute towards the enhanced mitochondrial suppression observed with guggul extract. 
Irrespective of their activity profile in the mitochondrial respiration assay, six out of seven 
guggul compounds strongly suppressed T47D cell viability (IC50 values 3.38 – 22.15 µM, 6-day 
assay). However, these guggul compounds were only weakly cytotoxic in 2-day cell viability 
studies. Direct mitochondrial ETC targeting does not seem to be the main cytotoxic mechanism 
for some of these compounds and it is possible that these substances exert their effects through 
non-mitochondrial mechanism. Alternatively, weak mitochondrial inhibition for a prolonged 
period or metabolic activation of the compounds may produce the observed suppression of cell 
proliferation/viability. It must be noted that while the guggul extract, E- and Z-guggulsterone, 
and other isolated guggul compounds are cytotoxic to T47D cells; their selectivity profile has not 
been established. Further investigations to characterize the toxicity and selectivity profile of the 
guggul extract and isolated guggul compounds are required. Until the toxicity profiles and 
mechanisms for toxicity are completely defined, caution should be exercised with the use of 
botanical dietary supplements/herbal remedies that contain guggul. 
 Another notable observation during this investigation was the inability of ursolic acid 
(28) (0.03 – 30 µM) to uncouple oxidative phosphorylation in both intact and permeabilized 
T47D and Hep3B cells. This contradicts a previous report that demonstrated the mitochondrial 
uncoupling effect of 28 in isolated rat heart mitochondria (Liobikas et al., 2011). However, the 
selection of the experimental model to evaluate the mitochondrial function during screening and 
respiration studies of mitochondriotoxic agents is critical. Intact or permeabilized cells are more 
complex systems than isolated mitochondria. The difference in plasma membrane permeability 
and/or protein binding between intact and permeabilized cells might affect the activity observed 
172 
 
in either system. While it can be argued that respiration in cell-based systems may be influenced 
by non-mitochondrial factors, intact cells may be more physiologically relevant as models for the 
study of chemical toxins with unknown membrane permeability profiles. Further, the loss of 
intracellular communication between organelles and the loss of mitochondrial network structure 
might also produce artifactual results in studies that evaluate potential mitochonriotoxic agents in 
isolated mitochondria (Brand and Nicholls, 2011). 
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SUMMARY
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 Small-molecules that target cellular bioenergetics are an emerging class of antitumor 
agents. Successful discovery of natural product small-molecules that inhibit glycolysis and/or 
oxidative phosphorylation depends on proper identification and valiadation of a target; a robust 
screening system; bioassay-guided fractionation; structure elucidation; biological 
characterization, and multiple other factors. Selection of chromatographic media for bioassay-
guided isolation is one of the many critical steps in the drug discovery process. Hypoxia-
inducible factor-1 (HIF-1) is an important antitumor target that regulates cellular bioenergetics. 
One of the major functions of HIF-1 is regulation of cellular bioenergetics. Mitochondrial 
inhibitors and uncouplers inhibit HIF-1 activation. During a controlled evaluation of 
chromatographic media in HIF-1-targeted natural product antitumor drug discovery, it was 
observed that Si gel has the highest potential to cause poor sample recovery, chemical 
alterations, and loss of bioactivity. HP20SS, a polystyrenic resin, can be used as an alternative to 
Si gel in the large scale pre-fractionation of plant or marine organism-derived extracts. However 
a final wash with an organic solvent, such as EtOAc, is required to completely elute the materials 
from the HP20SS columns. Highly lipophilic extracts also tend to lose bioactivity after elution 
through HP20SS columns. 
A high rate of aerobic glycolysis in tumor cells is an attractive antitumor target. To 
discover natural product aerobic glycolysis inhibitors, a bioenergetics-based screening system 
was developed to evaluatea total of 10,648 10,000 extracts fom the NCI’s Open Repository 
Program... Bioassay-guided isolation of the Moronobea coccinea extract resulted in isolation of a 
new compound named moronone (1). Moronone (1) is a protonophore that was active in the 
glycolysis inhibitor screening system. A prototypical protonophore (FCCP) was similarly active. 
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For successful identification of glycolysis inhibitors, the protonophoric compounds (nuisance 
compounds or false positives) should be rapidly dereplicated. 
Even though mitochondrial inhibitors are useful as potential antitumor agents, long term 
exposure to mitochondrial inhibitors may result in adverse effects. The potential of 
mitochondrotoxic agents to cause idiosyncratic adverse effects was evident in the withdrawal of 
FDA-approved drugs from the market, due to their mitochondrial toxicity. Plant extracts used in 
botanical dietary supplement (BDS) products were evaluated for mitochondriotoxic activity. 
Among 46 active extracts, two extracts (blue cohosh and guggul) were subjected to further 
investigations. Three saponin-type compounds from blue cohosh [cauloside A (3), saponin PE 
(4), and cauloside C (5)] permeabilized the plasma and mitochondrial membranes, and produced 
cytotoxic effects in human breast tumor (T47D) and hepatocellular carcinoma (Hep3B) cell 
lines. Sesamin (6) and guggulsterol III (7) from guggul selectively inhibited complex I of the 
electron transport chain. Six compounds from guggul (including 6 and 7) produced cytotoxic 
effects in a human breast tumor cell line (T47D). However, guggul extract was more potent than 
any of the individual compounds. Further investigation is required to identify the presence of 
other mitochondrial inhibitors in guggul extract. Purified compounds from blue cohosh 
andguggul, as well asthe extracts, need to be evaluated in primary cell lines or purified 
mitochondria, in order to assesstheir tumor selectivity profiles and potential in vivo toxicity. 
These results indicate a necessity for a large scale, systematic investigation of dietary 
supplements for the presence of the mitochondrial inhibitors.
176 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
177 
 
Abo-Khatwa, A. N.; al-Robai, A. A.; al-Jawhari, D. A. Lichen acids as uncouplers of oxidative 
phosphorylation of mouse-liver mitochondria. Nat Toxins 1996, 4 (2), 96–102. 
Acuna, U. M.; Jancovski, N.; Kennelly, E. J. Polyisoprenylated benzophenones from Clusiaceae: 
potential drugs and lead compounds. Curr Top Med Chem 2009, 9 (16), 1560–1580. 
Adams, J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4 (5), 349–
360. 
Agani, F. H.; Pichiule, P.; Chavez, J. C.; LaManna, J. C. The role of mitochondria in the 
regulation of hypoxia-inducible factor 1 expression during hypoxia. J Biol Chem 2000, 275 
(46), 35863–35867. 
Alali, F. Q.; Liu, X. X.; McLaughlin, J. L. Annonaceous acetogenins: recent progress. J Nat 
Prod 1999, 62 (3), 504–540. 
Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K. Walter, P.  Molecular biology of the 
cell. 4th ed.; Garland Science: New York, 2002; pp 771–772. 
Almeida, A.; Bolanos, J. P.; Moncada, S. E3 ubiquitin ligase APC/C-Cdh1 accounts for the 
Warburg effect by linking glycolysis to cell proliferation. Proc Natl Acad Sci U S A 2010, 
107 (2), 738–741. 
Ambekar, C. S.; Lee, J. S.; Cheung, B. M.; Chan, L. C.; Liang, R.; Kumana, C. R. 
Chloramphenicol succinate, a competitive substrate and inhibitor of succinate 
dehydrogenase: possible reason for its toxicity. Toxicol In Vitro 2004, 18 (4), 441–447. 
Arany, Z.; Huang, L. E.; Eckner, R.; Bhattacharya, S.; Jiang, C.; Goldberg, M. A.; Bunn, H. F.; 
Livingston, D. M. An essential role for p300/CBP in the cellular response to hypoxia. Proc 
Natl Acad Sci U S A 1996, 93 (23), 12969–12973. 
178 
 
Arora, K. K.; Pedersen, P. L. Functional significance of mitochondrial bound hexokinase in 
tumor cell metabolism. Evidence for preferential phosphorylation of glucose by 
intramitochondrially generated ATP. J Biol Chem 1988, 263 (33), 17422–17428. 
Ashkenazi, A.; Dixit, V. M. Death receptors: signaling and modulation. Science 1998, 281 
(5381), 1305–1308. 
Avula, B.; Wang, Y. -H.; Rumalla, C. S.; Ali, Z.; Smillie, T. J.; Khan, I. A. Analytical methods 
for determination of magnoflorine and saponins from roots of Caulophyllum thalictroides 
(L.) Michx. using UPLC, HPLC and HPTLC. J Pharm Biomed Anal 2011, 56 (5), 895–903. 
Bae, S. H.; Jeong, J. W.; Park, J. A.; Kim, S. H.; Bae, M. K.; Choi, S. J.; Kim, K. W. 
Sumoylation increases HIF-1α stability and its transcriptional activity. Biochem Biophys Res 
Commun 2004, 324 (1), 394–400. 
Baek, J. H.; Liu, Y. V.; McDonald, K. R.; Wesley, J. B.; Zhang, H.; Semenza, G. L. 
Spermidine/spermine N(1)-acetyltransferase-1 binds to hypoxia-inducible factor-1α (HIF-1α) 
and RACK1 and promotes ubiquitination and degradation of HIF-1α. J Biol Chem 2007, 282 
(46), 33358–33366. 
Baggett, S.; Mazzola, E. P.; Kennelly, E. J. The benzophenones: Isolation, structural elucidation 
and biological activities; Atta-ur-Rahman, Ed.; Elsevier: Amsterdam, The Netherlands, 2005; 
Vol. 32, pp 721–771. 
Ballot, C.; Kluza, J.; Lancel, S.; Martoriati, A.; Hassoun, S. M.; Mortier, L.; Vienne, J. C.; 
Briand, G.; Formstecher, P.; Bailly, C.; Neviere, R.; Marchetti, P. Inhibition of mitochondrial 
respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D. Apoptosis 
2010, 15 (7), 769–781. 
179 
 
Barger, J. F.; Plas, D. R. Balancing biosynthesis and bioenergetics: metabolic programs in 
oncogenesis. Endocr Relat Cancer 2010, 17 (4), R287–R304. 
Begriche, K.; Massart, J.; Robin, M. A.; Borgne-Sanchez, A.; Fromenty, B. Drug-induced 
toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious 
consequences for the liver. J Hepatol 2011, 54 (4), 773–794. 
Bell, E. L.; Emerling, B. M.; Ricoult, S. J.; Guarente, L. SIRT3 suppresses hypoxia inducible 
factor-1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene 2011, 30 
(26), 2986-96. 
Bell, E. L.; Klimova, T. A.; Eisenbart, J.; Moraes, C. T.; Murphy, M. P.; Budinger, G. R.; 
Chandel, N. S. The Qo site of the mitochondrial complex III is required for the transduction 
of hypoxic signaling via reactive oxygen species production. J Cell Biol 2007, 177 (6), 1029–
1036. 
Benson, J. D.; Chen, Y. N.; Cornell-Kennon, S. A.; Dorsch, M.; Kim, S.; Leszczyniecka, M.; 
Sellers, W. R.; Lengauer, C. Validating cancer drug targets. Nature 2006, 441 (7092), 451–
456. 
Berra, E.; Benizri, E.; Ginouves, A.; Volmat, V.; Roux, D.; Pouyssegur, J. HIF prolyl-
hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in 
normoxia. Embo J 2003, 22 (16), 4082–4090. 
Bert, A. G.; Grepin, R.; Vadas, M. A.; Goodall, G. J. Assessing IRES activity in the HIF-1α and 
other cellular 5' UTRs. RNA 2006, 12 (6), 1074–1083. 
Betancur-Galvis, L.; Palomares, E.; Marco, J. A.; Estornell, E. Tigliane diterpenes from the latex 
of Euphorbia obtusifolia with inhibitory activity on the mammalian mitochondrial respiratory 
chain. J Ethnopharmacol 2003, 85 (2-3), 279–282. 
180 
 
Bhattacharya, S.; Michels, C. L.; Leung, M. K.; Arany, Z. P.; Kung, A. L.; Livingston, D. M. 
Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-
1. Genes Dev 1999, 13 (1), 64–75. 
Bjornsti, M. A.; Houghton, P. J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 
2004, 4 (5), 335–348. 
Bobkova, E. V.; Weber, M. J.; Xu, Z.; Zhang, Y. L.; Jung, J.; Blume-Jensen, P.; Northrup, A.; 
Kunapuli, P.; Andersen, J. N.; Kariv, I. Discovery of PDK1 kinase inhibitors with a novel 
mechanism of action by ultrahigh throughput screening. J Biol Chem 2010, 285 (24), 18838–
18846. 
Bokesch, H. R.; Groweiss, A.; McKee, T. C.; Boyd, M. R. Laxifloranone, a new phloroglucinol 
derivative from Marila laxiflora. J Nat Prod 1999, 62 (8), 1197–1199. 
Boonlarppradab, C.; Faulkner, D. J. Eurysterols A and B, cytotoxic and antifungal steroidal 
sulfates from a marine sponge of the genus Euryspongia. J Nat Prod 2007, 70 (5), 846–848.  
Böttger, S.; Hofmann, K.; Melzig, M. F. Saponins can perturb biologic membranes and reduce 
the surface tension of aqueous solutions: A correlation? Bioorg Med Chem 2012, 20 (9), 
2822–2828. 
Bramati, L.; Minoggio, M.; Gardana, C.; Simonetti, P.; Mauri, P.; Pietta, P. Quantitative 
characterization of flavonoid compounds in Rooibos tea (Aspalathus linearis) by LC-
UV/DAD. J Agric Food Chem 2002, 50 (20), 5513–5519. 
Brand, K. A.; Hermfisse, U. Aerobic glycolysis by proliferating cells: a protective strategy 
against reactive oxygen species. Faseb J 1997, 11 (5), 388–395. 
Brand, M. D.; Nicholls, D. G. Assessing mitochondrial dysfunction in cells. Biochem J 2011, 
435 (2), 297–312. 
181 
 
Brandt, U.; Schagger, H.; von Jagow, G. Characterisation of binding of the methoxyacrylate 
inhibitors to mitochondrial cytochrome c reductase. Eur J Biochem 1988, 173 (3), 499–506. 
Bredel, M.; Jacoby, E. Chemogenomics: an emerging strategy for rapid target and drug 
discovery. Nat Rev Genet 2004, 5 (4), 262–275. 
Bronchud, M. H. Principles of molecular oncology. 3rd ed. ed.; Humana ; London : Springer 
[distributor]: Totowa, N.J., 2007. 
Brown, G. C.; Lakin-Thomas, P. L.; Brand, M. D. Control of respiration and oxidative 
phosphorylation in isolated rat liver cells. Eur J Biochem 1990, 192 (2), 355–362. 
Broxterman, H. J.; Georgopapadakou, N. H. New cancer therapeutics: target-specific in, 
cytotoxics out? Drug Resist Updat 2004, 7 (2), 79–87. 
Bruick, R. K.; McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. 
Science 2001, 294 (5545), 1337–1340. 
Bugni, T. S.; Harper, M. K.; McCulloch, M. W.; Reppart, J.; Ireland, C. M. Fractionated marine 
invertebrate extract libraries for drug discovery. Molecules 2008a, 13 (6), 1372–1383. 
Bugni, T. S.; Richards, B.; Bhoite, L.; Cimbora, D.; Harper, M. K.; Ireland, C. M. Marine natural 
product libraries for high-throughput screening and rapid drug discovery. J Nat Prod 2008b, 
71 (6), 1095–1098. 
Cadenas, E.; Han, D. Generation of reactive oxygen species by mitochondria In Free Radicals 
and the Oxygen Paradox: Oxidative Stress in Biology, Aging and Disease, Davies, K., Ed. 
The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd: London, 2007. 
Cain, K.; Bratton, S. B.; Cohen, G. M. The Apaf-1 apoptosome: a large caspase-activating 
complex. Biochimie 2002, 84 (2–3), 203–214. 
182 
 
Calgaro-Helena, A. F.; Devienne, K. F.; Rodrigues, T.; Dorta, D. J.; Raddi, M. S.; Vilegas, W.; 
Uyemura, S. A.; Santos, A. C.; Curti, C. Effects of isocoumarins isolated from Paepalanthus 
bromelioides on mitochondria: uncoupling, and induction/inhibition of mitochondrial 
permeability transition. Chem Biol Interact 2006, 161 (2), 155–164. 
Cao, S.; Schilling, J. K.; Miller, J. S.; Andriantsiferana, R.; Rasamison, V. E.; Kingston, D. G. 
Cytotoxic compounds from Mundulea chapelieri from the Madagascar Rainforest. J Nat 
Prod 2004, 67 (3), 454–456. 
Chan, S. Y.; Zhang, Y. Y.; Hemann, C.; Mahoney, C. E.; Zweier, J. L.; Loscalzo, J. MicroRNA-
210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster 
assembly proteins ISCU1/2. Cell Metab 2009, 10 (4), 273–284. 
Chandel, N. S.; Maltepe, E.; Goldwasser, E.; Mathieu, C. E.; Simon, M. C.; Schumacker, P. T. 
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad 
Sci U S A 1998, 95 (20), 11715–11720. 
Chandel, N. S.; Budinger, G. R.; Choe, S. H.; Schumacker, P. T. Cellular respiration during 
hypoxia. Role of cytochrome oxidase as the oxygen sensor in hepatocytes. J Biol Chem 1997, 
272 (30) 18808–18816,. 
Chang, Q.; Qin, R.; Huang, T.; Gao, J.; Feng, Y. Effect of antisense hypoxia-inducible factor-1α 
on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas 2006, 32 (3), 
297–305. 
Cheng, G.; Zielonka, J.; Dranka, B. P.; McAllister, D.; Mackinnon, A. C., Jr.; Joseph, J.; 
Kalyanaraman, B. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger 
breast cancer cell death. Cancer Res 2012, 72 (10), 2634–2644. 
183 
 
Cheng, J.; Kang, X.; Zhang, S.; Yeh, E. T. SUMO-specific protease 1 is essential for 
stabilization of HIF1α during hypoxia. Cell 2007, 131 (3), 584–595. 
Chikamori, K.; Grozav, A. G.; Kozuki, T.; Grabowski, D.; Ganapathi, R.; Ganapathi, M. K. 
DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr Cancer 
Drug Targets 2010, 10 (7), 758–771. 
Choi, H.; Chun, Y. -S.; Kim, S. -W.; Kim, M. -S.; Park, J. -W. Curcumin inhibits hypoxia-
inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism 
of tumor growth inhibition. Mol Pharmacol 2006, 70 (5), 1664–1671. 
Christofk, H. R.; Vander Heiden, M. G.; Harris, M. H.; Ramanathan, A.; Gerszten, R. E.; Wei, 
R.; Fleming, M. D.; Schreiber, S. L.; Cantley, L. C. The M2 splice isoform of pyruvate 
kinase is important for cancer metabolism and tumour growth. Nature 2008, 452 (7184), 
230–233. 
Chudapongse, N.; Kamkhunthod, M.; Poompachee, K. Effects of Phyllanthus urinaria extract on 
HepG2 cell viability and oxidative phosphorylation by isolated rat liver mitochondria. J 
Ethnopharmacol 2010, 130 (2), 315–319. 
Chun, L. J.; Tong, M. J.; Busuttil, R. W.; Hiatt, J. R. Acetaminophen hepatotoxicity and acute 
liver failure. J Clin Gastroenterol 2009, 43 (4), 342–349. 
Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358 (11), 
1160–1174. 
Clark, E. P. A relation between rotenone, deguelin and Tephrosin. Science 1931, 73 (1879), 17–
18. 
ClinicalTrials.gov A phase I/II trial of 2-deoxy-d-glucose (2DG) for the treatment of advanced 
cancer and hormone refractory prostate cancer. 
184 
 
http://clinicaltrials.gov/ct2/show/NCT00633087?term=2-DG&rank=3 (accessed July 3rd 
2012). 
ClinicalTrials.gov Dose escalation trial of 2-deoxy-D-glucose (2DG) in subjects with advanced 
solid tumors. http://clinicaltrials.gov/ct2/show/NCT00096707 (accessed April 3rd ). 
ClinicalTrials.gov http://clinicaltrials.gov/ct2/results?term=AT-101 (accessed July 6th 2012). 
ClinicalTrials.gov Phase II study of CAP-232 in patients with refractory metastatic renal cell 
carcinoma. http://clinicaltrials.gov/ct2/show/NCT00422786 (accessed July 7th 2012). 
Coley, A. F.; Dodson, H. C.; Morris, M. T.; Morris, J. C. Glycolysis in the african trypanosome: 
targeting enzymes and their subcellular compartments for therapeutic development. Mol Biol 
Int 2011, 2011, 123702. 
Collins, I.; Workman, P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006, 
2 (12), 689–700. 
Colombo, S. L.; Palacios-Callender, M.; Frakich, N.; De Leon, J.; Schmitt, C. A.; Boorn, L.; 
Davis, N.; Moncada, S. Anaphase-promoting complex/cyclosome-Cdh1 coordinates 
glycolysis and glutaminolysis with transition to S phase in human T lymphocytes. Proc Natl 
Acad Sci U S A 2010, 107 (44), 18868–18873. 
Coothankandaswamy, V.; Liu, Y.; Mao, S. C.; Morgan, J. B.; Mahdi, F.; Jekabsons, M. B.; 
Nagle, D. G.; Zhou, Y. -D. The alternative medicine pawpaw and its acetogenin constituents 
suppress tumor angiogenesis via the HIF-1/VEGF pathway. J Nat Prod 2010, 73 (5), 956–
961. 
Cosse, J. P.; Michiels, C. Tumour hypoxia affects the responsiveness of cancer cells to 
chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008, 8 (7), 
790–797. 
185 
 
Cotmore, J. M.; Burke, A.; Lee, N. H.; Shapiro, I. M. Respiratory inhibition of isolated rat liver 
mitochondria by eugenol. Arch Oral Biol 1979, 24 (8), 565–568. 
Cox, C. D.; Garbaccio, R. M. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) 
for the treatment of taxane-refractory cancer: MK-0731 and analogs. Anticancer Agents Med 
Chem 2010, 10 (9), 697–712. 
Cragg, G. M.; Newman D. J. A tale of two tumor targets: Topoisomerase I and tubulin. The 
Wall and Wani contribution to cancer chemotherapy. J Nat Prod 2004, 67 (2), 232–244. 
Cuesta-Rubio, O.; Piccinelli, A. L.; Rastrelli, L. Chemistry and biological activity of 
polyisoprenylated benzophenone derivatives. 2005; Vol. 32 pp 671–720. 
Czyzyk-Krzeska, M. F.; Meller, J. von Hippel-Lindau tumor suppressor: not only HIF's 
executioner. Trends Mol Med 2004, 10 (4), 146–149. 
Das, A. M. Regulation of mitochondrial ATP synthase activity in human myocardium. Clin Sci 
(Lond) 1998, 94 (5), 499–504. 
De Benedetti, A.; Graff, J. R. eIF-4E expression and its role in malignancies and metastases. 
Oncogene 2004, 23 (18), 3189–3199. 
Degli Esposti, M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys 
Acta 1998, 1364 (2), 222–235. 
Degli Esposti, M.; Ghelli, A.; Crimi, M.; Estornell, E.; Fato, R.; Lenaz, G. Complex I and 
complex III of mitochondria have common inhibitors acting as ubiquinone antagonists. 
Biochem Biophys Res Commun 1993, 190 (3), 1090–1096. 
Deng, Y.; Nicholson, R. A. Antifungal properties of surangin B, a coumarin from Mammea 
longifolia. Planta Med 2005, 71 (4), 364–365. 
186 
 
DeYoung, M. P.; Horak, P.; Sofer, A.; Sgroi, D.; Ellisen, L. W. Hypoxia regulates TSC1/2-
mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes 
Dev 2008, 22 (2), 239–251. 
Di Cosimo, S.; Ferretti, G.; Papaldo, P.; Carlini, P.; Fabi, A.; Cognetti, F. Lonidamine: efficacy 
and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc) 2003, 39 
(3), 157–174. 
 Du, L.; Mahdi, F.; Jekabsons, M. B.; Nagle, D. G.; Zhou, Y. -D. Mammea E/BB, an 
isoprenylated dihydroxycoumarin protonophore that potently uncouples mitochondrial 
electron transport, disrupts hypoxic signaling in tumor cells. J Nat Prod 2010, 73 (11), 1868–
1872. 
Du, L.; Mahdi, F.; Jekabsons, M. B.; Nagle, D. G.; Zhou, Y. -D. Natural and semisynthetic 
mammea-type isoprenylated dihydroxycoumarins uncouple cellular respiration. J Nat Prod 
2011, 74 (2), 240–248. 
Duesberg, P. H.; Vogt, P. K. Differences between the ribonucleic acids of transforming and 
nontransforming avian tumor viruses. Proc Natl Acad Sci U S A 1970, 67 (4), 1673–1680. 
Dugoua, J. J.; Perri, D.; Seely, D.; Mills, E.; Koren, G. Safety and efficacy of blue cohosh 
(Caulophyllum thalictroides) during pregnancy and lactation. Can J Clin Pharmacol 2008, 
15 (1), e66–e73. 
Dykens, J. A.; Will, Y. The significance of mitochondrial toxicity testing in drug development. 
Drug Discov Today 2007, 12 (17-18), 777–785. 
Eaton, S.; Bartlett, K.; Pourfarzam, M. Mammalian mitochondrial β-oxidation. Biochem J 1996, 
320 ( Pt 2), 345–357. 
187 
 
Elingold, I.; Isollabella, M. P.; Casanova, M. B.; Celentano, A. M.; Perez, C.; Cabrera, J. L.; 
Diez, R. A.; Dubin, M. Mitochondrial toxicity and antioxidant activity of a prenylated 
flavonoid isolated from Dalea elegans. Chem Biol Interact 2008, 171 (3), 294–305. 
Elmore, S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35 (4), 495–516. 
Fath, M. A.; Diers, A. R.; Aykin-Burns, N.; Simons, A. L.; Hua, L; Spitz, D. R. Mitochondrial 
electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and 
cell killing in human colon carcinoma cells. Cancer Biol Ther 2009, 8 (13), 1228–1236. 
Ferrara, N. VEGF as a therapeutic target in cancer. Oncology 2005, 69 (Suppl. 3), 11–16. 
Finley, L. W.; Carracedo, A.; Lee, J.; Souza, A.; Egia, A.; Zhang, J.; Teruya-Feldstein, J.; 
Moreira, P. I.; Cardoso, S. M.; Clish, C. B.; Pandolfi, P. P.; Haigis, M. C. SIRT3 opposes 
reprogramming of cancer cell metabolism through HIF-1α destabilization. Cancer Cell 
2011a, 19 (3), 416-28. 
Finley, L. W.; Haas, W.; Desquiret-Dumas, V.; Wallace, D. C.; Procaccio, V.; Gygi, S. P.; 
Haigis, M. C. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. 
PLoS One 2011b, 6 (8), e23295. 
Flugel, D.; Gorlach, A.; Michiels, C.; Kietzmann, T. Glycogen synthase kinase 3 phosphorylates 
hypoxia-inducible factor-1α and mediates its destabilization in a VHL-independent manner. 
Mol Cell Biol 2007, 27 (9), 3253–3265. 
Fontenay, M.; Cathelin, S.; Amiot, M.; Gyan, E.; Solary, E. Mitochondria in hematopoiesis and 
hematological diseases. Oncogene 2006, 25 (34), 4757–4767. 
Francis, G.; Kerem, Z.; Makkar, H. P.; Becker, K. The biological action of saponins in animal 
systems: a review. Br J Nutr 2002, 88 (6), 587–605. 
188 
 
Frazier, T. H.; Krueger, K. J. Hepatotoxic herbs: will injury mechanisms guide treatment 
strategies? Curr Gastroenterol Rep 2009, 11 (4), 317–324. 
Friedrich, T.; Ohnishi, T.; Forche, E.; Kunze, B.; Jansen, R.; Trowitzsch, W.; Hofle, G.; 
Reichenbach, H.; Weiss, H. Two binding sites for naturally occurring inhibitors in 
mitochondrial and bacterial NADH:ubiquinone oxidoreductase (complex I). Biochem Soc 
Trans 1994, 22 (1), 226–230. 
Fukuda, R.; Zhang, H.; Kim, J. W.; Shimoda, L.; Dang, C. V.; Semenza, G. L. HIF-1 regulates 
cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 
129 (1), 111–122. 
Fuller, R. W.; Blunt, J. W.; Boswell, J. L.; Cardellina, J. H., II; Boyd, M. R. Guttiferone F, the 
first prenylated benzophenone from Allanblackia stuhlmannii. J Nat Prod 1999a, 62 (1), 
130–132. 
Fuller, R. W.; Westergaard, C. K.; Collins, J. W.; Cardellina, J. H., 2nd; Boyd, M. R. 
Vismiaphenones D-G, new prenylated benzophenones from Vismia cayennensis. J Nat Prod 
1999b, 62 (1), 67–69. 
Gabardi, S.; Munz, K.; Ulbricht, C. A review of dietary supplement-induced renal dysfunction. 
Clin J Am Soc Nephrol 2007, 2 (4), 757–765. 
Galban, S.; Kuwano, Y.; Pullmann, R., Jr.; Martindale, J. L.; Kim, H. H.; Lal, A.; Abdelmohsen, 
K.; Yang, X.; Dang, Y.; Liu, J. O.; Lewis, S. M.; Holcik, M.; Gorospe, M. RNA-binding 
proteins HuR and PTB promote the translation of hypoxia-inducible factor-1α. Mol Cell Biol 
2008, 28 (1), 93–107. 
Gatenby, R. A.; Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 
2004, 4 (11), 891–899. 
189 
 
Gauthier, C.; Legault, J.; Girard-Lalancette, K.; Mshvildadze, V.; Pichette, A. Haemolytic 
activity, cytotoxicity and membrane cell permeabilization of semi-synthetic and natural 
lupane- and oleanane-type saponins. Bioorg Med Chem 2009, 17 (5), 2002–2008. 
Gerald, D.; Berra, E.; Frapart, Y. M.; Chan, D. A.; Giaccia, A. J.; Mansuy, D.; Pouyssegur, J.; 
Yaniv, M.; Mechta-Grigoriou, F. JunD reduces tumor angiogenesis by protecting cells from 
oxidative stress. Cell 2004, 118 (6), 781–794. 
Gledhill, J. R.; Montgomery, M. G.; Leslie, A. G.; Walker, J. E. Mechanism of inhibition of 
bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci U S A 2007, 
104 (34), 13632–13637. 
Gledhill, J. R.; Walker, J. E. Inhibitors of the catalytic domain of mitochondrial ATP synthase. 
Biochem Soc Trans 2006, 34 (Pt 5), 989–992. 
Goonewardene, T. I.; Sowter, H. M.; Harris, A. L. Hypoxia-induced pathways in breast cancer. 
Microsc Res Tech 2002, 59 (1), 41–48. 
Goyal, S. K.; Samsher; Goyal, R. K. Stevia (Stevia rebaudiana) a bio-sweetener: a review. Int J 
Food Sci Nutr 2010, 61 (1), 1–10. 
Granchi, C.; Roy, S.; Giacomelli, C.; Macchia, M.; Tuccinardi, T.; Martinelli, A.; Lanza, M.; 
Betti, L.; Giannaccini, G.; Lucacchini, A.; Funel, N.; Leon, L. G.; Giovannetti, E.; Peters, G. 
J.; Palchaudhuri, R.; Calvaresi, E. C.; Hergenrother, P. J.; Minutolo, F. Discovery of N-
hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as 
starvation agents against cancer cells. J Med Chem 2011– 54 (6), 1599–1612. 
Green, D. R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science 2004, 305 
(5684), 626–629. 
190 
 
Gregus, Z., Mechanisms of toxicity. In Casarett and Doull's Toxicology: The basic science of 
poisons, Klaassen, C. D., Ed. McGraw-Hill: New York 2008; pp 45-106. 
Grieco, A.; Miele, L.; Pompili, M.; Biolato, M.; Vecchio, F. M.; Grattagliano, I.; Gasbarrini, G. 
Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no 
"alternative" at all. J Hepatol 2009, 50 (6), 1273–1277. 
Gupta, P. B.; Onder, T. T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R. A.; Lander, E. S. 
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 
2009, 138 (4), 645–659. 
Gustafson, K. R. Natural product chemistry group, National Cancer Institute, Frederick, MD; and 
Nagle, D. G. Department of Pharmacognosy, The University of Mississippi, Oxford, MS. 
Personal communication 2008. 
Gustafson, K. R.; Blunt, J. W.; Munro, M. G. H.; Fuller, R. W.; McKee, T. C.; Cardellina, J. H., 
II; McMahon, J. B.; Cragg, G. M.; Boyd, M. R. The guttiferones, HIV-inhibitory 
benzophenones from Symphonia globulifera, Garcinia livingstonei, Garcinia ovalifolia and 
Clusia rosea. Tetrahedron 1992, 48 (46), 10093–101102. 
Guzy, R. D.; Hoyos, B.; Robin, E.; Chen, H.; Liu, L.; Mansfield, K. D.; Simon, M. C.; 
Hammerling, U.; Schumacker, P. T. Mitochondrial complex III is required for hypoxia-
induced ROS production and cellular oxygen sensing. Cell Metab 2005, 1 (6), 401–408. 
Guzy, R. D.; Sharma, B.; Bell, E.; Chandel, N. S.; Schumacker, P. T. Loss of the SdhB, but Not 
the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-
inducible factor activation and tumorigenesis. Mol Cell Biol 2008, 28 (2), 718–731. 
Hagen, T.; Taylor, C. T.; Lam, F.; Moncada, S. Redistribution of intracellular oxygen in hypoxia 
by nitric oxide: effect on HIF1α. Science 2003, 302 (5652), 1975–1978. 
191 
 
Haller, C. A.; Benowitz, N. L. Adverse cardiovascular and central nervous system events 
associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000, 343 
(25), 1833–1838. 
Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144 (5), 
646–674. 
Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100 (1), 57–70. 
Haridas, V.; Higuchi, M.; Jayatilake, G. S.; Bailey, D.; Mujoo, K.; Blake, M. E.; Arntzen, C. J.; 
Gutterman, J. U. Avicins: triterpenoid saponins from Acacia victoriae (Bentham) induce 
apoptosis by mitochondrial perturbation. Proc Natl Acad Sci U S A 2001, 98 (10), 5821–
5826. 
Harvey, A. L. Natural products in drug discovery. Drug Discov Today 2008, 13 (19-20), 894–
901. 
Hayes, A. W. Action of rubratoxin B on mouse liver mitochondria. Toxicology 1976, 6 (2), 253–
261. 
Hellerstein, M. K. A critique of the molecular target-based drug discovery paradigm based on 
principles of metabolic control: Advantages of pathway-based discovery. Metab Eng 2008, 
10 (1), 1–9. 
Herrero-Mendez, A.; Almeida, A.; Fernandez, E.; Maestre, C.; Moncada, S.; Bolanos, J. P. The 
bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a 
key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol 2009, 11 (6), 747–752. 
Higashimura, Y.; Nakajima, Y.; Yamaji, R.; Harada, N.; Shibasaki, F.; Nakano, Y.; Inui, H. Up-
regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity 
depending on Sp1 in hypoxic breast cancer cells. Arch Biochem Biophys 2011, 509 (1), 1–8. 
192 
 
Hirota, K.; Semenza, G. L. Regulation of hypoxia-inducible factor-1 by prolyl and asparaginyl 
hydroxylases. Biochem Biophys Res Commun 2005, 338 (1), 610–616. 
Hockel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular 
aspects. J Natl Cancer Inst 2001, 93 (4), 266–276. 
Hodges, T. W.; Hossain, C. F.; Kim, Y. -P.; Zhou, Y. -D.; Nagle, D. G. Molecular-targeted 
antitumor agents: The Saururus cernuus dineolignans manassantin B and 4-O-
demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1. J Nat Prod 2004, 
67 (5), 767–771. 
Hossain, C. F.; Kim, Y. -P.; Baerson, S. R.; Zhang, L.; Bruick, R. K.; Mohammed, K. A.; 
Agarwal, A. K.; Nagle, D. G.; Zhou, Y. -D. Saururus cernuus lignans - potent small 
molecule inhibitors of hypoxia-inducible factor-1. Biochem Biophys Res Commun 2005, 333 
(3), 1026–1033. 
Hostettmann, K. M.; Marston, A. Triterpene saponins - pharmacological and biological 
properties. In Chemistry and pharmacology of natural products: Saponins, Chambridge 
University Press: New York, USA, 1995; p 284–286. 
Huang, L. E.; Arany, Z.; Livingston, D. M.; Bunn, H. F. Activation of hypoxia-inducible 
transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J 
Biol Chem 1996, 271 (50), 32253–32259. 
Huang, L. E.; Gu, J.; Schau, M.; Bunn, H. F. Regulation of hypoxia-inducible factor-1α is 
mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. 
Proc Natl Acad Sci U S A 1998, 95 (14), 7987–7992. 
193 
 
Hussain, R. A.; Owegby, A. G.; Parimoo, P.; Waterman, P. G. Kolanone, a novel 
polyisoprenylated benzophenone with antimicrobial properties from the fruit of Garcinia 
kola. Planta Med 1982, 44 (2), 78–81. 
Inglese, J.; Auld, D. S.; Jadhav, A.; Johnson, R. L.; Simeonov, A.; Yasgar, A.; Zheng, W.; 
Austin, C. P. Quantitative high-throughput screening: a titration-based approach that 
efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S 
A 2006, 103 (31), 11473–11478. 
Isaacs, J. S.; Jung, Y. J.; Mimnaugh, E. G.; Martinez, A.; Cuttitta, F.; Neckers, L. M. Hsp90 
regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative 
pathway. J Biol Chem 2002, 277 (33), 29936–29944. 
Isaacs, J. S.; Jung, Y. J.; Mole, D. R.; Lee, S.; Torres-Cabala, C.; Chung, Y. L.; Merino, M.; 
Trepel, J.; Zbar, B.; Toro, J.; Ratcliffe, P. J.; Linehan, W. M.; Neckers, L. HIF 
overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role 
of fumarate in regulation of HIF stability. Cancer Cell 2005, 8 (2), 143–153. 
Jain, M.; Arvanitis, C.; Chu, K.; Dewey, W.; Leonhardt, E.; Trinh, M.; Sundberg, C. D.; Bishop, 
J. M.; Felsher, D. W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. 
Science 2002, 297 (5578), 102–104. 
Jiang, B. H.; Zheng, J. Z.; Leung, S. W.; Roe, R.; Semenza, G. L. Transactivation and inhibitory 
domains of hypoxia-inducible factor-1α. Modulation of transcriptional activity by oxygen 
tension. J Biol Chem 1997, 272 (31), 19253–19260. 
Jiang, C.; Liu, S.; He, W.; Luo, X.; Zhang, S.; Xiao, Z.; Qiu, X.; Yin, H. A new prenylated 
flavanone from Derris trifoliata Lour. Molecules 2012, 17 (1), 657–663. 
194 
 
Jin, Z.; El-Deiry, W. S. Overview of cell death signaling pathways. Cancer Biol Ther 2005, 4 
(2), 139–163. 
Jones, D. P.; Lemasters, J. J.; Han, D.; Boelsterli, U. A.; Kaplowitz, N. Mechanisms of 
pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv 2010, 10 
(2), 98–111. 
Jones, P.; Steinkühler, C. From natural products to small molecule ketone histone deacetylase 
inhibitors: development of new class specific agents. Curr Pharm Des 2008, 14 (6), 545–
561. 
Juzyszyn, Z.; Czerny, B.; Mysliwiec, Z.; Pawlik, A.; Drozdzik, M. The effect of artichoke 
(Cynara scolymus L.) extract on respiratory chain system activity in rat liver mitochondria. 
Phytother Res 2010, 24 Suppl 2, S123–S128. 
Kallio, P. J.; Okamoto, K.; O'Brien, S.; Carrero, P.; Makino, Y.; Tanaka, H.; Poellinger, L. 
Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the 
CBP/p300 coactivator by the hypoxia-inducible factor-1α. Embo J 1998, 17 (22), 6573–6586. 
Kallio, P. J.; Wilson, W. J.; O'Brien, S.; Makino, Y.; Poellinger, L. Regulation of the hypoxia-
inducible transcription factor-1α by the ubiquitin-proteasome pathway. J Biol Chem 1999, 
274 (10), 6519–6525. 
Kaluz, S.; Kaluzova, M.; Stanbridge, E. J. Proteasomal inhibition attenuates transcriptional 
activity of hypoxia-inducible factor-1 (HIF-1) via specific effect on the HIF-1α C-terminal 
activation domain. Mol Cell Biol 2006, 26 (15), 5895–5907. 
Kamal, R.; Mathur, N. Rotenoids from Lablab purpureus L. and their bioefficacy against human 
disease vectors. Parasitol Res 2010, 107 (6), 1481–1488. 
195 
 
Kamara, B. I.; Brandt, E. V.; Ferreira, D.; Joubert, E. Polyphenols from Honeybush tea 
(Cyclopia intermedia). J Agric Food Chem 2003, 51 (13), 3874–3879. 
Kamura, T.; Koepp, D. M.; Conrad, M. N.; Skowyra, D.; Moreland, R. J.; Iliopoulos, O.; Lane, 
W. S.; Kaelin, W. G., Jr.; Elledge, S. J.; Conaway, R. C.; Harper, J. W.; Conaway, J. W. 
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 
1999, 284 (5414), 657–661. 
Katschinski, D. M.; Le, L.; Schindler, S. G.; Thomas, T.; Voss, A. K.; Wenger, R. H. Interaction 
of the PAS B domain with Hsp90 accelerates hypoxia-inducible factor-1α stabilization. Cell 
Physiol Biochem 2004, 14 (4-6), 351–360. 
Ke, Q.; Costa, M., Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006, 70 (5), 1469–
1480. 
Kelmer Bracht, A.; Alvarez, M.; Bracht, A. Effects of Stevia rebaudiana natural products on rat 
liver mitochondria. Biochem Pharmacol 1985, 34 (6), 873–882. 
Kessler, R. J.; Vande Zande, H.; Tyson, C. A.; Blondin, G. A.; Fairfield, J.; Glasser, P.; Green, 
D. E., Uncouplers and the molecular mechanism of uncoupling in mitochondria. Proc Natl 
Acad Sci U S A 1977, 74 (6), 2241–2245. 
Khan, M. A.; Ali, M.; Alam, P. Phytochemical investigation of the fruit peels of Citrus reticulata 
Blanco. Nat Prod Res 2010, 24 (7), 610–620. 
Kim, J. Protective effects of Asian dietary items on cancers - soy and ginseng. Asian Pac J 
Cancer Prev 2008, 9 (4), 543–548. 
Kim, J. W.; Dang, C. V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 
2006, 66 (18), 8927–8930. 
196 
 
Kim, J. W.; Tchernyshyov, I.; Semenza, G. L.; Dang, C. V. HIF-1-mediated expression of 
pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to 
hypoxia. Cell Metab 2006, 3 (3), 177–185. 
Kitagawa, M.; Misawa, M.; Ogawa, S.; Tashiro, E.; Imoto, M. A new, convenient cell-based 
screening method for small-molecule glycolytic inhibitors. Biosci Biotechnol Biochem 2011, 
75 (2), 367–369. 
Klausmeyer, P.; McCloud, T. G.; Melillo, G.; Scudiero, D. A.; Cardellina, J. H., II; Shoemaker, 
R. H. Identification of a new natural camptothecin analogue in targeted screening for HIF-1α 
inhibitors. Planta Med 2007, 73 (1), 49–52. 
Klawitter, J.; Kominsky, D. J.; Brown, J. L.; Christians, U.; Leibfritz, D.; Melo, J. V.; Eckhardt, 
S. G.; Serkova, N. J. Metabolic characteristics of imatinib resistance in chronic myeloid 
leukaemia cells. Br J Pharmacol 2009, 158 (2), 588–600. 
Klimova, T.; Chandel, N. S. Mitochondrial complex III regulates hypoxic activation of HIF. Cell 
Death Differ 2008, 15 (4), 660–666. 
Ko, Y. H.; Pedersen, P. L.; Geschwind, J. F. Glucose catabolism in the rabbit VX2 tumor model 
for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001, 173 (1), 83–91. 
Ko, Y. H.; Smith, B. L.; Wang, Y.; Pomper, M. G.; Rini, D. A.; Torbenson, M. S.; Hullihen, J.; 
Pedersen, P. L. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to 
deplete ATP. Biochem Biophys Res Commun 2004, 324 (1), 269–275. 
Koehn, F. E., High impact technologies for natural products screening. Prog Drug Res 2008, 65, 
175–210. 
Koumenis, C.; Naczki, C.; Koritzinsky, M.; Rastani, S.; Diehl, A.; Sonenberg, N.; Koromilas, 
A.; Wouters, B. G. Regulation of protein synthesis by hypoxia via activation of the 
197 
 
endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor 
eIF2α. Mol Cell Biol 2002, 22 (21), 7405–7416. 
 
Kroemer, G.; Dallaporta, B.; Resche-Rigon, M. The mitochondrial death/life regulator in 
apoptosis and necrosis. Annu Rev Physiol 1998, 60, 619–642. 
Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death. 
Physiol Rev 2007, 87 (1), 99–163. 
Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 
13 (6), 472–482. 
Kunze, B.; Sasse, F.; Wieczorek, H.; Huss, M. Cruentaren A, a highly cytotoxic benzolactone 
from Myxobacteria is a novel selective inhibitor of mitochondrial F1-ATPases. FEBS Lett 
2007, 581 (18), 3523–3527. 
Kurtoglu, M.; Gao, N.; Shang, J.; Maher, J. C.; Lehrman, M. A.; Wangpaichitr, M.; Savaraj, N.; 
Lane, A. N.; Lampidis, T. J. Under normoxia, 2-deoxy-D-glucose elicits cell death in select 
tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. 
Mol Cancer Ther 2007, 6 (11), 3049–3058. 
Labbe, G.; Pessayre, D.; Fromenty, B. Drug-induced liver injury through mitochondrial 
dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin 
Pharmacol 2008, 22 (4), 335–353. 
Lagoa, R.; Graziani, I.; Lopez-Sanchez, C.; Garcia-Martinez, V.; Gutierrez-Merino, C. Complex 
I and cytochrome c are molecular targets of flavonoids that inhibit hydrogen peroxide 
production by mitochondria. Biochim Biophys Acta 2011, 1807 (12), 1562–1572. 
198 
 
Lando, D.; Peet, D. J.; Whelan, D. A.; Gorman, J. J.; Whitelaw, M. L. Asparagine hydroxylation 
of the HIF transactivation domain a hypoxic switch. Science 2002, 295 (5556), 858–861. 
Lang, K. J.; Kappel, A.; Goodall, G. J. Hypoxia-inducible factor-1α mRNA contains an internal 
ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol 
Cell 2002, 13 (5), 1792–1801. 
Lehninger, A. L.; Nelson, D. L.; Cox, M. M. Lehninger Principles of Biochemistry. 4th ed. ed.; 
W.H. Freeman: New York, N.Y. ; Basingstoke, 2005. 
Lemeshko, V. V.; Haridas, V.; Quijano Perez, J. C.; Gutterman, J. U. Avicins, natural anticancer 
saponins, permeabilize mitochondrial membranes. Arch Biochem Biophys 2006, 454 (2), 
114–122. 
Lessene, G.; Czabotar, P. E.; Colman, P. M. BCL-2 family antagonists for cancer therapy. Nat 
Rev Drug Discov 2008, 7 (12), 989–1000. 
Li, J.; Mahdi, F.; Du, L.; Datta, S.; Nagle, D. G.; Zhou, Y. -D. Mitochondrial respiration 
inhibitors suppress protein translation and hypoxic signaling via the hyperphosphorylation 
and inactivation of translation initiation factor eIF2α and elongation factor eEF2. J Nat Prod 
2011, 74 (9), 1894–1901. 
Li, X.; Wu, J. F. Recent developments in patent anti-cancer agents targeting the matrix 
metalloproteinases (MMPs). Recent Pat Anticancer Drug Discov 2010, 5 (2), 109–141. 
Li, Z.; Wang, D.; Messing, E. M.; Wu, G. VHL protein-interacting deubiquitinating enzyme 2 
deubiquitinates and stabilizes HIF-1α. EMBO Rep 2005, 6 (4), 373–378. 
Liebler, D. C.; Guengerich, F. P. Elucidating mechanisms of drug-induced toxicity. Nat Rev 
Drug Discov 2005, 4 (5), 410–420. 
199 
 
Lim, C. H. U., H.; Miyoshi, H.; Miyagawa, H.; Iwamura, H.; Ueno, T. Phytotoxic compounds 
cochlioquinones are inhibitors of mitochondrial NADH-ubiquinone reductase. J. Pest. Sci. 
1996, 21 (2), 213–215. 
Lim, J. H.; Lee, Y. M.; Chun, Y. S.; Chen, J.; Kim, J. E.; Park, J. W. Sirtuin 1 modulates cellular 
responses to hypoxia by deacetylating hypoxia-inducible factor-1α. Mol Cell 2010, 38 (6), 
864–878. 
Lin, X.; David, C. A.; Donnelly, J. B.; Michaelides, M.; Chandel, N. S.; Huang, X.; Warrior, U.; 
Weinberg, F.; Tormos, K. V.; Fesik, S. W.; Shen, Y. A chemical genomics screen highlights 
the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A 2008, 105 
(1), 174–179. 
Linington, R. G.; Gonzalez, J.; Urena, L. D.; Romero, L. I.; Ortega-Barria, E.; Gerwick, W. H. 
Venturamides A and B: antimalarial constituents of the panamanian marine Cyanobacterium 
Oscillatoria sp. J Nat Prod 2007, 70 (3), 397–401. 
Linnett, P. E.; Beechey, R. B. Inhibitors of the ATP synthethase system. Methods Enzymol 1979, 
55, 472–518. 
 Liobikas, J.; Majiene, D.; Trumbeckaite, S.; Kursvietiene, L.; Masteikova, R.; Kopustinskiene, 
D. M.; Savickas, A.; Bernatoniene, J. Uncoupling and antioxidant effects of ursolic acid in 
isolated rat heart mitochondria. J Nat Prod 2011, 74 (7), 1640–1644. 
Liu, Y. V.; Baek, J. H.; Zhang, H.; Diez, R.; Cole, R. N.; Semenza, G. L. RACK1 competes with 
Hsp90 for binding to HIF-1α and is required for O2-independent and Hsp90 inhibitor-induced 
degradation of HIF-1α. Mol Cell 2007, 25 (2), 207–217. 
Liu, Y. V.; Semenza, G. L. RACK1 vs. Hsp90: competition for HIF-1α degradation vs. 
stabilization. Cell Cycle 2007, 6 (6), 656–659. 
200 
 
Liu, Y.; Liu, R.; Mao, S. C.; Morgan, J. B.; Jekabsons, M. B.; Zhou, Y. -D.; Nagle, D. G. 
Molecular-targeted antitumor agents. 19. Furospongolide from a marine Lendenfeldia sp. 
sponge inhibits hypoxia-inducible factor-1 activation in breast tumor cells. J Nat Prod 2008, 
71 (11), 1854–1860. 
Liu, Y.; Morgan, J. B.; Coothankandaswamy, V.; Liu, R.; Jekabsons, M. B.; Mahdi, F.; Nagle, 
D. G.; Zhou, Y. -D. The Caulerpa pigment caulerpin inhibits HIF-1 activation and 
mitochondrial respiration. J Nat Prod 2009b, 72 (12), 2104–2109. 
Liu, Y.; Veena, C. K.; Morgan, J. B.; Mohammed, K. A.; Jekabsons, M. B.; Nagle, D. G.; Zhou, 
Y. -D. Methylalpinumisoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by 
simultaneously targeting multiple pathways. J Biol Chem 2009a, 284 (9), 5859–5868. 
Lobell, R. B.; Omer, C. A.; Abrams, M. T.; Bhimnathwala, H. G.; Brucker, M. J.; Buser, C. A.; 
Davide, J. P.; deSolms, S. J.; Dinsmore, C. J.; Ellis-Hutchings, M. S.; Kral, A. M.; Liu, D.; 
Lumma, W. C.; Machotka, S. V.; Rands, E.; Williams, T. M.; Graham, S. L.; Hartman, G. 
D.; Oliff, A. I.; Heimbrook, D. C.; Kohl, N. E. Evaluation of farnesyl:protein transferase and 
geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 
2001, 61 (24), 8758–8768. 
Loscalzo, J. The cellular response to hypoxia: tuning the system with microRNAs. J Clin Invest 
2010, 120 (11), 3815–3817. 
Luo, W.; Hu, H.; Chang, R.; Zhong, J.; Knabel, M.; O'Meally, R.; Cole, R. N.; Pandey, A.; 
Semenza, G. L. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible 
factor 1. Cell 2011, 145 (5), 732–744. 
Luo, W.; Semenza, G. L. Pyruvate kinase M2 regulates glucose metabolism by functioning as a 
coactivator for hypoxia-inducible factor-1 in cancer cells. Oncotarget 2011, 2 (7), 551–556. 
201 
 
Macheda, M. L.; Rogers, S.; Best J. D. Molecular and cellular regulation of glucose transporter 
(GLUT) proteins in cancer. J Cell Physiol 2005, 202 (3) 654–662. 
Macheda, M. L.; Rogers, S.; Best, J. D. Molecular and cellular regulation of glucose transporter 
(GLUT) proteins in cancer. J Cell Physiol 2005, 202 (3), 654–662. 
Mahdi, F.; Falkenberg, M.; Ioannou, E.; Roussis, V.; Zhou, Y. -D.; Nagle, D. G. Thyrsiferol 
inhibits mitochondrial respiration and HIF-1 activation. Phytochem Lett 2011, 4 (2), 75–78. 
Mahon, P. C.; Hirota, K.; Semenza, G. L. FIH-1: a novel protein that interacts with HIF-1α and 
VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001, 15 (20), 2675–
2686. 
Mai, H. D.; Nguyen, T. T.; Pham, V. C.; Litaudon, M.; Guéritte, F.; Tran, D. T.; Nguyen, V. H. 
Cytotoxic prenylated isoflavone and bipterocarpan from Millettia pachyloba. Planta Med 
2010, 76 (15), 1739–1742. 
Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev 
Cancer 2009, 9 (3), 153–166. 
Man, S.; Gao, W.; Zhang, Y.; Huang, L.; Liu, C. Chemical study and medical application of 
saponins as anti-cancer agents. Fitoterapia 2010, 81 (7), 703–714. 
Mao, S. C.; Liu, Y.; Morgan, J. B.; Jekabsons, M. B.; Zhou, Y. -D.; Nagle, D. G. Lipophilic 2,5-
disubstituted pyrroles from the marine sponge Mycale sp. inhibit mitochondrial respiration 
and HIF-1 activation. J Nat Prod 2009, 72 (11), 1927–1936. 
Marcillat, O.; Zhang, Y.; Davies, K. J. Oxidative and non-oxidative mechanisms in the 
inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. 
Biochem J 1989, 259 (1), 181–189. 
202 
 
Marti, G.; Eparvier, V.; Moretti, C.; Susplugas, S.; Prado, S.; Grellier, P.; Retailleau, P.; 
Gueritte, F.; Litaudon, M. Antiplasmodial benzophenones from the trunk latex of Moronobea 
coccinea (Clusiaceae). Phytochemistry 2009, 70 (1), 75–85. 
Martinez-Abundis, E.; Garcia, N.; Correa, F.; Hernandez-Resendiz, S.; Pedraza-Chaverri, J.; 
Zazueta, C. Effects of α-mangostin on mitochondrial energetic metabolism. Mitochondrion 
2010, 10 (2), 151–157. 
Mason, E. F.; Zhao, Y.; Goraksha-Hicks, P.; Coloff, J. L.; Gannon, H.; Jones, S. N.; Rathmell, J. 
C. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis 
upon loss of growth signals or inhibition of BCR-Abl. Cancer Res 2010, 70 (20), 8066–8076. 
Mathupala, S. P.; Ko, Y. H.; Pedersen, P. L. The pivotal roles of mitochondria in cancer: 
Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys 
Acta 2010, 1797 (6-7), 1225–1230. 
Matsuno-Yagi, A.; Hatefi, Y. Studies on the mechanism of oxidative phosphorylation. ATP 
synthesis by submitochondrial particles inhibited at F0 by venturicidin and organotin 
compounds. J Biol Chem 1993, 268 (9), 6168–6173. 
Maxwell, P. H.; Wiesener, M. S.; Chang, G. W.; Clifford, S. C.; Vaux, E. C.; Cockman, M. E.; 
Wykoff, C. C.; Pugh, C. W.; Maher, E. R.; Ratcliffe, P. J. The tumour suppressor protein 
VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399 
(6733), 271–275. 
McChesney, J. D.; Venkataraman, S. K.; Henri, J. T. Plant natural products: back to the future or 
into extinction? Phytochemistry 2007, 68 (14), 2015–2022. 
McDonald, E.; Workman, P.; Jones, K. Inhibitors of the Hsp90 molecular chaperone: attacking 
the master regulator in cancer. Curr Top Med Chem 2006, 6 (11), 1091–107. 
203 
 
McFarlin, B. L.; Gibson, M. H.; O'Rear, J.; Harman, P. A national survey of herbal preparation 
use by nurse-midwives for labor stimulation. Review of the literature and recommendations 
for practice. J Nurse Midwifery 1999, 44 (3), 205–216. 
McLaughlin, J. L. Paw paw and cancer: annonaceous acetogenins from discovery to commercial 
products. J Nat Prod 2008, 71 (7), 1311–1321. 
Melzig, M. F.; Bader, G.; Loose, R. Investigations of the mechanism of membrane activity of 
selected triterpenoid saponins. Planta Med 2001, 67 (1), 43–48. 
Minchenko, A.; Leshchinsky, I.; Opentanova, I.; Sang, N.; Srinivas, V.; Armstead, V.; Caro, J. 
Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 
2002, 277 (8), 6183–6187. 
Mishra, K. P.; Ganju, L.; Sairam, M.; Banerjee, P. K.; Sawhney, R. C. A review of high 
throughput technology for the screening of natural products. Biomed Pharmacother 2008, 62 
(2), 94–98. 
Moeller, B. J.; Dreher, M. R.; Rabbani, Z. N.; Schroeder, T.; Cao, Y.; Li, C. Y.; Dewhirst, M. W. 
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005, 8 (2), 99–
110. 
Mogi, T.; Kawakami, T.; Arai, H.; Igarashi, Y.; Matsushita, K.; Mori, M.; Shiomi, K.; Omura, 
S.; Harada, S.; Kita, K. Siccanin rediscovered as a species-selective succinate dehydrogenase 
inhibitor. J Biochem 2009, 146 (3), 383–387. 
Mohammed, K. A.; Hossain, C. F.; Zhang, L.; Bruick, R. K.; Zhou, Y. -D.; Nagle, D. G. 
Laurenditerpenol, a new diterpene from the tropical marine alga Laurencia intricata that 
204 
 
potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells. J Nat Prod 2004, 
67 (12), 2002–2007. 
Montoya, M. Translation under hypoxia. Nat Struct Mol Biol 2012, 19 (6), 602. 
Monzote, L.; Stamberg, W.; Staniek, K.; Gille, L. Toxic effects of carvacrol, caryophyllene 
oxide, and ascaridole from essential oil of Chenopodium ambrosioides on mitochondria. 
Toxicol Appl Pharmacol 2009, 240 (3), 337–347. 
Moraes, R. M.; Bedir, E.; Barrett, H.; Burandt, C., Jr.; Canel, C.; Khan, I. A. Evaluation of 
Podophyllum peltatum accessions for podophyllotoxin production. Planta Med 2002, 68 (4), 
341–344. 
Moreno-Sanchez, R.; Rodriguez-Enriquez, S.; Saavedra, E.; Marin-Hernandez, A.; Gallardo-
Perez, J. C. The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor 
cells? Biofactors 2009, 35 (2), 209–225. 
Morgan, J. B.; Mahdi, F.; Liu, Y.; Coothankandaswamy, V.; Jekabsons, M. B.; Johnson, T. A.; 
Sashidhara, K. V.; Crews, P.; Nagle, D. G.; Zhou, Y. -D. The marine sponge metabolite 
mycothiazole: a novel prototype mitochondrial complex I inhibitor. Bioorg Med Chem 2010, 
18 (16), 5988–5994. 
Mori, M.; Miura, S.; Morita, T.; Takiguchi, M.; Tatibana, M. Synthesis, intracellular transport 
and processing of mitochondrial urea cycle enzymes. Adv Enzyme Regul 1983, 21, 121–132. 
Morikawa, N.; Nakagawa-Hattori, Y.; Mizuno, Y. Effect of dopamine, 
dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial 
respiration and complex I activity. J Neurochem 1996, 66 (3), 1174–1181. 
Mottram, J. C. A Factor of Importance in the Radio Sensitivity of Tumours. British journal of 
radiology 1936, 9, 606–614. 
205 
 
Munoz-Pinedo, C.; El Mjiyad, N.; Ricci, J. E. Cancer metabolism: current perspectives and 
future directions. Cell Death Dis 2012, 3, e248. 
Mylonis, I.; Chachami, G.; Paraskeva, E.; Simos, G. Atypical CRM1-dependent nuclear export 
signal mediates regulation of hypoxia-inducible factor-1α by MAPK. J Biol Chem 2008, 283 
(41), 27620–27627. 
Mylonis, I.; Chachami, G.; Samiotaki, M.; Panayotou, G.; Paraskeva, E.; Kalousi, A.; 
Georgatsou, E.; Bonanou, S.; Simos, G. Identification of MAPK phosphorylation sites and 
their role in the localization and activity of hypoxia-inducible factor-1α. J Biol Chem 2006, 
281 (44), 33095–33106. 
Nadia, B. H.; Wided, K.; Kheira, B.; Hassiba, R.; Lamia, B.; Rhouati, S.; Alyane, M.; Zellagui, 
A.; Lahouel, M. Disruption of mitochondrial membrane potential by ferulenol and restoration 
by propolis extract: antiapoptotic role of propolis. Acta Biol Hung 2009, 60 (4), 385–398. 
Nagle, D. G.; Zhou, Y.-D. 2.20 - Natural products as probes of selected targets in tumor cell 
biology and hypoxic signaling. In: Comprehensive natural products II, Mander, L.; Liu, H. -
W. Eds.; Elsevier: Oxford, United Kingdom, 2010; pp 651–683. 
Nagle, D. G.; Zhou, Y.-D. Natural products as inhibitors of hypoxia-inducible factor-1. In 
Bioactive compounds from natural sources, second edition: natural products as lead 
compounds in drug discovery, Tringali, C. Ed. CRC press: 2011; pp 187–263. 
Nakano, A.; Tsuji, D.; Miki, H.; Cui, Q.; El Sayed, S. M.; Ikegame, A.; Oda, A.; Amou, H.; 
Nakamura, S.; Harada, T.; Fujii, S.; Kagawa, K.; Takeuchi, K.; Sakai, A.; Ozaki, S.; Okano, 
K.; Nakamura, T.; Itoh, K.; Matsumoto, T.; Abe, M. Glycolysis inhibition inactivates ABC 
transporters to restore drug sensitivity in malignant cells. PLoS One 2011, 6 (11), e27222. 
206 
 
Nakashima, R. A.; Mangan, P. S.; Colombini, M.; Pedersen, P. L. Hexokinase receptor complex 
in hepatoma mitochondria: evidence from N,N'-dicyclohexylcarbodiimide-labeling studies 
for the involvement of the pore-forming protein VDAC. Biochemistry 1986, 25 (5), 1015–
1021. 
Napiwotzki, J.; Kadenbach, B. Extramitochondrial ATP/ADP-ratios regulate cytochrome c 
oxidase activity via binding to the cytosolic domain of subunit IV. Biol Chem 1998, 379 (3), 
335–339. 
Narita, T.; Yin, S.; Gelin, C. F.; Moreno, C. S.; Yepes, M.; Nicolaou, K. C.; Van Meir, E. G. 
Identification of a novel small molecule HIF-1α translation inhibitor. Clin Cancer Res 2009, 
15 (19), 6128–6136. 
National Institutes of Health Molecular libraries program: pathways to discovery. 
http://mli.nih.gov/mli/secondary-menu/nih-resources/ (accessed on March 11th 2012).  
Neckers L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. 
Curr Top Med Chem 2006, 6 (11), 1163–1171. 
Neto, C. C. Cranberry and its phytochemicals: a review of in vitro anticancer studies. J Nutr 
2007, 137 (1 Suppl), 186S–193S. 
 Newman, D. J. Natural Products Branch, National Cancer Institute, Frederick, MD; and Nagle, 
D. G. Department of Pharmacognosy, The University of Mississippi, Oxford, MS. Personal 
communication 2008. 
Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the 30 years from 
1981 to 2010. J Nat Prod 2012, 75 (3), 311–315. 
Nicholls, D. G.; Ferguson, S. J. Bioenergetics 3. [3rd ed.] ed.; Amsterdam ; London ; Academic 
Press: 2002. 
207 
 
Nieminen, A. L.; Saylor, A. K.; Herman, B.; Lemasters, J. J. ATP depletion rather than 
mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition. Am J 
Physiol 1994, 267 (1 Pt 1), C67–C74. 
Onnis, B.; Rapisarada, A.; Melillo, G. Development of HIF-1 inhibitors for cancer therapy. J 
Cell Mol Med 2009, 13 (9A), 2780–2786. 
Overall, C. M.; Klefield, O. Tumour microenvironment - opinion: validating matrix 
metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 
6 (3), 227–239. 
Palmer, M. E.; Haller, C.; McKinney, P. E.; Klein-Schwartz, W.; Tschirgi, A.; Smolinske, S. C.; 
Woolf, A.; Sprague, B. M.; Ko, R.; Everson, G.; Nelson, L. S.; Dodd-Buter, T.; Bartlett, W. 
D.; Landzberg, B. R. Adverse events associated with dietary supplements: an observational 
study. Lancet 2003, 361 (9352), 101–106. 
Pan, Y.; Mansfield, K. D.; Bertozzi, C. C.; Rudenko, V.; Chan, D. A.; Giaccia, A. J.; Simon, M. 
C. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-
inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 2007, 27 (3), 
912–925. 
Papandreou, I.; Cairns, R. A.; Fontana, L.; Lim, A. L.; Denko, N. C. HIF-1 mediates adaptation 
to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006, 
3 (3), 187–197. 
Papandreou, I.; Goliasova, T.; Denko, N. C. Anticancer drugs that target metabolism: Is 
dichloroacetate the new paradigm? Int J Cancer 2011, 128 (5), 1001–1008. 
208 
 
Pardini, R. S.; Kim, C. H.; Biagini, R.; Morris, R. J.; Fletcher, D. C. Inhibition of mitochondrial 
electron-transport systems by nor-isoguaiacin. Biochem Pharmacol 1973, 22 (15), 1921–
1925. 
Pardo-Andreu, G. L.; Nunez-Figueredo, Y.; Tudella, V. G.; Cuesta-Rubio, O.; Rodrigues, F. P.; 
Pestana, C. R.; Uyemura, S. A.; Leopoldino, A. M.; Alberici, L. C.; Curti, C. The anti-cancer 
agent nemorosone is a new potent protonophoric mitochondrial uncoupler. Mitochondrion 
2011, 11 (2), 255–263. 
Pastorino, J. G.; Shulga, N.; Hoek, J. B. Mitochondrial binding of hexokinase II inhibits Bax-
induced cytochrome c release and apoptosis. J Biol Chem 2002, 277 (9), 7610–7618. 
Patiar, S.; Harris, A. L. Role of hypoxia-inducible factor-1α as a cancer therapy target. Endocr 
Relat Cancer 2006, 13 Suppl 1, S61–S75. 
Perry, W. L. III; Weitzman, A. The development of molecularly targeted anticancer therapies: an 
Eli Lilly and Company perspective. Clin Adv Hematol Oncol 2005, 3 (3), 199–202. 
Pitroda, S. P.; Wakim, B. T.; Sood, R. F.; Beveridge, M. G.; Beckett, M. A.; MacDermed, D. M.; 
Weichselbaum, R. R.; Khodarev, N. N. STAT1-dependent expression of energy metabolic 
pathways links tumour growth and radioresistance to the Warburg effect. BMC Med 2009, 7, 
68. 
Podolak, I.; Galanty, A.; Sobolewska, D. Saponins as cytotoxic agents: a review. Phytochem Rev 
2010, 9 (3), 425–474. 
Pollard, P. J.; Briere, J. J.; Alam, N. A.; Barwell, J.; Barclay, E.; Wortham, N. C.; Hunt, T.; 
Mitchell, M.; Olpin, S.; Moat, S. J.; Hargreaves, I. P.; Heales, S. J.; Chung, Y. L.; Griffiths, 
J. R.; Dalgleish, A.; McGrath, J. A.; Gleeson, M. J.; Hodgson, S. V.; Poulsom, R.; Rustin, P.; 
Tomlinson, I. P. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in 
209 
 
tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005, 14 (15), 
2231–2239. 
Radad, K.; Rausch, W. D.; Gille, G. Rotenone induces cell death in primary dopaminergic 
culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem 
Int 2006, 49 (4), 379–386. 
Rademakers, S. E.; Span, P. N.; Kaanders, J. H.; Sweep, F. C.; van der Kogel, A. J.; Bussink, J. 
Molecular aspects of tumour hypoxia. Mol Oncol 2008, 2 (1), 41–53. 
Raez, L. E. R., J.; Schlesselman, J.; Langmuir, V.; Tidmarsh, G.; Rocha-Lima, C.; Papadopoulos, 
K.; O’Connor, J.; Baldie, P.; Lampidis, T. Combining glycolytic inhibitors with 
chemotherapy: phase I trial of 2-deoxy-D-glucose and docetaxel in patients with solid tumors. 
Journal of Clinical Oncology 2005, 23 (16S), 3190. 
Rane, S.; He, M.; Sayed, D.; Vashistha, H.; Malhotra, A.; Sadoshima, J.; Vatner, D. E.; Vatner, 
S. F.; Abdellatif, M. Downregulation of miR-199a derepresses hypoxia-inducible factor-1α 
and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009, 
104 (7), 879–886. 
Rao, K. V.; Rao, N. S. Chemistry of Saururus cernuus, VI: Three new neolignans. J Nat Prod 
1990, 53 (1), 212–215. 
Rasmussen, J. A. H., A. M.; Einhellig, F. A.; Thomas, J. A. Sorgoleone from root exudate 
inhibits mitochondrial functions. J. Chem. Ecol. 1992, 18 (2), 197–207. 
Reiling, J. H.; Sabatini, D. M. Stress and mTORture signaling. Oncogene 2006, 25 (48), 6373–
6383. 
Robertson, J. D.; Orrenius, S. Role of mitochondria in toxic cell death. Toxicology 2002, 181-
182, 491–496. 
210 
 
Robey, I. F.; Stephen, R. M.; Brown, K. S.; Baggett, B. K.; Gatenby, R. A.; Gillies, R. J. 
Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 2008, 10 
(8), 745–756. 
Rodriguez-Enriquez, S.; Marin-Hernandez, A.; Gallardo-Perez, J. C.; Carreno-Fuentes, L.; 
Moreno-Sanchez, R. Targeting of cancer energy metabolism. Mol Nutr Food Res 2009, 53 
(1), 29–48. 
Rosenthal, P. J. Antimalarial drug discovery: old and new approaches. J Exp Biol 2003, 206 (Pt 
21), 3735–3744. 
Roth, G. N.; Chandra, A.; Nair, M. G. Novel bioactivities of Curcuma longa constituents. J Nat 
Prod 1998, 61 (4), 542–545. 
Rous, P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp 
Med 1911, 13 (4), 397–411. 
Rowinsky, E. K. Lately, it occurs to me what a long, strange trip it's been for the 
farnesyltransferase inhibitors. J Clin Oncol 2006, 24 (19), 2981–2984. 
Roy, A.; Volgin, D. V.; Baby, S. M.; Mokashi, A.; Kubin, L.; Lahiri, S. Activation of HIF-1α 
mRNA by hypoxia and iron chelator in isolated rat carotid body. Neurosci Lett 2004, 363 (3), 
229–232. 
Rukachaisirikul, V.; Pailee, P.; Hiranrat, A.; Tuchinda, P.; Yoosook, C.; Kasisit, J.; Taylor, W. 
C.; Reutrakul, V. Anti-HIV-1 protostane triterpenes and digeranylbenzophenone from trunk 
bark and stems of Garcinia speciosa. Planta Med 2003, 69 (12), 1141–1146. 
Runeberg, L. Uncoupling of oxidative phosphorylation in rat liver mitochondria with desaspidin 
and related phlorobutyrophenone derivative. Biochem Pharmacol 1962, 11, 237–242. 
211 
 
Ruvinsky, I.; Sharon, N.; Lerer, T.; Cohen, H.; Stolovich-Rain, M.; Nir, T.; Dor, Y.; Zisman, P.; 
Meyuhas, O. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose 
homeostasis. Genes Dev 2005, 19 (18), 2199–2211. 
Saito, K.; Kondo, E.; Matsushita, M. MicroRNA 130 family regulates the hypoxia response 
signal through the P-body protein DDX6. Nucleic Acids Res 2011, 39 (14), 6086–6099. 
Saling, S. C.; Comar, J. F.; Mito, M. S.; Peralta, R. M.; Bracht, A. Actions of juglone on energy 
metabolism in the rat liver. Toxicol Appl Pharmacol 2011, 257 (3), 319–327. 
Salomon, A. R.; Voehringer, D. W.; Herzenberg, L. A.; Khosla, C. Apoptolidin, a selective 
cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem Biol 2001, 8 (1), 71–80. 
Salomon, A. R.; Voehringer, D. W.; Herzenberg, L. A.; Khosla, C. Understanding and exploiting 
the mechanistic basis for selectivity of polyketide inhibitors of F0F1-ATPase. Proc Natl Acad 
Sci U S A 2000, 97 (26), 14766–14771. 
Sams-Dodd, F. Target-based drug discovery: is something wrong? Drug Discov Today 2005, 10 
(2), 139–147. 
Sanchez, W.; Maple, J. T.; Burquart, L. J.; Kamath, P. S. Severe hepatotoxicity associated with 
use of a dietary supplement containing usnic acid. Mayo Clin Proc 2006, 81 (4), 541–544. 
Sarafian, T. A.; Kouyoumjian, S.; Khoshaghideh, F.; Tashkin, D. P.; Roth, M. D. Δ9-
tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am J Physiol Lung 
Cell Mol Physiol 2003, 284 (2), L298–L306. 
Scatena, R.; Bottoni, P.; Botta, G.; Martorana, G. E.; Giardina, B. The role of mitochondria in 
pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell 
Physiol 2007, 293 (1), C12–21. 
212 
 
Scatena, R.; Bottoni, P.; Pontoglio, A.; Mastrototaro, L.; Giardina, B. Glycolytic enzyme 
inhibitors in cancer treatment. Expert Opin Investig Drugs 2008, 17 (10), 1533–1545. 
Schepens, B.; Tinton, S. A.; Bruynooghe, Y.; Beyaert, R.; Cornelis, S. The polypyrimidine tract-
binding protein stimulates HIF-1α IRES-mediated translation during hypoxia. Nucleic Acids 
Res 2005, 33 (21), 6884–6894. 
Schofield, C. J.; Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 
2004, 5 (5), 343–354. 
Schwartz, D. L.; Powis, G.; Thitai-Kumar, A.; He, Y.; Bankson, J.; Williams, R.; Lemos, R.; Oh, 
J.; Volgin, A.; Soghomonyan, S.; Nishii, R.; Alauddin, M.; Mukhopadhay, U.; Peng, Z.; 
Bornmann, W.; Gelovani, J. The selective hypoxia inducible factor-1 inhibitor PX-478 
provides in vivo radiosensitization through tumor stromal effects. Mol Cander Ther 2009, 8 
(4), 947–958. 
Schwartz, J. D.; Rowinsky, E. K.; Youssoufian, H.; Pytowski, B.; Wu Y. Vascular endothelial 
growth factor receptor-1 in human cancer: concise review and rationale for development of 
IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer 
2010, 116 (4 Suppl.) 1027–1032. 
Seeram, N. P.; Schulman, R. N.; Heber, D. Pomegranates : ancient roots to modern medicine. 
CRC/Taylor & Francis: Boca Raton, 2006; p 244 p. 
Seidel, V. Initial and Bulk Extraction. In Natural products isolation, 2nd ed.; Sarker, S. D.; Latif, 
Z.; Gray, A. I. Eds. Humana Press: Totowa, N.J., 2005; pp 27-46. 
Selak, M. A.; Armour, S. M.; MacKenzie, E. D.; Boulahbel, H.; Watson, D. G.; Mansfield, K. 
D.; Pan, Y.; Simon, M. C.; Thompson, C. B.; Gottlieb, E. Succinate links TCA cycle 
213 
 
dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 2005, 7 (1), 
77–85. 
Semenza, G. L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007, 
12 (19–20) 853–859. 
Semenza, G. L. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008, 60 (9), 
591–597. 
Semenza, G. L. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator 
of ischemic preconditioning. Biochim Biophys Acta 2011, 1813 (7), 1263–1268. 
Semenza, G. L. Hypoxia-inducible factors: mediators of cancer progression and targets for 
cancer therapy. Trends Pharmacol Sci 2012, 33 (4), 207–214. 
Semenza, G. L. Regulation of cancer cell metabolism by hypoxia-inducible factor-1. Semin 
Cancer Biol 2009, 19 (1), 12–16. 
Semenza, G. L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor-1. Annu 
Rev Cell Dev Biol 1999, 15, 551–578. 
Semenza, G. L.; Agani, F.; Booth, G.; Forsythe, J.; Iyer, N.; Jiang, B. H.; Leung, S.; Roe, R.; 
Wiener, C.; Yu, A. Structural and functional analysis of hypoxia-inducible factor-1. Kidney 
Int 1997, 51 (2), 553–555. 
Semenza, G. L.; Jiang, B. H.; Leung, S. W.; Passantino, R.; Concordet, J. P.; Maire, P.; 
Giallongo, A. Hypoxia response elements in the aldolase A, enolase 1, and lactate 
dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor-
1. J Biol Chem 1996, 271 (51), 32529–32537. 
214 
 
Semenza, G. L.; Roth, P. H.; Fang, H. M.; Wang, G. L. Transcriptional regulation of genes 
encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994, 269 (38), 
23757–23763. 
Semenza, G. L.; Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis 
binds to the human erythropoietin gene enhancer at a site required for transcriptional 
activation. Mol Cell Biol 1992, 12 (12), 5447–5454. 
Sharlow, E. R.; Lyda, T. A.; Dodson, H. C.; Mustata, G.; Morris, M. T.; Leimgruber, S. S.; Lee, 
K. H.; Kashiwada, Y.; Close, D.; Lazo, J. S.; Morris, J. C. A target-based high throughput 
screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic 
activity. PLoS Negl Trop Dis 2010, 4 (4), e659. 
Shawver, L. K.; Slamon, D.; Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer 
therapy. Cancer Cell 2002, 1 (2), 117–123. 
Shimizu, Y. L., B. Purification of Water-Soluble Natural Products. In Natural products isolation, 
2nd ed.; Sarker, S. D.; Latif, Z.; Gray, A. I. Eds. Humana Press: Totowa, N.J., 2005; pp 415–
438. 
Shin, D. H.; Li, S. H.; Chun, Y. S.; Huang, L. E.; Kim, M. S.; Park, J. W. CITED2 mediates the 
paradoxical responses of HIF-1α to proteasome inhibition. Oncogene 2008, 27 (13), 1939–
1944. 
Shishodia, S.; Harikumar, K. B.; Dass, S.; Ramawat, K. G.; Aggarwal, B. B. The guggul for 
chronic diseases: ancient medicine, modern targets. Anticancer Res 2008, 28 (6A), 3647–
3664. 
Shoshan, M. C. 3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr 2012, 44 (1),    
7–15. 
215 
 
Siems, W.; Sommerburg, O.; Schild, L.; Augustin, W.; Langhans, C. D.; Wiswedel, I. β-carotene 
cleavage products induce oxidative stress in vitro by impairing mitochondrial respiration. 
Faseb J 2002, 16 (10), 1289–1291. 
Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; 
Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-
drug screening. J Natl Cancer Inst 1990, 82 (13), 1107–1112. 
Society of toxicology, http://www.toxicology.org/ai/pub/si05/SI05_Define.asp (accessed on May 
4th 2012) 
Soltoff, S. P. Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and 
indirectly blocks protein kinase Cδ tyrosine phosphorylation. J Biol Chem 2001, 276 (41), 
37986–37992. 
Song, X.; Liu, X.; Chi, W.; Liu, Y.; Wei, L.; Wang, X.; Yu, J. Hypoxia-induced resistance to 
cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α 
gene. Cancer Chemother Pharmacol 2006, 58 (6), 776–784. 
Sonveaux, P.; Vegran, F.; Schroeder, T.; Wergin, M. C.; Verrax, J.; Rabbani, Z. N.; De 
Saedeleer, C. J.; Kennedy, K. M.; Diepart, C.; Jordan, B. F.; Kelley, M. J.; Gallez, B.; Wahl, 
M. L.; Feron, O.; Dewhirst, M. W. Targeting lactate-fueled respiration selectively kills 
hypoxic tumor cells in mice. J Clin Invest 2008, 118 (12), 3930–3942. 
Spannuth, W. A.; Sood, A. K.; Coleman, R. L. Angiogenesis as a strategic target for ovarian 
cancer therapy. Nat Clin Pract Oncol 2008, 5 (4), 194–204. 
Sparg, S. G.; Light, M. E.; van Staden, J. Biological activities and distribution of plant saponins. 
J Ethnopharmacol 2004, 94 (2-3), 219–243. 
216 
 
Staab, A.; Loffler, J.; Said, H. M.; Katzer, A.; Beyer, M.; Polat, B.; Einsele, H.; Flentje, M.; 
Vordermark, D. Modulation of glucose metabolism inhibits hypoxic accumulation of 
hypoxia-inducible factor-1α (HIF-1α). Strahlenther Onkol 2007, 183 (7), 366–373. 
Stickel, F.; Kessebohm, K.; Weimann, R.; Seitz, H. K. Review of liver injury associated with 
dietary supplements. Liver Int 2011, 31 (5), 595–605. 
Sturdik, E.; Cully, J.; Sturdikova, M.; Durcova, E. Stimulation of glycolysis in Ehrlich ascites 
carcinoma cells with phenylhydrazonopropanedinitrile and others uncouplers of oxidative 
phosphorylation. Neoplasma 1986, 33 (5), 575–582. 
 Sturdy, M.; Krunic, A.; Cho, S.; Franzblau, S.; Orjala, J. Eucapsitrione, an anti-Mycobacterium 
tuberculosis anthraquinone derivative from the cultured freshwater cyanobacterium Eucapsis 
sp. J Nat Prod 2010, 73 (8), 1441–1443. 
Su, Y.; Yang, S.; Xiao, Z.; Wang, W.; Okunieff, P.; Zhang, L. Triptolide alters mitochondrial 
functions. Adv Exp Med Biol 2007, 599, 139–146. 
Sudarshan, S.; Sourbier, C.; Kong, H. S.; Block, K.; Valera Romero, V. A.; Yang, Y.; Galindo, 
C.; Mollapour, M.; Scroggins, B.; Goode, N.; Lee, M. J.; Gourlay, C. W.; Trepel, J.; Linehan, 
W. M.; Neckers, L. Fumarate hydratase deficiency in renal cancer induces glycolytic 
addiction and hypoxia-inducible transcription factor-1α stabilization by glucose-dependent 
generation of reactive oxygen species. Mol Cell Biol 2009, 29 (15), 4080–4090. 
Sugden, M. C.; Holness, M. J. Recent advances in mechanisms regulating glucose oxidation at 
the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab 
2003, 284 (5), E855–E862. 
217 
 
Sun, L.; Luo, C.; Long, J.; Wei, D.; Liu, J. Acrolein is a mitochondrial toxin: effects on 
respiratory function and enzyme activities in isolated rat liver mitochondria. Mitochondrion 
2006, 6 (3), 136–142. 
Sun, Y. E3 Ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006, 8 (8), 645–654. 
Suski, J.; Lebiedzinska, M.; Machado, N. G.; Oliveira, P. J.; Pinton, P.; Duszynski, J.; 
Wieckowski, M. R. Mitochondrial tolerance to drugs and toxic agents in ageing and disease. 
Curr Drug Targets 2011, 12 (6), 827–849. 
Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting 
multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5 (3), 219–234. 
Tamura, S. T., N.; Miyamoto, S.; Mori, R.; Suzuki, S.; Nagatsu, J. Isolation and physiological 
activities of piericidin A, a natural insecticide produced by Streptomyces. Agr. Biol. Chem. 
1963, 27, 576–582. 
Tatum, J. L.; Kelloff, G. J.; Gillies, R. J.; Arbeit, J. M.; Brown, J. M.; Chao, K. S.; Chapman, J. 
D.; Eckelman, W. C.; Fyles, A. W.; Giaccia, A. J.; Hill, R. P.; Koch, C. J.; Krishna, M. C.; 
Krohn, K. A.; Lewis, J. S.; Mason, R. P.; Melillo, G.; Padhani, A. R.; Powis, G.; Rajendran, 
J. G.; Reba, R.; Robinson, S. P.; Semenza, G. L.; Swartz, H. M.; Vaupel, P.; Yang, D.; Croft, 
B.; Hoffman, J.; Liu, G.; Stone, H.; Sullivan, D. Hypoxia: importance in tumor biology, 
noninvasive measurement by imaging, and value of its measurement in the management of 
cancer therapy. Int J Radiat Biol 2006, 82 (10), 699–757. 
Taylor, C. T. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J 2008, 
409 (1), 19–26. 
Teicher, B. A.; Holden, S. A.; al-Achi, A.; Herman, T. S. Classification of antineoplastic 
treatments by their differential toxicity toward putative oxygenated and hypoxic tumor 
218 
 
subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990, 50 (11), 3339–
3344. 
Tello, D.; Balsa, E.; Acosta-Iborra, B.; Fuertes-Yebra, E.; Elorza, A.; Ordonez, A.; Corral-
Escariz, M.; Soro, I.; Lopez-Bernardo, E.; Perales-Clemente, E.; Martinez-Ruiz, A.; 
Enriquez, J. A.; Aragones, J.; Cadenas, S.; Landazuri, M. O. Induction of the mitochondrial 
NDUFA4L2 protein by HIF-1α decreases oxygen consumption by inhibiting Complex I 
activity. Cell Metab 2011, 14 (6), 768–779. 
Thierbach, G.; Reichenbach, H. Myxothiazol, a new inhibitor of the cytochrome b-c1 segment of 
th respiratory chain. Biochim Biophys Acta 1981, 638 (2), 282–289. 
Tormos, K. V.; Chandel, N. S. Inter-connection between mitochondria and HIFs. J Cell Mol Med 
2010, 14 (4), 795–804. 
Tredan, O.; Galmarini, C. M.; Patel, K.; Tannock, I. F. Drug resistance and the solid tumor 
microenvironment. J Natl Cancer Inst 2007, 99 (19), 1441–1454. 
Trumpower, B. L. The protonmotive Q cycle. Energy transduction by coupling of proton 
translocation to electron transfer by the cytochrome bc1 complex. J Biol Chem 1990, 265 
(20), 11409–11412. 
Turner, N.; Li, J. Y.; Gosby, A.; To, S. W.; Cheng, Z.; Miyoshi, H.; Taketo, M. M.; Cooney, G. 
J.; Kraegen, E. W.; James, D. E.; Hu, L. H.; Li, J.; Ye, J. M. Berberine and its more 
biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory 
complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase 
and improve insulin action. Diabetes 2008, 57 (5), 1414–1418. 
219 
 
Ullah, M. S.; Davies, A. J.; Halestrap, A. P. The plasma membrane lactate transporter MCT4, but 
not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J Biol Chem 
2006, 281 (14), 9030–9037. 
Uniacke, J.; Holterman, C. E.; Lachance, G.; Franovic, A.; Jacob, M. D.; Fabian, M. R.; Payette, 
J.; Holcik, M.; Pause, A.; Lee, S. An oxygen-regulated switch in the protein synthesis 
machinery. Nature 2012, 486 (7401), 126–129. 
Usta, J.; Kreydiyyeh, S.; Bajakian, K.; Nakkash-Chmaisse, H. In vitro effect of eugenol and 
cinnamaldehyde on membrane potential and respiratory chain complexes in isolated rat liver 
mitochondria. Food Chem Toxicol 2002, 40 (7), 935–940. 
Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg effect: the 
metabolic requirements of cell proliferation. Science 2009, 324 (5930), 1029–1033. 
Vander Heiden, M. G.; Christofk, H. R.; Schuman, E.; Subtelny, A. O.; Sharfi, H.; Harlow, E. E.; 
Xian, J.; Cantley, L. C., Identification of small molecule inhibitors of pyruvate kinase M2. 
Biochem Pharmacol 2010, 79 (8), 1118–1124. 
Varmus, H. The new era in cancer research. Science 2006, 312 (5777), 1162–1165. 
Varmus, H.; Pao, W.; Politi, K.; Podsypanina, K.; Du, Y. C. Oncogenes come of age. Cold 
Spring Harb Symp Quant Biol 2005, 70, 1–9. 
Vaupel, P.; Harrison, L. Tumor hypoxia: causative factors, compensatory mechanisms, and 
cellular response. Oncologist 2004, 9 Suppl 5, 4–9. 
Vaupel, P.; Kelleher, D. K.; Hockel, M. Oxygen status of malignant tumors: pathogenesis of 
hypoxia and significance for tumor therapy. Semin Oncol 2001, 28 (2 Suppl 8), 29–35. 
220 
 
Von Jagow, G.; Gribble, G. W.; Trumpower, B. L. Mucidin and strobilurin A are identical and 
inhibit electron transfer in the cytochrome bc1 complex of the mitochondrial respiratory chain 
at the same site as myxothiazol. Biochemistry 1986, 25 (4), 775–780. 
Von Jagow, G.; Link, T. A. Use of specific inhibitors on the mitochondrial bc1 complex. 
Methods Enzymol 1986, 126, 253–271. 
Wallace, K. B. Mitochondrial off targets of drug therapy. Trends Pharmacol Sci 2008, 29 (7), 
361–366. 
Wang, G. L.; Jiang, B. H.; Rue, E. A.; Semenza, G. L. Hypoxia-inducible factor-1 is a basic-
helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 
1995, 92 (12), 5510–5514. 
Wang, T.; Marquardt, C.; Foker, J. Aerobic glycolysis during lymphocyte proliferation. Nature 
1976, 261 (5562), 702–705. 
Wang, Y.; Zhang, Y.; Yu, B., The cytotoxicity of saponins correlates with their cellular 
internalization. ChemMedChem 2007b, 2 (3), 288-91. 
Wang, Y.; Zhang, Y.; Zhu, Z.; Zhu, S.; Li, Y.; Li, M.; Yu, B. Exploration of the correlation 
between the structure, hemolytic activity, and cytotoxicity of steroid saponins. Bioorg Med 
Chem 2007a, 15 (7), 2528–2532. 
Warburg, O. On the origin of cancer cells. Science 1956, 123 (3191), 309–314. 
Ward, R. A.; Brassington, C.; Breeze, A. L.; Caputo, A.; Critchlow, S.; Davies, G.; Goodwin, L.; 
Hassall, G.; Greenwood, R.; Holdgate, G. A.; Mrosek, M.; Norman, R. A.; Pearson, S.; Tart, 
J.; Tucker, J. A.; Vogtherr, M.; Whittaker, D.; Wingfield, J.; Winter, J.; Hudson, K. Design 
and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation. 
J Med Chem 2012, 55 (7), 3285–3306. 
221 
 
Wassler, M.; Jonasson, I.; Persson, R.; Fries, E. Differential permeabilization of membranes by 
saponin treatment of isolated rat hepatocytes. Biochem J 1987, 247 (2), 407–415. 
Weeks, A. J.; Paul, R. L.; Marsden, P. K.; Blower, P. J.; Lloyd, D. R. Radiobiological effects of 
hypoxia-dependent uptake of 64Cu-ATSM: enhanced DNA damage and cytotoxicity in 
hypoxic cells. Eur J Nucl Med Mol Imaging 2010, 37 (2), 330–338. 
Wei, Y. H.; Lu, C. Y.; Lin, T. N.; Wei, R. D. Effect of ochratoxin A on rat liver mitochondrial 
respiration and oxidative phosphorylation. Toxicology 1985, 36 (2-3), 119–130. 
Weinstein, I. B. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002, 297 
(5578), 63–64. 
Wellcome trust Sanger Institute, http://www.sanger.ac.uk/genetics/CGP/Census/ (accessed on 
July 7th 2012). 
Wesche, H.; Xiao, S. H.; Young, S. W. High throughput screening for protein kinase inhibitors. 
Comb Chem High Throughput Screen 2005, 8 (2), 181–195. 
Wolf, A.; Agnihotri, S.; Micallef, J.; Mukherjee, J.; Sabha, N.; Cairns, R.; Hawkins, C.; Guha, A. 
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human 
glioblastoma multiforme. J Exp Med 2011, 208 (2), 313–326. 
Wolvetang, E. J.; Johnson, K. L.; Krauer, K.; Ralph, S. J.; Linnane, A. W. Mitochondrial 
respiratory chain inhibitors induce apoptosis. FEBS Lett 1994, 339 (1-2), 40–44. 
Xu, D.; Yao, Y.; Lu, L.; Costa, M.; Dai, W. Plk3 functions as an essential component of the 
hypoxia regulatory pathway by direct phosphorylation of HIF-1α. J Biol Chem 2010, 285 
(50), 38944–38950. 
222 
 
Xu, Z.; Nagashima, K.; Sun, D.; Rush, T.; Northrup, A.; Andersen, J. N.; Kariv, I.; Bobkova, E. 
V. Development of high-throughput TR-FRET and AlphaScreen assays for identification of 
potent inhibitors of PDK1. J Biomol Screen 2009, 14 (10), 1257–1262. 
Yee Koh, M.; Spivak-Kroizman, T. R.; Powis, G. HIF-1 regulation: not so easy come, easy go. 
Trends Biochem Sci 2008, 33 (11), 526–534. 
Yeh, G. Y.; Eisenberg, D. M. Kaptchuk, T. J.; Phillips, R. S. Systematic review of herbs and 
dietary supplements for glycemic control in diabetes. Diabetes Care 2003, 26 (4), 1277–
1294. 
Yellapu, R. K.; Mittal, V.; Grewal, P.; Fiel, M.; Schiano, T. Acute liver failure caused by 'fat 
burners' and dietary supplements: a case report and literature review. Can J Gastroenterol 
2011, 25 (3), 157–160. 
Yeung, S. J.; Pan, J.; Lee, M. H. Roles of p53, MYC and HIF-1 in regulating glycolysis - the 
seventh hallmark of cancer. Cell Mol Life Sci 2008, 65 (24), 3981–3999. 
Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug 
Discov 2006, 5 (1), 37–50. 
Young, R. M.; Wang, S. J.; Gordan, J. D.; Ji, X.; Liebhaber, S. A.; Simon, M. C. Hypoxia-
mediated selective mRNA translation by an internal ribosome entry site-independent 
mechanism. J Biol Chem 2008, 283 (24), 16309–16319. 
Zafra-Polo, M. C.; Gonzalez, M. C.; Tormo, J. R.; Estornell, E.; Cortes, D. Polyalthidin: new 
prenylated benzopyran inhibitor of the mammalian mitochondrial respiratory chain. J Nat 
Prod 1996, 59 (10), 913–916. 
223 
 
Zhang, H.; Bosch-Marce, M.; Shimoda, L. A.; Tan, Y. S.; Baek, J. H.; Wesley, J. B.; Gonzalez, 
F. J.; Semenza, G. L. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic 
response to hypoxia. J Biol Chem 2008, 283 (16), 10892–10903. 
Zhang, H.; Gao, P.; Fukuda, R.; Kumar, G.; Krishnamachary, B.; Zeller, K. I.; Dang, C. V.; 
Semenza, G. L. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-
deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11 (5), 
407–420. 
Zhao, F.; Mancuso, A.; Bui, T. V.; Tong, X.; Gruber, J. J.; Swider, C. R.; Sanchez, P. V.; Lum, J. 
J.; Sayed, N.; Melo, J. V.; Perl, A. E.; Carroll, M.; Tuttle, S. W.; Thompson, C. B. Imatinib 
resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced 
metabolic reprograming. Oncogene 2010, 29 (20), 2962–2972. 
Zhong, L.; D'Urso, A.; Toiber, D.; Sebastian, C.; Henry, R. E.; Vadysirisack, D. D.; Guimaraes, 
A.; Marinelli, B.; Wikstrom, J. D.; Nir, T.; Clish, C. B.; Vaitheesvaran, B.; Iliopoulos, O.; 
Kurland, I.; Dor, Y.; Weissleder, R.; Shirihai, O. S.; Ellisen, L. W.; Espinosa, J. M.; 
Mostoslavsky, R. The histone deacetylase Sirt6 regulates glucose homeostasis via HIF-1α. 
Cell 2010, 140 (2), 280–293. 
Zhou, J.; Callapina, M.; Goodall, G. J.; Brune, B. Functional integrity of nuclear factor kappaB, 
phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase signaling allows tumor 
necrosis factor α-evoked Bcl-2 expression to provoke internal ribosome entry site-dependent 
translation of hypoxia-inducible factor-1α. Cancer Res 2004, 64 (24), 9041–9048. 
Zhou, J.; Hara, K.; Inoue, M.; Hamada, S.; Yasuda, H.; Moriyama, H.; Endo, H.; Hirota, K.; 
Yonezawa, K.; Nagata, M.; Yokono, K. Regulation of hypoxia-inducible factor-1 by glucose 
availability under hypoxic conditions. Kobe J Med Sci 2007, 53 (6), 283–296. 
224 
 
Zhou, M.; Zhao, Y.; Ding, Y.; Liu, H.; Liu, Z.; Fodstad, O.; Riker, A. I.; Kamarajugadda, S.; Lu, 
J.; Owen, L. B.; Ledoux, S. P.; Tan, M. Warburg effect in chemosensitivity: targeting lactate 
dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer 2010, 9, 33. 
Zhou, Y.; Garcia-Prieto, C.; Carney, D. A.; Xu, R. H.; Pelicano, H.; Kang, Y.; Yu, W.; Lou, C.; 
Kondo, S.; Liu, J.; Harris, D. M.; Estrov, Z.; Keating, M. J.; Jin, Z.; Huang, P. OSW-1: a 
natural compound with potent anticancer activity and a novel mechanism of action. J Natl 
Cancer Inst 2005, 97 (23), 1781–1785. 
Zhu, H.; Chen, X. P.; Luo, S. F.; Guan, J.; Zhang, W. G.; Zhang, B. X. Involvement of hypoxia-
inducible factor-1α in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin 
Cancer Res 2005, 24 (4), 565–574. 
Zu, X. L.; Guppy, M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res 
Commun 2004, 313 (3), 459–465. 
225 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
226 
 
 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
Jul 25, 2012 
This is a License Agreement between Sandipan Datta ("You") and Nature Publishing Group 
("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by Nature Publishing 
Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2915450131484 
License date May 24, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Chemical Biology 
Licensed content title 
New approaches to molecular cancer 
therapeutics 
Licensed content author Ian Collins and Paul Workman 
Licensed content date Dec 1, 2006 
Volume number 2 
Issue number 12 
227 
 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of figures/tables/illustrations 5 
High-res required no 
Figures figure 1 figure 2 figure 5 
Author of this NPG article no 
Your reference number 
 
Title of your thesis / dissertation  
Discovery of small-molecule natural products 
that target cellular bioenergetics 
Expected completion date  Jul 2012 
Estimated size (number of pages) 150 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this 
material for this purpose, and for no other use, subject to the conditions below:  
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of 
this material. However, you should ensure that the material you are requesting is 
original to Nature Publishing Group and does not carry the copyright of another 
228 
 
entity (as credited in the published version). If the credit line on any part of the 
material you have requested indicates that it was reprinted or adapted by NPG with 
permission from another source, then you should also seek permission from that 
source to reuse the material.  
   
2. Permission granted free of charge for material in print is also usually granted for any 
electronic version of that work, provided that the material is incidental to the work 
as a whole and that the electronic version is essentially equivalent to, or substitutes 
for, the print version. Where print permission has been granted for a fee, separate 
permission must be obtained for any additional, electronic re-use (unless, as in the 
case of a full paper, this has already been accounted for during your initial request in 
the calculation of a print run). NB: In all cases, web-based use of full-text articles 
must be authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
   
3. Permission granted for a first edition does not apply to second and subsequent 
editions and for editions in other languages (except for signatories to the STM 
Permissions Guidelines, or where the first edition permission was granted for free). 
  
4. Nature Publishing Group's permission must be acknowledged next to the figure, 
table or abstract in print. In electronic form, this acknowledgement must be visible 
at the same time as the figure/table/abstract, and must be hyperlinked to the journal's 
homepage.  
229 
 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX)  
Note: For republication from the British Journal of Cancer, the following credit 
lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX)  
6. Adaptations of single figures do not require NPG approval. However, the adaptation 
should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the following credit 
line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
230 
 
publication)  
7. Translations of 401 words up to a whole article require NPG approval. Please visit 
http://www.macmillanmedicalcommunications.com for more information. 
Translations of up to a 400 words do not require NPG approval. The translation 
should be credited as follows: 
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication). 
Note: For translation from the British Journal of Cancer, the following credit 
line applies. 
Translated by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication)  
We are certain that all parties will benefit from this agreement and wish you the best in the 
use of this material. Thank you. 
Special Terms:  
v1.1 
If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you 
will be invoiced within 48 hours of the license date. Payment should be in the form of a 
check or money order referencing your account number and this invoice number 
RLNK500786204. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
231 
 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
For suggestions or comments regarding this order, contact RightsLink Customer 
Support: customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1-
978-646-2777. 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
license for your reference. No payment is required. 
 
232 
 
 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
Jul 25, 2012 
This is a License Agreement between Sandipan Datta ("You") and Nature Publishing Group 
("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by Nature Publishing 
Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2926250631558 
License date Jun 11, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Cell Death and Differentiation 
Licensed content title 
Mitochondrial complex III regulates hypoxic 
activation of HIF 
Licensed content author T Klimova, N S Chandel 
Licensed content date Jan 25, 2008 
Volume number 15 
Issue number 4 
233 
 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of figures/tables/illustrations 3 
High-res required no 
Figures 3,4,5 
Author of this NPG article no 
Your reference number 
 
Title of your thesis / dissertation  
Discovery of small-molecule natural products that 
target cellular bioenergetics 
Expected completion date  Jul 2012 
Estimated size (number of pages) 150 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this 
material for this purpose, and for no other use, subject to the conditions below:  
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of 
this material. However, you should ensure that the material you are requesting is 
original to Nature Publishing Group and does not carry the copyright of another 
234 
 
entity (as credited in the published version). If the credit line on any part of the 
material you have requested indicates that it was reprinted or adapted by NPG with 
permission from another source, then you should also seek permission from that 
source to reuse the material.  
2. Permission granted free of charge for material in print is also usually granted for any 
electronic version of that work, provided that the material is incidental to the work 
as a whole and that the electronic version is essentially equivalent to, or substitutes 
for, the print version. Where print permission has been granted for a fee, separate 
permission must be obtained for any additional, electronic re-use (unless, as in the 
case of a full paper, this has already been accounted for during your initial request in 
the calculation of a print run). NB: In all cases, web-based use of full-text articles 
must be authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and subsequent 
editions and for editions in other languages (except for signatories to the STM 
Permissions Guidelines, or where the first edition permission was granted for free).  
4. Nature Publishing Group's permission must be acknowledged next to the figure, 
table or abstract in print. In electronic form, this acknowledgement must be visible 
at the same time as the figure/table/abstract, and must be hyperlinked to the journal's 
homepage.  
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
235 
 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX)  
Note: For republication from the British Journal of Cancer, the following credit 
lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX)    
6. Adaptations of single figures do not require NPG approval. However, the adaptation 
should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the following credit 
line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication)  
7. Translations of 401 words up to a whole article require NPG approval. Please visit 
http://www.macmillanmedicalcommunications.com for more information. 
236 
 
Translations of up to a 400 words do not require NPG approval. The translation 
should be credited as follows: 
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication). 
Note: For translation from the British Journal of Cancer, the following credit 
line applies. 
Translated by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication)  
We are certain that all parties will benefit from this agreement and wish you the best in the 
use of this material. Thank you. 
Special Terms: v1.1 
If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you 
will be invoiced within 48 hours of the license date. Payment should be in the form of a 
check or money order referencing your account number and this invoice number 
RLNK500797024. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
237 
 
Boston, MA 02284-3006 
For suggestions or comments regarding this order, contact RightsLink Customer 
Support: customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1-
978-646-2777. 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
license for your reference. No payment is required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
238 
 
 
 
VITA 
 Sandipan Datta, son of Swapan Kumar Datta and Anuradha Datta was born in Howrah, 
West Bengal, India on October 6, 1980. After completing his schooling from Vivekananda 
Institution, Howrah, he obtained the Bachelor of Pharmacy degree from Sree Siddaganga 
College of Pharmacy, Rajiv Gandhi University of Health Sciences, Tumkur, Karnataka, India. 
Subsequently, he was awarded Govt. of India scholarship and obtained the degree of Master of 
Pharmacy (Pharmacognosy) at Bharati Vidyapeeth Deemed University’s Poona College of 
Pharmacy, Pune, Maharashtra, India. He joined the Department of Pharmacognosy, The 
University of Mississippi under the supervision of Dr. Dale G. Nagle and Yu-Dong Zhou in 
2007. He was awarded Natural Products and Neuroscience Predoctoral Fellowship from the NIH 
in 2009 and 2010. He was elected as the president of the Graduate Student Council in 2010 and 
was inducted in the 2010-2011 class of Who’s Who Among Students in American Universities 
and Colleges. He received the Department of Pharmacognosy, The University of Mississippi 
service award in 2011. Following are the publications/potential publications from his research: 
Li, J.; Mahdi, F.; Du, L.; Datta, S.; Nagle, D. G.; Zhou, Y. -D. Mitochondrial Respiration 
Inhibitors Suppress Protein Translation and Hypoxic Signaling via the 
Hyperphosphorylation and Inactivation of Translation Initiation Factor eIF2α and 
Elongation Factor eEF2 J Nat Prod. 2011, 74(9), 1894-1901. 
239 
 
Du, L.; Mahdi, F.; Datta, S.; Jekabsons, M. B.; Zhou, Y. -D.; Nagle, D. G. “Structures 
and Mechanisms of Antitumor Agents – Xestoquinones Uncouple Cellular Respiration 
and Disrupt HIF Signaling in Human Breast Tumor Cells” (in press) 
Datta, S.; Li, J.; Zhou, Y. -D.; Nagle, D. G. “Identification of Small-molecule Glycolysis 
Inhibitors Through a Bioenergetics-based Screening” (in preparation).  
Datta, S.; Li, J.; Zhou, Y. -D.; Nagle, D. G. “Comparative Evaluation of 
Chromatographic Media in Molecular-targeted Antitumor Drug Discovery” (in 
preparation). 
Datta, S.; Mahdi, F.; Li, J.; Du, L.; Smillie, T. J.; Khan, I. A.; Jekabsons, M. B.; Zhou, Y. 
-D.; Nagle, D. G. “Assessing the potential mitochondrial-mediated toxicity of herbal 
dietary supplements” (planned manuscript). 
 
